Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 

FORM 10-KSB
(Mark one) 
 	 	 	
☑ 	 	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934	
For the fiscal year ended December 31, 2004 
 	 	 	
o 	 	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934	
For the transition period from                      to                     . 
Commission file number 000-28637 

BIOSANTE PHARMACEUTICALS, INC. 
(Name of small business issuer in its charter)
 	 	 	
Delaware 	 	58-2301143	
(State or other jurisdiction of incorporation or organization) 	 	(I.R.S. Employer Identification No.)	
 	 	 	
111 Barclay Boulevard	 	 	
Lincolnshire, Illinois 	 	60069	
(Address of principal executive offices) 	 	(Zip Code)	
(847) 478-0500
(Issuer’s telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act: 
 	 	 	
Title of Each Class 	 	Name of Each Exchange on Which Registered	
Common Stock, par value $0.0001 per share 	 	The American Stock Exchange	
Securities registered under Section 12(g) of the Exchange Act: 
None 
     Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO o 
     Check if there is no disclosure of delinquent filers pursuant to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. o 
     The issuer’s revenues for the fiscal year ended December 31, 2004 were $77,886. 
     As of March 16, 2005, 18,993,276 shares of common stock of the registrant were outstanding, and the aggregate market value of the common stock of the registrant as of that date (based upon the last reported sale price of the common stock on that date as reported by the American Stock Exchange), beneficially owned by non-affiliates of the registrant was $60,565,356. Directors, executive officers and beneficial owners of 10% or more of the registrant’s outstanding common stock are considered “affiliates” of the registrant for this purpose. 
DOCUMENTS INCORPORATED BY REFERENCE 
     Part III of this Annual Report on Form 10-KSB incorporates by reference information (to the extent specific sections are referred to herein) from the registrant’s Proxy Statement for its 2005 Annual Meeting of Stockholders to be held June 6, 2005. 
Transitional Small Business Disclosure Format (check one): YES o NO ☒ 

  

Table of Contents
TABLE OF CONTENTS 
 	 	 	 	 	 	 	
Item 1.	 	DESCRIPTION OF BUSINESS	 	 	1	 	
 	 	General	 	 	1	 	
 	 	Business Strategy	 	 	2	 	
 	 	Hormone Therapy Market	 	 	3	 	
 	 	Description of Our Hormone Therapy Products	 	 	6	 	
 	 	Description of Our CAP Technology and Products	 	 	8	 	
 	 	Sales and Marketing	 	 	12	 	
 	 	Research and Product Development	 	 	12	 	
 	 	Manufacturing	 	 	13	 	
 	 	Patents, Licenses and Proprietary Rights	 	 	13	 	
 	 	Competition	 	 	16	 	
 	 	Governmental Regulation	 	 	17	 	
 	 	Employees	 	 	19	 	
 	 	Forward-Looking Statements	 	 	19	 	
 	 	Available Information	 	 	31	 	
 	 	 	 	 	 	 	
Item 2.	 	DESCRIPTION OF PROPERTY	 	 	32	 	
 	 	 	 	 	 	 	
Item 3.	 	LEGAL PROCEEDINGS	 	 	32	 	
 	 	 	 	 	 	 	
Item 4.	 	SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS	 	 	32	 	
 	 	 	 	 	 	 	
Item 4A.	 	EXECUTIVE OFFICERS OF THE REGISTRANT	 	 	32	 	
 	 	 	 	 	 	 	
Item 5.	 	MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS	 	 	34	 	
 	 	Market Price	 	 	34	 	
 	 	Number of Record Holders; Dividends	 	 	34	 	
 	 	Previous Sales of Unregistered Securities	 	 	35	 	
 	 	Small Business Issuer Purchases of Equity Securities	 	 	35	 	
 	 	 	 	 	 	 	
Item 6.	 	MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION	 	 	36	 	
 	 	Overview	 	 	36	 	
 	 	Critical Accounting Policies	 	 	40	 	
 	 	Results of Operations	 	 	40	 	
 	 	Liquidity and Capital Resources	 	 	42	 	
 	 	Quantitative and Qualitative Disclosure About Market Risk	 	 	45	 	
 	 	 	 	 	 	 	
Item 7.	 	FINANCIAL STATEMENTS	 	 	46	 	
 	 	 	 	 	 	 	
Item 8.	 	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	 	 	71	 	
 	 	 	 	 	 	 	
Item 8A.	 	CONTROLS AND PROCEDURES	 	 	71	 	
 	 	Evaluation of Disclosure Controls and Procedures	 	 	71	 	
 	 	Change in Internal Control Over Financial Reporting	 	 	71	 	
i 

Table of Contents
 	 	 	 	 	 	 		
Item 8B.	 	OTHER INFORMATION	 	 	71	 		
 	 	 	 	 	 	 		
Item 9.	 	DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH	 	 	 	 		
 	 	SECTION 16(a) OF THE EXCHANGE ACT	 	 	72	 		
 	 	Directors, Executive Officers, Promoters and Control Persons	 	 	72	 		
 	 	Section 16(a) Beneficial Ownership Reporting Compliance	 	 	72	 		
 	 	Audit Committee Matters	 	 	72	 		
 	 	Procedures by which Security Holders Recommend Board Nominees	 	 	72	 		
 	 	Code of Conduct and Ethics for Employees, Officers and Directors	 	 	73	 		
 	 	 	 	 	 	 		
Item 10.	 	EXECUTIVE COMPENSATION	 	 	73	 		
 	 	 	 	 	 	 		
Item 11.	 	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED	 	 	 	 		
 	 	STOCKHOLDER MATTERS	 	 	73	 		
 	 	Securities Authorized for Issuance Under Equity Compensation Plans	 	 	73	 		
 	 	 	 	 	 	 		
Item 12.	 	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS	 	 	74	 		
 	 	 	 	 	 	 		
Item 13.	 	EXHIBITS	 	 	74	 		
 	 	 	 	 	 	 		
Item 14.	 	PRINCIPAL ACCOUNTANT FEES AND SERVICES	 	 	75	 		
 	 	 	 	 	 	 		
EXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-KSB	 	 	77-83	 		
 Employment Agreement, dated January 21, 1998	
 Description of Non-Employee Director Compensation Arrangements	
 Description of Executive Officer Compensation Arrangments	
 Consent of Deloitte & Touche LLP	
 Certification of Chief Executive Officer to Rule 13a-14	
 Certification of Chief Financial Officer to Rule 13a-14	
 Certification of Chief Executive Officer to Section 906	
 Certification of Chief Financial Officer to Section 906	
ii 

Table of Contents
PART I 

This Annual Report on Form 10-KSB contains forward-looking statements. For this purpose, any statements contained in this Form 10-KSB that are not statements of historical fact may be deemed to be forward-looking statements. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “continue” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including those listed below under the heading “Item 1. Description of Business – Forward-Looking Statements.” These factors may cause our actual results to differ materially from any forward-looking statement. 
As used in this report, references to “BioSante,” the “company,” “we,” “our” or “us,” unless the context otherwise requires, refer to BioSante Pharmaceuticals, Inc. 
We own or have the rights to use various trademarks, trade names or service marks used in this report, including BioSante®, BioVant™, NanoVant™, CAP-Oral™, BioAir™, Bio-E-Gel™, Bio-E/P-Gel™, LibiGel™, LibiGel-E/T™ and Bio-T-Gel™. This report also contains trademarks, trade names and service marks that are owned by other persons or entities. 
Item 1. DESCRIPTION OF BUSINESS 
General 
We are a development stage biopharmaceutical company that is developing a pipeline of hormone therapy products to treat men and women. We also are engaged in the development of our proprietary calcium phosphate nanotechnology, or CAP, for vaccine adjuvants or immune system boosters and drug delivery systems. 
Our hormone therapy products address a variety of hormone therapies for symptoms that affect both men and women. Symptoms addressed by these hormone therapies include impotence, lack of sex drive, muscle weakness and osteoporosis in men and menopausal symptoms in women including hot flashes, vaginal atrophy, decreased libido and osteoporosis. The products are gel formulations of testosterone, estradiol, a combination of estradiol and testosterone and a combination of estradiol and progestogen. 
The gels are designed to be quickly absorbed through the skin after application on the arms, shoulders, abdomen or thighs, delivering the hormone to the bloodstream evenly and in a non-invasive, painless manner. The gels are formulated to be applied once per day and to be absorbed into the skin without a trace of residue. 
The following is a list of our hormone therapy gel products in development: 
 	•  	Bio-E-Gel – once daily transdermal bioidentical estrogen gel in clinical development for treatment of menopausal symptoms in women.		
 	
 	•  	LibiGel – once daily transdermal bioidentical testosterone gel in clinical development for treatment of female sexual dysfunction (FSD).		
 	
 	•  	Bio-E/P-Gel – once daily transdermal combination gel of bioidentical estrogen and a progestogen in clinical development for treatment of menopausal symptoms in women.		
 	
 	•  	LibiGel-E/T – once daily transdermal combination gel of bioidentical estrogen and bioidentical testosterone in development for treatment of FSD in menopausal women.		
1 

Table of Contents
 	•  	Bio-T-Gel – once daily transdermal bioidentical testosterone gel in clinical development for treatment of hypogonadism, or testosterone deficiency, in men.	
Human clinical trials have begun on several of our hormone therapy products, which are required to obtain approval from the United States Food and Drug Administration (FDA) to market the products. Our proposed Bio-E-Gel product is currently in a pivotal Phase III clinical trial, which is expected to be completed by the end of March 2005. Our proposed LibiGel product recently successfully completed a Phase II clinical trial, and we are currently in the planning stage for our Phase III clinical trials to begin during the later half of 2005. Phase II trials of our proposed Bio-E/P-Gel product (licensed to Solvay Pharmaceuticals, B.V.) have been completed and we are hopeful Solvay will initiate the pivotal Phase III trial in 2005. Our proposed Bio-T-Gel product is also currently in development. 
Our CAP technology is based on the use of extremely small, solid, uniform particles, which we call “nanoparticles.” We are pursuing the development of the following potential initial applications for our CAP technology: 
 	•  	the creation of improved versions of current vaccines and of new vaccines by the “adjuvant” activity of our proprietary nanoparticles that enhance the ability of a vaccine to stimulate an immune response and allow for delivery of the vaccine via alternative routes of administration including non-injectable routes of administration;		
 	
 	•  	the creation of oral, buccal, intranasal, inhaled and longer acting forms of drugs that currently must be given by injection (e.g., insulin); and		
 	
 	•  	to a lesser extent, other areas, such as the purification of the milk of transgenic animals, in which protein pharmaceuticals are grown, among other potential uses.		
The following is a list of our CAP products in development: 
 	•  	BioVant — proprietary CAP adjuvant and delivery technology in development for improved versions of current vaccines and new vaccines against cancer, viral and bacterial infections and autoimmune diseases, among others, including biodefense vaccines such as anthrax and ricin.		
 	
 	•  	BioOral — a delivery system using CAP technology for oral/buccal administration of proteins and other therapies that currently must be injected.		
 	
 	•  	BioAir — a delivery system using CAP technology for inhalable versions of proteins and other therapies that currently must be injected.		
Business Strategy 
Our goal is to develop and commercialize our hormone therapy products and develop our CAP technology into a wide range of pharmaceutical products. Key elements of our strategy to obtain this goal are to: 
 	•  	Pursue the development of our hormone therapy products. We are focused on building a pipeline of hormone therapy products for the treatment of human hormone deficiencies. Human clinical trials have begun on several of our proposed hormone therapy products, a necessary step in the process of obtaining FDA approval to market the products. Our proposed Bio-E-Gel product is currently completing a pivotal Phase III clinical trial. Our proposed LibiGel product recently successfully completed a Phase II clinical trial, and we are currently in the planning stage	
2 

Table of Contents
 	   	for our Phase III clinical trials. Our proposed Bio-E/P-Gel product is licensed to Solvay Pharmaceuticals, B.V., and Phase II trials have been completed and we are hopeful Solvay will initiate the pivotal Phase III clinical trial in 2005. Our proposed Bio-T-Gel product is also currently in development.		
 	
 	•  	Continue to develop our nanoparticle-based CAP platform technology and seek assistance in the development through government agencies and corporate partner sublicenses. We are seeking opportunities to enter into business collaborations, joint ventures or sublicenses with companies that have businesses or technologies complementary to our CAP technology business, such as vaccine and/or drug delivery pharmaceutical or biotechnology companies, transgenic milk companies, and with various governmental entities focused on developing new vaccines and alternative drug delivery systems. We believe that this partnering strategy will enable us to capitalize on our partners’ strengths in product development, manufacturing and commercialization and thereby enable us to introduce into the market products incorporating our CAP technology sooner than which we otherwise would be able. In addition, these collaborations have enabled us to minimize our spending on the development products incorporating our CAP technology.		
 	
 	•  	Implement business collaborations or joint ventures with other pharmaceutical and biotechnology companies. We continually monitor opportunities to enter into business collaborations or joint ventures with entities that have businesses or technologies complementary to our business.		
 	
 	•  	License or otherwise acquire other drugs that will add value to our current product portfolio. We will consider opportunities to in-license or otherwise acquire other products in the late-stage development phase or products already on the market. In reviewing these opportunities, we consider products that cover therapeutic areas treated by a limited number of physicians and drugs that are in or require human clinical trials that involve a limited number of patients and not a significant amount of time and cost needed to complete them. We believe that products that are currently in or ready for human clinical trials would decrease the risks associated with product development and would likely shorten the time before we can introduce the products into the market. In addition to late-stage development products, we would also consider opportunities to in-license or otherwise acquire products that (1) have FDA approval, (2) have been or are about to be commercially introduced into the U.S. markets, (3) have a concentrated physician prescriber audience, and (4) have the potential to generate significant sales. This element of our strategy is of a lower priority than the others since we currently have an extensive portfolio under development.		
Hormone Therapy Market 
Hormone therapy is used to relieve one or more symptoms caused by declining or low hormone levels. Symptoms addressed by hormone therapies include menopausal symptoms in women, including hot flashes, vaginal atrophy, decreased libido and osteoporosis, and impotence, lack of sex drive, muscle weakness and osteoporosis in men. The primary goal of hormone therapy is to safely and conveniently relieve these symptoms with minimal side effects. 
Estrogen and Combined Estrogen Therapy for Women. There are more than 40 million postmenopausal women in the U.S., and this group is expected to grow 25 percent by 2010. Menopause begins when the ovaries cease to produce estrogen, or when both ovaries are removed surgically prior to natural menopause. The average age at which women experience natural menopause is 51 years. The most common physical symptoms of natural or surgical menopause and the resultant estrogen deficiency are 
3 

Table of Contents
hot flashes, vaginal atrophy, decreased libido and osteoporosis. Hot flashes occur in up to 85% of menopausal women and up to 40% experience some form of vaginal atrophy. Hormone therapy in women decreases the chance that women will experience the symptoms of menopause due to estrogen deficiency. According to industry estimates, approximately 10 million women in the U.S. currently are receiving some form of estrogen or combined estrogen hormone therapy. The current market in the U.S. for estrogen products is approximately $2.0 billion. As the “baby boomer” generation ages, the number of patients reaching menopause and needing estrogen or combined estrogen therapy is expected to increase. 
There are several treatment options for women experiencing menopausal symptoms, which vary according to which symptoms a woman experiences and whether or not she has had a hysterectomy. Estrogen only products are only recommended for use by women who do not have a uterus. Estrogen is most commonly given orally in pill or tablet form. There are several potential side effects, however, with the use of oral estrogen, including insufficient absorption by the circulatory system, stomach upset, gallstones, blood clots as well as an increase in C-reactive protein, a possible marker for cardiovascular inflammation. Although transdermal, or skin, patches have been shown to avoid some of these problems, transdermal patches have a physical presence, can fall off, and can result in skin irritation. However, transdermal delivery of estrogen via patches or gels may reduce the risks associated with oral estrogen, including having no effect on C-reactive protein. 
Women who have not had a hysterectomy must take estrogen in combination with progestogen (either progestin or progesterone) as estrogen alone increases endometrial hyperplasia and cancer risks. In July 2002, the National Institutes of Health (NIH) released data from its Women’s Health Initiative (WHI) study on the risks and benefits associated with long-term use of oral hormone (conjugated estrogen plus progestin) therapy by healthy women. The NIH announced that it was discontinuing the arm of the study investigating the use of the estrogen/progestogen tablet combination from the WHI study because Prempro, the combination oral hormone therapy product used in the study, was shown to cause an increase in the risk of invasive breast cancer after an average follow-up period of 5.2 years. The study also found an increased risk of stroke, heart attacks and blood clots and concluded that overall health risks exceeded benefits from use of the orally delivered combined estrogen plus progestogen product among healthy postmenopausal women. Also in July 2002, the National Cancer Institute (NCI) published the results of an observational study in which it found that postmenopausal women who used estrogen therapy for 10 or more years had a higher risk of developing ovarian cancer than women who never used hormone therapy. The markets for female hormone therapies for menopausal symptoms have declined as a result of these published studies. 
In March 2004, the NIH announced that the estrogen-alone study was discontinued after nearly seven years because the NIH concluded that estrogen alone does not affect (either increase or decrease) heart disease, the major question being evaluated in the study. The findings indicated a slightly increased risk of stroke as well as a decreased risk of hip fracture and breast cancer. Preliminary data from the memory portion of the WHI study suggested that estrogen alone may possibly be associated with a slight increase in the risk of dementia or mild cognitive impairment. 
As a result of the findings from the WHI and other studies, the FDA has required that “black box” labeling be included on all hormone therapy products marketed in the United States to warn, among other things, that these products have been associated with increased risks for heart disease, heart attacks, strokes, and breast cancer and that they are not approved for heart disease prevention. In addition, NIH guidelines, which are supported by many physicians and the FDA, recommend hormone therapy for treating menopausal symptoms in the lowest dose possible for the shortest duration of time consistent with therapeutic goals. 
4 

Table of Contents
The primary advantage of transdermal estrogen therapy products over oral products is that the estrogen avoids being metabolized and losing potency, thereby allowing a lower dosage of hormone to be used. In addition, unlike the oral products containing conjugated estrogens, which were evaluated in the NIH trials, transdermal products, such as our Bio-E-Gel and Bio-E/P-Gel, use bioidentical estradiol, which is identical to the estrogen produced naturally by a woman’s ovaries, and a progestogen, which is different than the type of progestogen in PremPro. No studies to date have evaluated the long-term effects of transdermal estrogen alone or estrogen combined with progestogen therapy. Despite the lack of such studies, however, the FDA has approved several transdermal estrogen or estrogen combined with progestogen products, including transdermal patches, manufactured by Noven Pharmaceuticals, Inc., Berlex Laboratories, Inc., Mylan Laboratories, Inc., Novartis Pharma AG, Pfizer Inc., and Watson Pharmaceuticals, Inc., a transdermal lotion by Novavax, Inc. and a transdermal gel by Solvay Pharmaceuticals, Inc. 
Testosterone Therapy for Women. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to cause low libido or sex drive. Studies have shown that testosterone therapy in women can boost sexual desire and pleasure, increase bone density, raise energy levels and improve mood. According to a study published in the Journal of the American Medical Association, 43 percent of American women, or about 40 million, experience some degree of impaired sexual function. Among the more than 1,400 women surveyed, 32 percent lacked interest in sex and 26 percent could not experience orgasm. Female sexual dysfunction, or FSD, is often defined as a lack of sexual desire, arousal or pleasure. The majority of women with FSD are postmenopausal, experiencing symptoms due to hormonal changes that occur with aging, or with natural or surgical menopause. 
There is no pharmaceutical product currently approved in the United States or anywhere in the world for FSD. While several therapies have been tested to treat FSD, thus far testosterone therapy appears to be the only treatment that results in a consistent significant increase in the number of satisfying sexual events in women, which represents the key efficacy endpoint chosen by the FDA for pivotal clinical trials of FSD therapies. There are several testosterone therapy products for the treatment of FSD in development, including our LibiGel product, Proctor & Gamble’s Intrinsa patch and products being developed by VIVUS, Inc. and Cellegy Pharmaceuticals, Inc. 
In December 2004, the FDA’s Reproductive Health Drugs Advisory Committee panel voted unanimously against recommending the approval of Procter & Gamble’s Intrinsa testosterone patch for hypoactive sexual desire disorder. The panel’s main concern was a desire to have available additional safety data particularly as it pertains to potential increased risk of cardiovascular disease and breast cancer in women treated chronically with testosterone in combination with estrogen. Despite the recommendation not to approve Intrinsa, the panel voted that Intrinsa provides a clinically meaningful benefit for women with hypoactive sexual desire disorder. Currently, the FDA has not stated publicly nor set any type of public policy as to what design of safety trial would be required for approval. Procter & Gamble has since withdrawn its New Drug Application, or NDA, for Intrinsa and it is our understanding that they have completed two additional Phase III studies in over 1,000 naturally menopausal women (i.e., with an intact uterus) and are determining when to resubmit an NDA to the FDA. This FDA action with respect to Intrinsa may impact the regulatory pathway for our LibiGel product, as well as other similarly competitive products to treat FSD with testosterone therapy. However, we are developing our own Phase III development plan for submission to the FDA and are not waiting for any action by Procter & Gamble. 
Testosterone Therapy for Men. Testosterone deficiency in men is known as hypogonadism. Low levels of testosterone may result in lethargy, depression, decreased sex drive, impotence, low sperm count and increased irritability. Men with severe and prolonged reduction of testosterone may also experience loss of body hair, reduced muscle mass, osteoporosis and bone fractures due to osteoporosis. Approximately 
5 

Table of Contents
five million men in the United States, primarily over age 40, have lower than normal levels of testosterone. Testosterone therapy has been shown to restore levels of testosterone with minimal side effects. 
There are currently several products on the market for the treatment of low testosterone levels in men. As opposed to estrogen therapy products, oral administration of testosterone is currently not possible as the hormone is, for the most part, rendered inactive in the liver making it difficult to achieve adequate levels of the compound in the bloodstream. Current methods of administration include testosterone injections, patches and gels. Testosterone injections require large needles, are painful and not effective for maintaining adequate testosterone blood levels throughout the day. Delivery of testosterone through transdermal patches was developed primarily to promote the therapeutic effects of testosterone therapy without the often painful side effects associated with testosterone injections. Transdermal patches, however, similar to estrogen patches, have a physical presence, can fall off, and can result in skin irritation. Testosterone formulated gel products for men are designed to deliver testosterone without the pain of injections and the physical presence, skin irritation and discomfort associated with transdermal patches. We are aware of two gel testosterone products for men currently on the market in the United States and several in development. The U.S. market for transdermal testosterone therapies grew 46% in 2004 to $501 million from $343 million in 2003. 
Description of Our Hormone Therapy Products 
Overview. Our hormone therapy products are gel formulations of bioidentical testosterone, bioidentical estradiol, a combination of bioidentical estradiol and bioidentical testosterone and a combination of bioidentical estradiol and a progestogen. The gels are designed to be quickly absorbed through the skin after application on the arms, shoulders, abdomen or thighs, delivering the hormone to the bloodstream evenly and in a non-invasive, painless manner. The gels are formulated to be applied once per day and to be absorbed into the skin without a trace of residue. 
We believe our hormone therapy products have a number of benefits over competitive hormone therapy products, including the following: 
 	•  	our transdermal gels can be spread over areas of skin where they dry rapidly and decrease the chance for skin irritation versus transdermal patches;		
 	
 	•  	our transdermal gels may have fewer side effects than many pills which have been known to cause gallstones, blood clots and complications related to metabolism;		
 	
 	•  	our transdermal gels have been shown to be well absorbed, thus allowing clinical hormone levels to reach the systemic circulation;		
 	
 	•  	hormone therapy using gels may allow for better dose adjustment than either transdermal patches or oral tablets or capsules; and		
 	
 	•  	gel formulations may be more appealing to patients since they are less conspicuous than transdermal patches, which may be aesthetically unattractive.		
Our strategy with respect to our hormone therapy products is to conduct human clinical trials, which are required to obtain FDA approval, and to market the products in the United States. Human clinical trials have begun on several of our hormone therapy products. 
6 

Table of Contents
Bio-E-Gel. Our estrogen formulated gel product, Bio-E-Gel, is a once daily gel designed to deliver estrogen without the skin irritation associated with, and the physical presence of, transdermal patches. Bio-E-Gel contains bioidentical estradiol versus conjugated equine estrogen contained in the most commonly prescribed oral estrogen. We are currently completing a pivotal Phase III clinical trial of Bio-E-Gel after successfully completing a Phase II clinical trial. We expect to complete our Phase III clinical trial by the end of March 2005 and file an NDA with the FDA in mid-2005. We hope to commercially launch our Bio-E-Gel product in the second half of 2006. 
The Phase II trial, conducted in the United States and Canada, was a double-blind placebo-controlled study of 161 patients. The objective of the Phase II clinical trial was to identify an effective dose of Bio-E-Gel to study in Phase III development. The Phase II trial demonstrated that Bio-E-Gel successfully delivers therapeutic doses of bioidentical estradiol and statistically significantly reduces the frequency and severity of moderate-to-severe hot flashes in menopausal women. 
Current FDA requirements for approval of new estradiol products include one 12-week Phase III clinical trial. In December 2004, we completed enrollment of over 450 women in the Phase III Bio-E-Gel clinical trial for the treatment of moderate-to-severe hot flashes and vaginal atrophy in menopausal women. This trial tests three doses of Bio-E-Gel to maximize the safety profile by identifying the lowest effective dose. The Phase III trial is being conducted in the United States and Canada and is a randomized, double-blind, placebo-controlled study of symptomatic menopausal women. The clinical endpoints of the required Phase III trial include a significant reduction in the severity and frequency of hot flashes at week 4 and week 12 of treatment as compared to placebo. 
LibiGel. Our LibiGel product is a once daily transdermal testosterone gel designed to treat female sexual dysfunction. The majority of women with FSD are postmenopausal, experiencing FSD due to hormonal changes following menopause, whether natural or surgical. We have successfully completed a Phase II clinical trial of our LibiGel. Currently we are working on our Phase III development plan in order to begin Phase III clinical trials, which we anticipate initiating in the later half of 2005. 
The Phase II trial, conducted in the United States, was a double-blind, placebo-controlled study to determine the effect of LibiGel on a women’s sexual activity. Our Phase II trial showed statistically significant results for the primary endpoints of the study. In the U.S.-based, double-blind, placebo-controlled study of 46 women to determine the effect of LibiGel on women’s sexual activity, there was a 238 percent increase from baseline (p<0.0001) in the frequency of satisfying sexual events as measured by individual patient diaries. This increase also was significant versus placebo (p< 0.05). The data indicate an effective LibiGel dose for the treatment of hypoactive sexual desire disorder (HSDD) in women, and that LibiGel was well tolerated during the course of the trial, and had a safety profile similar to that of the placebo, with no women discontinuing use due to adverse events. 
Our Other Hormone Therapy Products. In addition to Bio-E-Gel and LibiGel, our hormone therapy products include Bio-E/P-Gel, LibiGel-E/T and Bio-T-Gel. In addition, we have in-licensed three issued U.S. patents claiming triple hormone therapy via any route of administration (the combination use of estrogen plus progestogen plus androgen, e.g. testosterone) and an option for patents pertaining to triple hormone contraception. 
Through a sublicense agreement with Solvay Pharmaceuticals, B.V., Bio-E/P-Gel, a combined estrogen/progestogen gel product, is in development. Women whose uteri are intact often use a combined hormone therapy because evidence suggests adding progestogen to estrogen therapy may reduce the potential risks of endometrial hyperplasia and endometrial cancer associated with estrogen-alone therapy in these women. Solvay is responsible for all costs of development and marketing of the product. We have retained co-promotion rights to the product and will receive royalties on Solvay’s sales of the 
7 

Table of Contents
product upon approval, and we will be compensated for sales generated by us over and above those attributable to Solvay’s marketing efforts. 
In December 2002, we entered into a development and license agreement with Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which Teva USA agreed to develop one of our hormone therapy products for the U.S. market. Teva USA is also responsible under the terms of this agreement for continued development, regulatory filings and all manufacturing and marketing associated with the product. 
Bio-E-Gel and LibiGel are both non-partnered products; and therefore, we can control better the timing and future development and commercialization of these products, subject to customary and inevitable uncertainties associated with the product development process, regulatory approvals and market acceptance of such products. 
Those products we have licensed to others (e.g. Bio-E/P-Gel) are reliant on our partners for timely development, obtaining required regulatory approvals, commercialization and an ongoing commitment to the products, subject to regulatory and market conditions. From time to time, based on various circumstances including market analysis or a change in the strategic plan of the partner, a partner may elect to restructure its arrangement which may result in entering into a revised agreement or a mutual termination. Any restructuring or termination of these agreements by such partners as Solvay or Teva could adversely affect our business if we are unable to license the proposed products to another qualified partner on substantially the same or better economic terms or continue the development and future commercialization of the proposed products ourselves. 
Description of Our CAP Technology and Products 
We believe our CAP technology will serve as an effective vehicle for delivering drugs and vaccines and enhancing the effects of vaccines. Our CAP nanoparticles have successfully passed the first stage of toxicity studies for administration orally, into muscles, under the skin, and into the lungs by inhalation. We have successfully completed a Phase I human clinical safety trial of CAP. We have entered into several subcontract or development agreements with various corporate partners and governmental entities concerning our CAP technology. 
Overview of CAP Technology. Research and development involving our CAP technology originated in a project under an agreement dated April 6, 1989 between the University of California and one of our predecessor companies, relating to viral protein surface absorption studies. The discovery research was funded at UCLA School of Medicine and was based, in essence, on the use of extremely small, solid, uniform particles as components that could increase the stability of drugs and act as systems to deliver drugs into the body. Research in these areas at UCLA or our laboratory has resulted in the issuance of a number of patents, which we either license from the University of California or own. 
These ultra fine particles are made from inert, biologically acceptable materials, such as ceramics, pure crystalline carbon or biodegradable calcium phosphate-like particles. The size of the particles is in the nanometer range. A nanometer is one millionth of a millimeter and typically particles measure approximately 280 nanometers (nm). For comparison, a polio virus particle is about 27 nm in diameter, a herpes virus particle has a central core measuring 100 nm in diameter, contained in an envelope measuring 150-200 nm, while a tuberculosis bacterium is rod-shaped, about 1,200 nm long by 300 nm across. Because the size of these particles is measured in nanometers, we use the term “nanoparticles” to describe them. 
8 

Table of Contents
We use the nanoparticles as the basis of a delivery system. The critical property of these coated nanoparticles is that biologically active molecules, proteins, peptides or pharmacological agents, for example, vaccine components like bacterial or viral antigens or proteins like insulin, attached to them retain their activity and can be protected from natural alterations to their molecular structure by adverse environmental conditions. It has been shown in studies conducted by us and confirmed by others that when these combinations are injected into animals, the attachment can enhance the biological activity as compared to injection of the molecule alone. 
A major immune response that is triggered by these combination particles is the creation of antibody molecules, which can then specifically counteract an invading virus or bacterium. Similarly, a drug will produce an effect on an organ system only if it can attach to specific receptors on the surface of target cells (e.g., tumor cells). The stabilizing and slow release capabilities of a drug carrier and delivery system based on this discovery can lead to significant advances towards finding more effective and less toxic or harmful molecules to seek out and attach to such receptors. 
We believe our CAP technology has a number of benefits, including the following: 
 	•  	it is biodegradable (capable of being decomposed by natural biological processes) and non-toxic and therefore potentially safe to use and introduce into the human body;		
 	
 	•  	it is fast, easy and inexpensive to manufacture, which should keep costs down and potentially lead to higher profit margins compared to other delivery systems;		
 	
 	•  	the nanometer (one-millionth of a millimeter) size range makes it ideal for delivering drugs through aerosol sprays or through inhalation, instead of using often painful and inconvenient injections; and		
 	
 	•  	it has excellent “loading” capacity — the amount of molecules that can bond with the nanoparticles — thereby potentially decreasing the dose needed to be taken by patients while enhancing the release capabilities.		
Potential Commercial Applications for CAP. We plan to develop commercial applications of our CAP technology and any proprietary technology developed as a result of our ongoing research and development efforts. Initially, we plan to pursue primarily the development of: 
 	•  	injected and non-injected vaccines using CAP as a delivery system and vaccine adjuvant; and		
 	
 	•  	drug delivery systems, including a method of delivering proteins (e.g., insulin) orally or buccally, or through intranasal and subcutaneous routes of administration.		
Our pre-clinical research team in our laboratory in Smyrna, Georgia is currently pursuing the development of our CAP technology in these areas as well as exploring other areas, such as the purification of the milk of transgenic animals and allergy applications. 
Vaccine Adjuvant and Delivery System. We believe that our CAP nanoparticles may offer a means of preparing new improved formulations of current vaccines that are equal or better in their safety and immunogenicity, that is, in their capacity to elicit an immune response, compared to alum-formulated and non-adjuvanted vaccines but may be injected in lower concentrations and less often which could result in certain benefits, including cost savings and improved patient compliance. Also, we believe that CAP will allow for creation of safe and effective vaccines for diseases and conditions for which no vaccines 
9 

Table of Contents
currently exist. Further, we believe that CAP will allow for vaccines to be delivered by alternate routes of administration such as orally or intranasally rather than by injection 
Our nanoparticles when combined with vaccine antigens have been shown in animal studies conducted by us and others to possess an ability to elicit a higher immune response than non-adjuvanted vaccines and an immune response of the same magnitude as alum-formulated vaccines. These preclinical studies also have shown that our CAP nanoparticles also may sustain higher antibody levels over a longer time period than both alum-formulated vaccines and non-adjuvanted vaccines. Because our CAP nanoparticles are made of calcium phosphate-like material, which has a chemical nature similar to normal bone material and therefore is natural to the human body, as opposed to aluminum hydroxide, or alum, which is not natural to the human body, we believe that our nanoparticles may be safer to use than alum. In our animal studies, we observed no material adverse reactions when our CAP nanoparticles were administered at effective levels. 
We filed an investigational new drug, or IND, application with the FDA in July 2000 to commence a Phase I human clinical trial. We completed our Phase I human clinical trial in October 2000. As discussed in more detail under the heading “Government Regulation,” the purpose of a Phase I trial is to evaluate the metabolism and safety of the experimental product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence of possible effectiveness. The Phase I trial of our CAP specifically looked at safety parameters, including local irritation and blood chemistry changes. The trial was completed and there was no apparent difference in the side effects profile between CAP and placebo. 
Drug Delivery Systems. The second field of use in which we are exploring applying our CAP technology involves creating novel and improved forms of delivery of drugs, especially proteins (e.g., insulin). The attachment of drugs to CAP may enhance their effects in the body or enable the addition of further protective coatings to permit oral, delayed-release and mucosal (through mucous membranes) applications. Currently, insulin is given by frequent, inconvenient and often painful injections. However, several companies are in the process of developing and testing products that will deliver insulin orally or through inhalation. We have shown pre-clinical efficacy in the oral delivery of insulin in normal and diabetic mouse models. In the oral insulin mouse models in fasted mice, our proposed product, which we call BioOral, has shown an 80 percent reduction of glucose levels within the first hour of treatment. These reduced glucose levels were maintained for 12 hours versus 20-25 percent glucose reduction for three hours for free insulin. In fed mouse models, our oral formulation reduced glucose levels by 50 percent for six hours versus no significant reduction with free insulin. Furthermore, we believe we may have successfully created a formulation for the inhaled delivery of insulin, which we call BioAir. We are working with potential licensees for the further development of our BioOral and BioAir. Our research and development efforts in these areas are ongoing testing insulin and other drugs that must now be given by injection. Most recently, we have begun to develop a buccal formulation of insulin since buccal administration results in significantly higher bioavailability of insulin and may be better suited to insulin than oral delivery. 
Transgenic Milk Purification and Other Areas. Other fields of use in which we are exploring applying our CAP technology are in the purification of the milk of transgenic animals in which protein drugs are grown and allergy applications. The purification of the milk of transgenic animals in which protein drugs are grown is achieved by selectively isolating biologically active therapeutic proteins from the milk of transgenic animals. This method uses our CAP technology to recover greater than 90 percent of drug protein from the milk in a way that may require less downstream processing and may produce higher overall yields at lower cost than currently used methods. Our method dissolves casein clusters, thereby freeing the drug proteins, and then reforms the casein clusters using CAP as the core. Caseins are then removed from the milk, leaving high concentrations of the drug protein in the remaining crystal clear 
10 

Table of Contents
whey fraction. Since currently there are very limited numbers of companies pursuing transgenic animal drug production, this use of CAP has limited potential. 
CAP Products in Development. The following is a list of our CAP products in development: 
 	•  	BioVant — proprietary CAP adjuvant technology in development for improved versions of current vaccines and new vaccines against cancer, viral and bacterial infections and autoimmune diseases, among others including, biodefense vaccines such as anthrax, malaria and ricin. BioVant also serves as a delivery system for non-injected delivery of vaccines.		
 	
 	•  	BioOral — a delivery system using CAP technology for oral administration (including the buccal route of administration) of proteins and other therapies that currently must be injected.		
 	
 	•  	BioAir — a delivery system using CAP technology for inhalable versions of proteins and other therapies that currently must be injected.		
We have completed a Phase I human clinical trial of CAP as a vaccine adjuvant and delivery system, a necessary step in the process of obtaining FDA approval to market the product. The Phase I trial was a double blind, placebo controlled trial, in 18 subjects to determine the safety of CAP as a vaccine adjuvant. The trial results showed that there was no apparent difference in side-effect profile between CAP and placebo. Phase I and or Phase II clinical trials will need to be repeated for each CAP/vaccine and CAP/protein drug developed. 
We also have conducted preclinical studies of our BioAir delivery system for inhalable insulin. The studies showed that BioAir significantly increased the systemic residence time and duration of action of the insulin, increasing the amount of insulin that became available through the bloodstream (bioavailability) 1.8 times over that of injected insulin. The results indicate that our CAP technology may extend the duration of action many times over that of injecting insulin alone, which could allow diabetics to substantially reduce the number of injections needed to control blood glucose levels. 
License and Development Activities. In addition to continuing our own research and development in the potential commercial applications of our CAP technology, we have sought and continue to seek opportunities to enter into business collaborations or joint ventures with vaccine companies and others interested in development and marketing arrangements with respect to our CAP technology. We believe these collaborations may enable us to accelerate the development of potential improved vaccines and the delivery of injectable drugs by other routes of administration, such as orally, buccally or intranasally. 
Our outlicensing activities with respect to our CAP vaccine adjuvant and delivery system, which we call BioVant, for use in other companies’ vaccines, have to date included meeting with target companies and, in some cases, agreeing that the target company will test our CAP adjuvant and delivery system in their animal models. Thereafter, the target company may send to us its vaccine antigen or DNA that we will then formulate with our nanoparticles and return for use in the target company’s animal models. Once this is completed, if the results are positive, we would hope to negotiate an out-license agreement with the target company. 
In January 2004, we announced the signing of a subcontract with DynPort Vaccine Company LLC for the development of anthrax vaccines for delivery via alternative routes of administration, including nasal, oral and needle-free transcutaneous routes. Under the subcontract, we provide BioVant and DynPort provides recombinant antigens to be used in potential vaccines against anthrax. The objective is to assess the immunogenic potential of BioVant when used in anthrax vaccines versus the immunogenic response of anthrax vaccines that use Alhydrogel as the vaccine adjuvant. The subcontract is in support of the U.S. 
11 

Table of Contents
Department of Defense Joint Vaccine Acquisition Program. We have successfully completed the first year of this three-year contract and have progressed to the second phase. 
In September 2003, we announced that we were awarded a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health to support our development of formulations for the oral delivery of insulin using our CAP technology. We have completed the work outlined under this grant and are currently investigating our options with respect to a Phase II SBIR grant. 
In June 2003, we announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army’s Medical Research Institute of Infectious Disease (USAMRIID) for the development of non-injected biodefense vaccines, including anthrax, staph and ricin. The USAMRIID has agreed to grant us an exclusive license to any U.S. patent application or issued patent as a result of the work under the CRADA. 
In January 2003, we announced the signing of a CRADA with the U.S. Navy’s Naval Medical Research Center’s (NMRC) Malaria Program for the development of a malaria vaccine. The development agreement leverages our expertise with NMRC’s expertise to develop an enhanced vaccine for malaria. Under the agreement, we provide the NMRC with BioVant, our proprietary vaccine adjuvant and delivery system, and the NMRC provides DNA plasmids or proteins encoding antigens for Plasmodium spp., the parasite that causes malaria. It is hoped that the resulting DNA vaccine will improve the effectiveness of the ensuing humoral and cell-mediated immunity against malaria, and therefore, be more effective as it activates both arms of the immune system. 
It is important to point out that vaccine development is an expensive and long-term process. We have used our strategy of utilizing outside resources to fund CAP’s development in order to leverage other company’s and the government’s expertise and to minimize our spending on this long-term and expensive development work. 
Sales and Marketing 
We currently have no sales and marketing personnel to sell on a commercial basis any of our proposed products. Under our sub-license agreements, our sub-licensees have agreed to market the products covered by the agreements in certain countries. If and when we are ready to commercially launch a product not covered by our sub-license agreements, we will either contract with or hire qualified sales and marketing personnel or seek a joint marketing partner or licensee to assist us with this function. In addition, we retain co-promotion rights for Bio-E/P-Gel, the product covered under the Solvay sub-license agreement. 
Research and Product Development 
We expect to spend a significant amount of our financial resources on product development activities, with the largest portion being spent on clinical trials of our hormone therapy products. We spent approximately $9,162,000 in 2004 and $3,691,000 in 2003 on research and development activities. Since we are not yet engaged in the commercial distribution of any products and we have no revenues from the sale of our products, these research and development costs must be financed by us. We spent an average of approximately $700,000 to $800,000 per month on research and development activities in 2004. We expect our research and development expenses to remain at that level for the first quarter of 2005 and then upon the completion of the Phase III trial of our Bio-E-Gel product to decrease until the commencement of our LibiGel Phase III trial, which we expect to commence sometime during the later half of 2005. The amount of our actual research and development expenditures, however, may fluctuate from quarter-to-quarter and year-to-year depending upon: (1) resources available; (2) our development schedule, 
12 

Table of Contents
including the timing of our clinical trials; (3) whether we or our licensees are funding the development of our proposed products; (4) results of studies, clinical trials and regulatory decisions; and (5) competitive developments. 
Manufacturing 
We currently do not have any facilities suitable for manufacturing on a commercial scale basis any of our proposed products nor do we have any experience in volume manufacturing. Our plan is to use third-party current Good Manufacturing Practices, or cGMP, manufacturers to manufacture our proposed products in accordance with FDA and other appropriate regulations. Our gel hormone products for use in clinical trials are currently manufactured by a U.S.-based cGMP approved manufacturer. 
Patents, Licenses and Proprietary Rights 
Our success depends and will continue to depend in part upon our ability to maintain our exclusive licenses, to maintain patent protection for our products and processes, to preserve our proprietary information and trade secrets and to operate without infringing the proprietary rights of third parties. Our policy is to attempt to protect our technology by, among other things, filing patent applications or obtaining license rights for technology that we consider important to the development of our business. 
Hormone Therapy Products. In June 2000, we entered into a license agreement with Antares Pharma, Inc. pursuant to which Antares granted us an exclusive license to four proposed hormone therapy products including rights to sublicense the hormone therapy products, in order to develop and market the hormone therapy products in certain territories. Antares has an issued patent for these products in the United States and has filed additional patent applications for this licensed technology in the U.S. and several foreign jurisdictions, including Argentina, Australia, Canada, Europe, Italy, Japan, Korea, New Zealand, South Africa, and Taiwan. 
In a series of amendments executed during 2001 between us and Antares, we returned to Antares the license rights to one of the four previously licensed hormone products, namely the estradiol patch, in all countries of the licensed territory. Additionally, it was agreed that we are the owner of Bio-T-Gel, our testosterone gel for men with no milestone or royalty obligations to Antares. We also returned to Antares the license rights to the single entity estrogen and testosterone gel products in Malaysia and Australia. In exchange for the return to Antares of the estradiol patch in all the countries and the single entity estradiol and testosterone gel products in Malaysia and Australia, Antares granted us a credit for approximately $600,000 of manufacturing and formulation services and a license for a transdermal hormone therapy gel combination of testosterone and estradiol. In August 2002 and December 2002, BioSante and Antares further amended the license agreement to clarify interpretations of the license agreement, including products covered by the license agreement, and to terminate a supply agreement with Antares. 
The license agreement with Antares required us to pay a $1,000,000 up-front license fee to Antares, which we paid in June 2000. Also pursuant to the terms of the Antares license agreement, we expect to: 
 	•  	pay royalties to Antares based on a percentage of the net sales of any products we or our sublicensees sell incorporating the licensed technology;		
 	
 	•  	develop the hormone product portfolio, including:		
 	Ø  	testing proposed products;		
 	
 	Ø  	conducting clinical trials;		
13 

Table of Contents
 	Ø  	obtaining government approvals;		
 	
 	Ø  	introducing products incorporating the licensed technology into the market; and		
 	•  	enter into sublicense arrangements or agreements with other entities regarding development and commercialization of the products covered by the license.	
In August 2001, we entered into a sublicense agreement with Solvay Pharmaceuticals, B.V. covering the U.S. and Canadian rights to the estrogen/progestogen combination transdermal hormone therapy gel product licensed from Antares. Under the terms of the agreement, Solvay sublicenses our estrogen/progestogen combination transdermal hormone therapy gel product for an initial payment of $2.5 million ($1.7 million net of the related payments due to Antares and Paladin Labs Inc.), future milestone payments and escalating sales-based royalties. During the third quarter ended September 30, 2002, we received a $950,000 milestone payment pursuant to the Solvay sublicense agreement. Solvay is responsible for all costs of development and marketing of the product. We have retained co-promotion rights to the product and will be compensated for sales generated by us over and above those attributable to Solvay’s marketing efforts. As described further below, the Canadian rights to this product had previously been sublicensed to Paladin as part of that sublicense arrangement and were repurchased by us prior to the Solvay transaction in exchange for $125,000, paid by the issuance of 17,361 shares of our common stock with a market value of $125,000 at the date of the transaction. 
In September 2000, we sublicensed the marketing rights to our portfolio of female hormone therapy products in Canada to Paladin Labs Inc. In exchange for the sublicense, Paladin agreed to make an initial investment in our company, make future milestone payments and pay royalties on sales of the products in Canada. The milestone payments will be in the form of a series of equity investments by Paladin in our common stock at a 10 percent premium to the market price of our stock at the time the equity investment is made. Upon execution of the sublicense agreement, Paladin made an initial investment of $500,000 in our company in the form of a convertible debenture, convertible into our common stock at $10.50 per share. In August 2001, we exercised our right and declared the debenture converted in full. Accordingly, 47,619 shares of our common stock were issued to Paladin in August 2001. During the third quarter 2001, Paladin made a series of equity investments in BioSante as a result of certain sub-licensing transactions and BioSante reaching certain milestones. These equity investments resulted in issuing an additional 18,940 shares of our common stock to Paladin. 
In April 2002, we exclusively in-licensed from Wake Forest University and Cedars-Sinai Medical Center three issued U.S. patents claiming triple hormone therapy (the combination use of estrogen plus progestogen plus androgen, e.g. testosterone) and an option for triple hormone contraception. The financial terms of the license include an upfront payment by us, regulatory milestones, maintenance payments and royalty payments by us if the product gets approved and subsequently marketed. 
In December 2002, we entered into a development and license agreement with Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which Teva USA agreed to develop one of our hormone therapy products for the U.S. market. The financial terms of the development and license agreement included a $1.5 million upfront payment by Teva USA and royalties on sales of the commercialized product upon approval in exchange for rights to develop and market a hormone therapy product. Teva USA is also responsible under the terms of this agreement for continued development, regulatory filings and all manufacturing and marketing associated with the product. 
14 

Table of Contents
CAP Technology. In June 1997, we entered into a licensing agreement with the Regents of the University of California, which has subsequently been amended, pursuant to which the University has granted us an exclusive license to nine United States patents owned by the University, including rights to sublicense such patents, in fields of use initially pertaining to: (1) vaccine adjuvants; (2) vaccine constructs or combinations for use in immunization against herpes virus; (3) drug delivery systems; and (4) red blood cell surrogates. The University of California has filed patent applications for this licensed technology in several foreign jurisdictions, including Canada, Europe and Japan. 
The license agreement with the University of California requires us to undertake various obligations, including: 
 	•  	payment of royalties to the University based on a percentage of the net sales of any products we sell or a licensee sells, incorporating the licensed technology;		
 	
 	•  	payment of minimum annual royalties on February 28 of each year beginning for the year 2004 to be credited against earned royalties, for the life of the agreement;		
 	
 	•  	maintaining an annual minimum amount of available capital for development and commercialization of products incorporating the licensed technology until a product is introduced to the market;		
 	
 	•  	payment of the costs of patent prosecution and maintenance of the patents included in the agreement, which amounted to $13,404 in fiscal 2004;		
 	
 	•  	meeting performance milestones relating to:		
 	Ø  	hiring or contracting with personnel to perform research and development, regulatory and other activities relating to the commercial launch of a proposed product;		
 	
 	Ø  	testing proposed products;		
 	
 	Ø  	conducting clinical trials;		
 	
 	Ø  	obtaining government approvals;		
 	
 	Ø  	introducing products incorporating the licensed technology into the market; and		
 	•  	entering into partnership or alliance arrangements or agreements with other entities regarding commercialization of the technology covered by the license.	
The license agreement further provides that we have the right to abandon any project in any field of use without abandoning our license to pursue other projects in that or other fields of use covered by the agreement. In May 1999, we notified the University that we would not pursue the red blood cell surrogate use because we did not believe it would be proven an effective use of CAP. In October 1999, we signed an amendment to our license agreement with the University, which removed the red-blood cell surrogate use from the agreement. In addition, under the terms of the amendment, the University agreed to make other changes we suggested to the license agreement, including delaying minimum royalty payments until 2004 and limiting the University’s rights to terminate the agreement in cases where we do not perform under the agreement. If we violate or fail to perform any term or covenant of the license agreement and fail to cure this default within 60 days after written notice from the University, the University may terminate some projects included in the agreement. In May 2001, we signed a second amendment to our license agreement with the University to amend certain provisions of the license agreement for sublicensing arrangements with third parties. In June 2004, we signed a third amendment to our license agreement with the University to further amend certain provisions of the license agreement. 
15 

Table of Contents
Patents and patent applications. We own two United States patents and one foreign patent. In June 1999, we filed a patent application for our advanced method of selectively isolating biologically active therapeutic proteins from transgenic milk. This patent issued in February 2001. In February 2000, we filed a patent application with the U.S. Patent and Trademark Office relating to our development work with CAP, including its applications as a vaccine adjuvant, as a carrier for biologically active material and as part of a controlled release matrices for biologically active material. A patent directed to methods of formulating the CAP particles issued in March 2002. In addition, we have other patent applications pending in the U.S. and internationally for CAP products in development. 
Trademarks and trademark applications. We have filed trademark applications in the U.S. for the mark BIOSANTE for vaccines and vaccine adjuvants, drug delivery platforms, and for our proposed hormone therapy products. The BIOSANTE mark is registered for the hormone preparations. Another application that includes vaccines and vaccine adjuvants, drug delivery platforms and hormone preparations has been allowed and will register upon submission of proof of use. We have also filed U.S. trademark applications for the marks BIOVANT, BIOAIR, NANOVANT and LIBIGEL. Two other U.S. trademark applications are pending and have been allowed for BIO-E-GEL and BIO-T-GEL for products in development. The BIOSANTE mark is also registered in the European Union and Israel; BIOAIR is registered in the European Union and Israel; BIOVANT is registered in Israel and Mexico; NANOVANT is registered in the European Union, Israel and Mexico; and BIO-E-GEL and BIO-T-GEL are registered in Mexico. There are 17 other applications pending in the European Union, Canada, Mexico, Japan, China, Australia, Norway, and Switzerland, eight of them for LIBIGEL. We do not have any other registered trademarks. 
Confidentiality and assignment of inventions agreements. We require our employees, consultants and advisors having access to our confidential information to execute confidentiality agreements upon commencement of their employment or consulting relationships with us. These agreements generally provide that all confidential information we develop or make known to the individual during the course of the individual’s employment or consulting relationship with us must be kept confidential by the individual and not disclosed to any third parties. We also require all of our employees and consultants who perform research and development for us to execute agreements that generally provide that all inventions conceived by these individuals during their employment by BioSante will be our property. 
Competition 
There is intense competition in the biopharmaceutical industry, including in the hormone therapy market, the market for prevention and/or treatment of the same infectious diseases we target and in the acquisition of products in the late-stage development phase or already on the market. Potential competitors in the United States are numerous and include major pharmaceutical and specialized biotechnology companies, universities and other institutions. In general, competition in the pharmaceutical industry can be divided into four categories: (1) corporations with large research and developmental departments that develop and market products in many therapeutic areas; (2) companies that have moderate research and development capabilities and focus their product strategy on a small number of therapeutic areas; (3) small companies with limited development capabilities and only a few product offerings; and (4) university and other research institutions. All of our competitors in categories (1) and (2) and some of our competitors in category (3) have longer operating histories, greater name recognition, substantially greater financial resources and larger research and development staffs than we do, as well as substantially greater experience than us in developing products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. A significant amount of research in the field is being carried out at academic and government institutions. These institutions are becoming increasingly aware of the commercial value of their findings and are becoming more aggressive in pursuing patent protection and negotiating licensing arrangements to collect royalties for use of technology that they have developed. 
16 

Table of Contents
We expect our products, if and when approved for sale, to compete primarily on the basis of product efficacy, safety, patient convenience, reliability and patent position. In addition, the first product to reach the market in a therapeutic or preventative area is often at a significant competitive advantage relative to later entrants in the market and may result in certain marketing exclusivity as per federal legislation. Acceptance by physicians and other health care providers, including managed care groups, is also critical to the success of a product versus competitor products. 
There are several firms currently marketing or developing hormone therapy products similar to ours. They include The Procter & Gamble Company, Noven Pharmaceuticals, Inc., Novavax, Inc., Cellegy Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and Solvay Pharmaceuticals, Inc. Competitor hormone therapy products include oral tablets, transdermal patches, creams and gels. 
With regard to our CAP technology, the international vaccine industry is dominated by three companies: GlaxoSmithKline, Aventis (through its subsidiaries, including Institut Merieux International, Pasteur Merieux Serums et Vaccins, Connaught Laboratories Limited and Connaught Laboratories, Inc.) and Merck & Co., Inc. The larger, better known pharmaceutical companies have generally focused on a traditional synthetic drug approach, although some have substantial expertise in biotechnology. During the last decade, however, significant research activity in the biotechnology industry has been completed by smaller research and development companies, like us, formed to pursue new technologies. Competitive or comparable companies to us include Corixa Corporation, generally regarded as a leader in vaccine adjuvant development and ID Biomedical Corporation, which both develop sub-unit vaccines from mycobacteria and other organisms. 
Governmental Regulation 
Pharmaceutical products intended for therapeutic use in humans are governed by extensive FDA regulations in the United States and by comparable regulations in foreign countries. Any products developed by us will require FDA approvals in the United States and comparable approvals in foreign markets before they can be marketed. The process of seeking and obtaining FDA approval for a previously unapproved new human pharmaceutical product generally requires a number of years and involves the expenditure of substantial resources. 
Following drug discovery, the steps required before a drug product may be marketed in the United States include: 
 	•  	preclinical laboratory and animal tests;		
 	
 	•  	the submission to the FDA of an investigational new drug application, commonly known as an IND application;		
 	
 	•  	clinical and other studies to assess safety and parameters of use;		
 	
 	•  	adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug product;		
 	
 	•  	the submission to the FDA of a new drug application, commonly known as an NDA; and		
 	
 	•  	FDA approval of the NDA prior to any commercial sale or shipment of the product.		
17 

Table of Contents
Typically, preclinical studies are conducted in the laboratory and in animals to gain preliminary information on a proposed product’s uses and physiological effects and harmful effects, if any, and to identify any potential safety problems that would preclude testing in humans. The results of these studies, together with the general investigative plan, protocols for specific human studies and other information, are submitted to the FDA as part of the IND application. The FDA regulations do not, by their terms, require FDA approval of an IND. Rather, they allow a clinical investigation to commence if the FDA does not notify the sponsor to the contrary within 30 days of receipt of the IND. As a practical matter, however, FDA approval is often sought before a company commences clinical investigations. That approval may come within 30 days of IND receipt but may involve substantial delays if the FDA requests additional information. 
The initial phase of clinical testing, which is known as Phase I, is conducted to evaluate the metabolism, uses and physiological effects of the experimental product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence of possible effectiveness. Phase I studies can also evaluate various routes, dosages and schedules of product administration. These studies generally involve a small number of healthy volunteer subjects, but may be conducted in people with the disease the product is intended to treat. The total number of subjects is generally in the range of 20 to 80. A demonstration of therapeutic benefit is not required in order to complete Phase I trials successfully. If acceptable product safety is demonstrated, Phase II trials may be initiated. 
Phase II trials are designed to evaluate the effectiveness of the product in the treatment of a given disease and involve people with the disease under study. These trials often are well controlled, closely monitored studies involving a relatively small number of subjects, usually no more than several hundred. The optimal routes, dosages and schedules of administration are determined in these studies. If Phase II trials are completed successfully, Phase III trials are often commenced, although Phase III trials are not always required. 
Phase III trials are expanded, controlled trials that are performed after preliminary evidence of the effectiveness of the experimental product has been obtained. These trials are intended to gather the additional information about safety and effectiveness that is needed to evaluate the overall risk/benefit relationship of the experimental product and provide the substantial evidence of effectiveness and the evidence of safety necessary for product approval. Phase III trials usually include from several hundred to several thousand subjects. 
A clinical trial may combine the elements of more than one Phase and typically two or more Phase III studies are required. A company’s designation of a clinical trial as being of a particular Phase is not necessarily indicative that this trial will be sufficient to satisfy the FDA requirements of that Phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. In addition, a clinical trial may contain elements of more than one Phase notwithstanding the designation of the trial as being of a particular Phase. The FDA closely monitors the progress of the phases of clinical testing and may, at its discretion, re-evaluate, alter, suspend or terminate the testing based on the data accumulated and its assessment of the risk/benefit ratio to patients. It is not possible to estimate with any certainty the time required to complete Phase I, II and III studies with respect to a given product. 
Upon the successful completion of clinical testing, an NDA is submitted to the FDA for approval. This application requires detailed data on the results of preclinical testing, clinical testing and the composition of the product, specimen labeling to be used with the drug, information on manufacturing methods and samples of the product. The FDA typically takes from 10 to 18 months to review an NDA after it has been accepted for filing. Following its review of an NDA, the FDA invariably raises questions or requests additional information. The NDA approval process can, accordingly, be very lengthy. Further, 
18 

Table of Contents
there is no assurance that the FDA will ultimately approve an NDA. If the FDA approves that NDA, the new product may be marketed. The FDA often approves a product for marketing with a modification to the proposed label claims or requires that post-marketing surveillance, or Phase IV testing, be conducted. 
All facilities and manufacturing techniques used to manufacture products for clinical use or sale in the United States must be operated in conformity with “current good manufacturing practice” regulations, commonly referred to as “cGMP” regulations, which govern the production of pharmaceutical products. We currently do not have manufacturing capability. In the event we undertake any manufacturing activities or contract with a third-party manufacturer to perform our manufacturing activities, we intend to establish a quality control and quality assurance program to ensure that our products are manufactured in accordance with the cGMP regulations and any other applicable regulations. 
Products marketed outside of the United States are subject to regulatory approval requirements similar to those in the United States, although the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary widely from country to country. No action can be taken to market any product in a country until an appropriate application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain European countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. We intend to seek and utilize foreign partners to apply for foreign approvals of our products. 
Employees 
We had 17 full-time employees as of December 31, 2004, including 13 in product development and four in management or administrative positions. None of our employees is covered by a collective bargaining agreement. 
Forward-Looking Statements 
This Annual Report on Form 10-KSB contains or incorporates by reference not only historical information, but also forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In addition, we or others on our behalf may make forward-looking statements from time to time in oral presentations, including telephone conferences and/or web casts open to the public, in press releases or reports, on our Internet web site or otherwise. Statements that are not historical are forward-looking and reflect expectations and assumptions. We try to identify forward-looking statements in this report and elsewhere by using words such as “may,” “will,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “continue” or the negative of these or similar terms. Our forward-looking statements generally relate to: 
 	•  	the timing of the commencement and completion of our clinical trials and other regulatory status of our proposed products;		
 	
 	•  	our spending capital on research and development programs, pre-clinical studies and clinical trials, regulatory processes, establishment of marketing capabilities and licensure or acquisition of new products;		
 	
 	•  	our existing cash and whether and how long these funds will be sufficient to fund our operations;		
 	
 	•  	our need and ability to raise additional capital through future equity and other financings; and		
19 

Table of Contents
 	•  	our substantial and continuing losses.	
Forward-looking statements involve risks and uncertainties. These uncertainties include factors that affect all businesses as well as matters specific to BioSante. Below are some of the factors known to us that could cause our actual results to differ materially from what we have anticipated in our forward-looking statements. 
We wish to caution readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described above, as well as others that we may consider immaterial or do not anticipate at this time. The foregoing risks and uncertainties are not exclusive and further information concerning the company and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. We assume no obligation to update forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our quarterly reports on Form 10-Q and current reports on Form 8-K we file with or furnish to the Securities and Exchange Commission. 
We have a history of operating losses, expect continuing losses and may never achieve profitability. 
We have incurred losses in each year since our amalgamation in 1996 and expect to incur substantial and continuing losses for the foreseeable future. We incurred a net loss of $12,016,207 for the year ended December 31, 2004, and as of December 31, 2004, our accumulated deficit was $40,037,284. 
All of our revenue to date has been derived from upfront and milestone payments earned on licensing and sub-licensing transactions and revenue earned from a subcontract. We have not commercially introduced any products. We expect to incur substantial and continuing losses for the foreseeable future as our own product development programs expand and various preclinical and clinical trials commence. The amount of these losses may vary significantly from year-to-year and quarter-to-quarter and will depend on, among other factors: 
 	•  	the timing and cost of product development;		
 	
 	•  	the progress and cost of preclinical and clinical development programs;		
 	
 	•  	the costs of licensure or acquisition of new products;		
 	
 	•  	the timing and cost of obtaining necessary regulatory approvals;		
 	
 	•  	the timing and cost of obtaining third party reimbursement; and		
 	
 	•  	the timing and cost of sales and marketing activities.		
In order to generate new and significant revenues, we must successfully develop and commercialize our own proposed products or enter into collaborative agreements with others who can successfully develop and commercialize them. Even if our proposed products and the products we may license or otherwise acquire are commercially introduced, they may never achieve market acceptance and we may never generate significant revenues or achieve profitability. 
20 

Table of Contents
We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms. 
We currently do not have sufficient resources to complete the commercialization of any of our proposed products. Therefore, we will need to raise substantial additional capital to fund our operations sometime in the future. Based on our current rate of cash outflows, we believe that our cash and short-term investments of $17,268,688 at December 31, 2004, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next 12 months. We have based this estimate on assumptions, however, that may prove to be wrong. As a result, we may need to obtain additional financing prior to that time. Our future capital requirements will depend upon numerous factors, including: 
 	•  	the progress and costs of our research and development programs;		
 	
 	•  	the scope, timing and results of our clinical trials;		
 	
 	•  	patient recruitment and enrollment in our current and future clinical trials;		
 	
 	•  	the cost, timing and outcome of regulatory reviews;		
 	
 	•  	the rate of technological advances;		
 	
 	•  	ongoing determinations of the potential commercial success of our proposed products;		
 	
 	•  	our general and administrative expenses, and if we receive FDA approval of any of our proposed products and choose to commercialize them ourselves, the amount of resources we devote to sales and marketing capabilities;		
 	
 	•  	the activities of our competitors; and		
 	
 	•  	our opportunities to acquire new products or take advantage of other unanticipated opportunities.		
We cannot be certain that any financing will be available when needed or will be on terms acceptable to us. Insufficient funds may require us to delay, scale back or eliminate some or all of our programs designed to obtain regulatory approval of our proposed products, facilitate the commercial introduction of our proposed products, prevent commercial introduction of our products altogether or restrict us from acquiring new products that we believe may be beneficial to our business. 
We are a development stage company, making it difficult for you to evaluate our business and your investment. 
We are in the development stage and our operations and the development of our proposed products are subject to all of the risks inherent in the establishment of a new business enterprise, including: 
 	•  	the absence of an operating history;		
 	
 	•  	the lack of commercialized products;		
 	
 	•  	insufficient capital;		
 	
 	•  	expected substantial and continual losses for the foreseeable future;		
21 

Table of Contents
 	•  	limited experience in dealing with regulatory issues;		
 	
 	•  	limited marketing and manufacturing experience;		
 	
 	•  	an expected reliance on third parties for the development and commercialization of some of our proposed products;		
 	
 	•  	a competitive environment characterized by numerous, well-established and well-capitalized competitors;		
 	
 	•  	uncertain market acceptance of our proposed products; and		
 	
 	•  	reliance on key personnel.		
Because we are subject to these risks, you may have a difficult time evaluating our business and your investment in our company. 
Our proposed products are in the development stages and will likely not be commercially introduced for several years, if at all. 
Our proposed products are in the development stages and will require further development, preclinical and clinical testing and investment prior to commercialization in the United States and abroad. We have not commercially introduced any products and do not expect to do until mid-2006 at the earliest depending upon the timing of our filing with FDA of a New Drug Application with respect to our Bio-E-Gel product and the approval of such application. We cannot assure you that any of our proposed products will: 
 	•  	be successfully developed;		
 	
 	•  	prove to be safe and efficacious in clinical trials;		
 	
 	•  	meet applicable regulatory standards or obtain required regulatory approvals;		
 	
 	•  	demonstrate substantial protective or therapeutic benefits in the prevention or treatment of any disease;		
 	
 	•  	be capable of being produced in commercial quantities at reasonable costs;		
 	
 	•  	obtain coverage and favorable reimbursement rates from insurers and other third-party payors; or		
 	
 	•  	be successfully marketed or achieve market acceptance by physicians and patients.		
If we fail to obtain regulatory approval to commercially manufacture or sell any of our future products, or if approval is delayed or withdrawn, we will be unable to generate revenue from the sale of our products. 
We must obtain regulatory approval to sell any of our products in the United States and abroad. In the United States, we must obtain the approval of the FDA for each product or drug that we intend to commercialize. The FDA approval process is typically lengthy and expensive, and approval is never certain. Products to be commercialized abroad are subject to similar foreign government regulation. 
22 

Table of Contents
Generally, only a very small percentage of newly discovered pharmaceutical products that enter preclinical development are approved for sale. Because of the risks and uncertainties in biopharmaceutical development, our proposed products could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. If regulatory approval is delayed or never obtained, our management’s credibility, the value of our company and our operating results and liquidity would be adversely affected. Furthermore, even if a product gains regulatory approval, the product and the manufacturer of the product may be subject to continuing regulatory review. Even after obtaining regulatory approval, we may be restricted or prohibited from marketing or manufacturing a product if previously unknown problems with the product or its manufacture are subsequently discovered. The FDA may also require us to commit to perform lengthy post-approval studies, for which we would have to expend significant additional resources, which could have an adverse effect on our operating results and financial condition. 
To obtain regulatory approval to market our products, costly and lengthy pre-clinical studies and human clinical trials are required, and the results of the studies and trials are highly uncertain. 
As part of the FDA approval process, we must conduct, at our own expense or the expense of current or potential licensees, clinical trials on humans on each of our proposed products. Pre-clinical studies on animals must be conducted on some of our proposed products. We expect the number of pre-clinical studies and human clinical trials that the FDA will require will vary depending on the product, the disease or condition the product is being developed to address and regulations applicable to the particular product. We may need to perform multiple pre-clinical studies using various doses and formulations before we can begin human clinical trials, which could result in delays in our ability to market any of our products. Furthermore, even if we obtain favorable results in pre-clinical studies on animals, the results in humans may be different. 
After we have conducted pre-clinical studies in animals, we must demonstrate that our products are safe and effective for use on the target human patients in order to receive regulatory approval for commercial sale. The data obtained from pre-clinical and human clinical testing are subject to varying interpretations that could delay, limit or prevent regulatory approval. We face the risk that the results of our clinical trials in later phases of clinical trials may be inconsistent with those obtained in earlier phases. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after experiencing promising results in early animal or human testing. Adverse or inconclusive human clinical results would prevent us from filing for regulatory approval of our products. Additional factors that can cause delay or termination of our human clinical trials include: 
 	•  	slow patient enrollment;		
 	
 	•  	timely completion of clinical site protocol approval and obtaining informed consent from subjects;		
 	
 	•  	longer treatment time required to demonstrate efficacy or safety;		
 	
 	•  	adverse medical events or side effects in treated patients; and		
 	
 	•  	lack of effectiveness of the product being tested.		
Delays in our clinical trials could allow our competitors additional time to develop or market competing products and thus can be extremely costly in terms of lost sales opportunities and increased clinical trial costs. 
23 

Table of Contents
A decision by the FDA to require Procter & Gamble to conduct additional studies to learn more about the long-term safety of testosterone treatment in women for FSD prior to granting approval of Procter & Gamble’s Intrinsa testosterone patch could increase the time, cost and expense of obtaining regulatory approval for our LibiGel product, which might cause us to abandon the product depending on the extent of the additional time and cost to develop LibiGel. 
In December 2004, the FDA’s Reproductive Health Drugs Advisory Committee panel voted unanimously against recommendation for approval of Procter & Gamble’s Intrinsa testosterone patch for hypoactive sexual desire disorder. The panel’s main concern was the desire to have long-term safety data particularly as it pertains to potential increased risk of cardiovascular disease and breast cancer in women treated chronically with testosterone in combination with estrogen. Currently, the FDA has not publicly stated nor set any type of public policy as to what additional duration of a safety trial would be required for approval. This FDA action with respect to Intrinsa or testosterone products in general may impact the regulatory pathway for our LibiGel product, as well as other similarly competitive products to treat FSD with testosterone therapy. If the FDA requires Procter & Gamble to conduct additional studies to learn more about the long-term safety of testosterone treatment in women for FSD prior to granting approval of Procter & Gamble’s Intrinsa testosterone patch, such a decision could increase the time, cost and expense of obtaining regulatory approval for our LibiGel product, which might cause us to abandon further development of the product depending on the extent of the additional time and cost to develop LibiGel. 
Several pharmaceutical products were recently found to have potentially life threatening side effects and have been subsequently removed from the market. These drugs had been previously approved for sale by the FDA. The withdrawals of approved drugs from the market create an increased risk for the pharmaceutical industry in general and an increased risk specifically for our proposed products that they may not receive the required regulatory approval on a timely basis or ever. 
Several drugs have been recently removed from the market. Most recently, the withdrawal of Vioxx by Merck & Co., Inc. and Tysabri by Biogen Idec Inc. has increased safety concerns of various groups including physicians, patients, members of U.S. Congress and the FDA. Although marketed product withdrawals have occurred over time, the recent withdrawals may result in a more cautious approach by the FDA in terms of requirements for approval of new products before approval to market is granted. These recent withdrawals could also result in additional requirements for safety monitoring called pharmacovigilence after approval to market is granted. This collective concern could result in longer, more expensive clinical trials before approval and costly post-marketing surveillance programs and at the same time could affect physicians’ desire to prescribe new medication before they are on the market for a long period of time, all of which would adversely affect our business, operating results and financial condition. 
Uncertainties associated with the impact of published studies regarding the adverse health effects of certain forms of hormone therapy could adversely affect the market for hormone therapy products and the trading price of our common stock. 
The market for hormone therapy products has been negatively affected by the Women’s Health Initiative study and other studies that have found that the overall health risks from the use of certain hormone therapy products exceed the benefits from the use of those products among healthy postmenopausal women. In July 2002, the National Institutes of Health (NIH) released data from its Women’s Health Initiative (WHI) study on the risks and benefits associated with long-term use of oral hormone therapy by healthy women. The NIH announced that it was discontinuing the arm of the study investigating the use of oral estrogen/progestin combination hormone therapy products after an average follow-up period of 5.2 years because the product used in the study was shown to cause an increase in the risk of invasive breast cancer. The study also found an increased risk of stroke, heart attacks and blood clots and concluded that 
24 

Table of Contents
overall health risks exceeded benefits from use of combined estrogen plus progestin for an average of 5.2 year follow-up among healthy postmenopausal women. Also in July 2002, results of an observational study sponsored by the National Cancer Institute on the effects of estrogen therapy were announced. The main finding of the study was that postmenopausal women who used estrogen therapy for 10 or more years had a higher risk of developing ovarian cancer than women who never used hormone therapy. In October 2002, a significant hormone therapy study being conducted in the United Kingdom was also halted. Our proposed hormone therapy products differ from the products used in the Women’s Health Initiative study and the primary products observed in the National Cancer Institute and United Kingdom studies. In March 2004, the NIH announced that the estrogen-alone study was discontinued after nearly seven years because the NIH concluded that estrogen alone does not affect (either increase or decrease) heart disease, the major question being evaluated in the study. The findings indicated a slightly increased risk of stroke as well as a decreased risk of hip fracture and breast cancer. Preliminary data from the memory portion of the WHI study suggested that estrogen alone may possibly be associated with a slight increase in the risk of dementia or mild cognitive impairment. Researchers continue to analyze data from both arms of the WHI study and other studies. There currently are no studies published comparing the safety of our proposed hormone therapy products against other hormone therapies. The markets for female hormone therapies for menopausal symptoms have declined as a result of these published studies. The release of any follow-up or other studies that show adverse affects from hormone therapy, including in particular, hormone therapies similar to our proposed products, would also adversely affect our business. 
Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, manufacturing and marketing than us, we may not succeed in developing our proposed products and bringing them to market. 
Competition in the pharmaceutical industry is intense. Potential competitors in the United States and abroad are numerous and include pharmaceutical, chemical and biotechnology companies, most of which have substantially greater capital resources and more experience in research and development, manufacturing and marketing than us. Academic institutions, hospitals, governmental agencies and other public and private research organizations are also conducting research and seeking patent protection and may develop and commercially introduce competing products or technologies on their own or through joint ventures. We cannot assure you that our competitors (some of whom are our development partners) will not succeed in developing similar technologies and products more rapidly than we do, commercially introducing such technologies and products to the marketplace prior than us, or that these competing technologies and products will not be more effective or successful than any of those that we currently are developing or will develop. 
We license the technology underlying most of our proposed hormone therapy products and a portion of our CAP technology from third parties and may lose the rights to license them, which could have a material adverse effect on our business, financial position and operating results and could cause the market value of our common stock to decline. 
We license most of the technology underlying our proposed hormone therapy products from Antares Pharma, Inc. and a portion of our CAP technology from the University of California. We may lose our right to license these technologies if we breach our obligations under the license agreements. Although we intend to use our reasonable best efforts to meet these obligations, if we violate or fail to perform any term or covenant of the license agreements or with respect to the University of California’s license agreement within 60 days after written notice from the University of California, the other party to these agreements may terminate these agreements or certain projects contained in these agreements. The termination of these agreements, however, will not relieve us of our obligation to pay any royalty or license fees owing at the time of termination. Our failure to retain the right to license the technology 
25 

Table of Contents
underlying our proposed hormone therapy products or CAP technology could harm our business and future operating results. For example, if we were to enter into an outlicense agreement with a third party under which we agree to outlicense our hormone therapy technology or CAP technology for a license fee, the termination of the main license agreement with Antares Pharma, Inc. or the University of California could either, depending upon the terms of the outlicense agreement, cause us to breach our obligations under the outlicense agreement or give the other party a right to terminate that agreement, thereby causing us to lose future revenue generated by the outlicense fees. 
We have licensed two of our proposed hormone therapy products to third parties and any breach by these parties of their obligations under these sublicense agreements or a termination of these sublicense agreements by these parties could adversely affect our business. In addition, these third parties also may compete with us with respect to some of our proposed products. 
We have licensed two of our proposed hormone therapy product to third parties, Solvay Pharmaceuticals, B.V. and Teva Pharmaceuticals USA, Inc., which have agreed to be responsible for continued development, regulatory filings and manufacturing and marketing associated with the products. These proposed products are thus subject to not only customary and inevitable uncertainties associated with the drug development process, regulatory approvals and market acceptance of products, but also depend on the respective licensees for timely development, obtaining required regulatory approvals, commercialization and otherwise continued commitment to the products. Solvay and Teva may have different and, sometimes, competing priorities. We cannot assure you that Solvay and Teva will remain focused on the development and commercialization of our partnered products or will not otherwise breach the terms of our agreements with them, especially since these third parties may also compete with us with respect to some of our proposed products. Any breach by Solvay or Teva of their obligations under these agreements or a termination of these agreements by these parties could adversely affect our business if we are unable to sublicense the proposed products to another party on substantially the same or better terms or continue the development and future commercialization of the proposed products ourselves. 
We do not have any facilities appropriate for clinical testing, we lack significant manufacturing experience and we have very limited sales and marketing personnel. We are currently dependent upon our licensees or others for several of these functions and may remain dependent upon others for these functions. 
We do not have a manufacturing facility that can be used for production of our products. In addition, at this time, we have very limited sales and marketing personnel. We are currently dependent upon our licensees or others for several of these functions. In the course of our development program, we may be required to enter into additional arrangements with other companies, universities or clinical investigators for our animal testing, human clinical testing, manufacturing and sales and marketing activities. Alternatively, we may decide to add additional personnel and perform some of these functions ourselves, such as sales and marketing activities. If our licensees or other third parties in which we have entered into agreements breach their obligations under our agreements to perform these functions or if we are otherwise unable to retain third parties for these purposes on acceptable terms or perform such functions successfully ourselves, we may be unable to successfully develop, manufacture and market our proposed products. In addition, any failures by our licensees or other third parties to adequately perform their responsibilities may delay the submission of our proposed products for regulatory approval, impair our ability to deliver our products on a timely basis or otherwise impair our competitive position. Our dependence on our licensees and other third parties for the development, manufacture, sale and marketing of our products also may adversely affect our profit margins. 
26 

Table of Contents
Even if our proposed products receive FDA approval, they may not achieve expected levels of market acceptance, which could have a material adverse effect on our business, financial position and operating results and could cause the market value of our common stock to decline. 
Even if we are able to obtain required regulatory approvals for our proposed products, the success of those products is dependent upon market acceptance by physicians and patients. Levels of market acceptance for our new products could be impacted by several factors, including: 
 	•  	the availability of alternative products from competitors;		
 	
 	•  	the price of our products relative to that of our competitors;		
 	
 	•  	the timing of our market entry; and		
 	
 	•  	the ability to market our products effectively.		
Some of these factors are not within our control. Our proposed products may not achieve expected levels of market acceptance. Additionally, continuing studies of the proper utilization, safety and efficacy of pharmaceutical products are being conducted by the industry, government agencies and others. Such studies, which increasingly employ sophisticated methods and techniques, can call into question the utilization, safety and efficacy of previously marketed products. In some cases, these studies have resulted, and may in the future result, in the discontinuance of product marketing. These situations, should they occur, could have a material adverse effect on our business, financial position and results of operations, and the market value of our common stock could decline. 
Because the pharmaceutical industry is heavily regulated, we face significant costs and uncertainties associated with our efforts to comply with applicable regulations. Should we fail to comply we could experience material adverse effects on our business, financial position and results of operations, and the market value of our common stock could decline. 
The pharmaceutical industry is subject to regulation by various federal and state governmental authorities. For example, we must comply with FDA requirements with respect to the development of our proposed products and our clinical trials, and if any of our proposed products are approved, the manufacture, labeling, sale, distribution, marketing, advertising and promotion of our products. Failure to comply with FDA and other governmental regulations can result in fines, disgorgement, unanticipated compliance expenditures, recall or seizure of products, total or partial suspension of production and/or distribution, suspension of the FDA’s review of NDAs, enforcement actions, injunctions and criminal prosecution. Under certain circumstances, the FDA also has the authority to revoke previously granted drug approvals. Despite our efforts at compliance, there is no guarantee that we may not be deemed to be deficient in some manner in the future. If we were deemed to be deficient in any significant way, our business, financial position and results of operations could be materially affected and the market value of our common stock could decline. 
If we are unable to protect our proprietary technology, we may not be able to compete as effectively. 
The pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Our success will depend, in part, upon our ability to obtain, enjoy and enforce protection for any products we develop or acquire under United States and foreign patent laws and other intellectual property laws, preserve the confidentiality of our trade secrets and operate without infringing the proprietary rights of third parties. 
27 

Table of Contents
Where appropriate, we seek patent protection for certain aspects of our technology. However, our owned and licensed patents and patent applications may not ensure the protection of our intellectual property for a number of other reasons: 
 	•  	We do not know whether our licensee’s patent applications will result in actual patents.		
 	
 	•  	Competitors may interfere with our patents and patent process in a variety of ways. Competitors may claim that they invented the claimed invention before us or may claim that we are infringing on their patents and therefore we cannot use our technology as claimed under our patent. Competitors may also contest our patents by showing the patent examiner that the invention was not original or novel or was obvious.		
 	
 	•  	We are in the development stage and are in the process of developing proposed products. Even if we receive a patent, it may not provide much practical protection. If we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent. Even if the development of our proposed products is successful and approval for sale is obtained, there can be no assurance that applicable patent coverage, if any, will not have expired or will not expire shortly after this approval. Any expiration of the applicable patent could have a material adverse effect on the sales and profitability of our proposed product.		
 	
 	•  	Enforcing patents is expensive and may require significant time by our management. In litigation, a competitor could claim that our issued patents are not valid for a number of reasons. If the court agrees, we would lose those patents.		
 	
 	•  	We also may support and collaborate in research conducted by government organizations or universities. We cannot guarantee that we will be able to acquire any exclusive rights to technology or products derived from these collaborations. If we do not obtain required licenses or rights, we could encounter delays in product development while we attempt to design around other patents or we may be prohibited from developing, manufacturing or selling products requiring these licenses. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties.		
It also is unclear whether our trade secrets will provide useful protection. While we use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally or willfully disclose our proprietary information to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Finally, our competitors may independently develop equivalent knowledge, methods and know-how. 
Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition. 
The pharmaceutical industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Patent applications are maintained in secrecy in the United States until the patents are issued and also are maintained in secrecy for a period of time outside the United States. Accordingly, we can conduct only limited searches to determine whether our technology infringes any patents or patent applications of others. Any claims of patent infringement would be time-consuming and could likely: 
28 

Table of Contents
 	•  	result in costly litigation;		
 	
 	•  	divert the time and attention of our technical personnel and management;		
 	
 	•  	cause product development delays;		
 	
 	•  	require us to develop non-infringing technology; or		
 	
 	•  	require us to enter into royalty or licensing agreements.		
Although patent and intellectual property disputes in the pharmaceutical industry often have been settled through licensing or similar arrangements, costs associated with these arrangements may be substantial and often require the payment of ongoing royalties, which could hurt our gross margins. In addition, we cannot be sure that the necessary licenses would be available to us on satisfactory terms, or that we could redesign our products or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing, manufacturing and selling some of our products, which could harm our business, financial condition and operating results. 
We have very limited staffing and will continue to be dependent upon key employees. 
Our success is dependent upon the efforts of a small management team and staff. We have employment arrangements in place with all of our executive officers, but none of our executive officers is legally bound to remain employed for any specific term. Although we have key man life insurance on our President and Chief Executive Officer, Stephen M. Simes, we do not have key man life insurance policies covering any of our other executive officers or employees. If key individuals leave BioSante, we could be adversely affected if suitable replacement personnel are not quickly recruited. There is competition for qualified personnel in all functional areas, which makes it difficult to attract and retain the qualified personnel necessary for the development and growth of our business. Our future success depends upon our ability to continue to attract and retain qualified personnel. 
The price and trading volume of our common stock has been, and may continue to be, volatile. 
Historically, the market price and trading volume of our common stock has fluctuated over a wide range. In 2004, our common stock traded in a range from a low of $3.92 to a high of $10.89, and our daily trading volume ranged from 9,300 shares to 5,042,300 shares. It is likely that the price and trading volume of our common stock will continue to fluctuate in the future. The securities of small capitalization, biopharmaceutical companies, including our company, from time to time experience significant price and volume fluctuations, often unrelated to the operating performance of these companies. In particular, the market price and trading volume of our common stock may fluctuate significantly due to a variety of factors, including: 
 	•  	governmental agency actions, including in particular decisions or actions by the FDA or FDA advisory committee panels with respect to our products or our competitors’ products;		
 	
 	•  	the results of our clinical trials or those of our competitors;		
 	
 	•  	announcements of technological innovations or new products by us or our competitors;		
 	
 	•  	announcements by licensors or licensees of our technology;		
29 

Table of Contents
 	•  	public concern as to the safety or efficacy of or market acceptance of products developed by us or our competitors;		
 	
 	•  	developments or disputes concerning patents or other proprietary rights;		
 	
 	•  	our ability to obtain needed financing;		
 	
 	•  	period-to-period fluctuations in our financial results, including our cash, cash equivalents and short-term investment balance, operating expenses, cash burn rate or revenues;		
 	
 	•  	loss of key management;		
 	
 	•  	common stock sales in the public market by one or more of our larger stockholders, officers or directors;		
 	
 	•  	other potentially negative financial announcements, including delisting of our common stock from the American Stock Exchange, review of any of our filings by the SEC, changes in accounting treatment or restatement of previously reported financial results or delays in our filings with the SEC; and		
 	
 	•  	economic conditions in the United States and abroad.		
In addition, the occurrence of any of the risks described above or elsewhere in this report or otherwise in reports we file with or submit to the SEC from time to time could have a material and adverse impact on the market price of our common stock. For example, in December 2004, primarily as a result of the unanimous vote by the FDA’s Reproductive Health Drugs Advisory Committee panel against recommendation for approval of Procter & Gamble’s Intrinsa testosterone patch for hypoactive sexual desire disorder, the price of our common stock decreased over 35% in one trading day and over 50% over the course of three trading days. In addition, on the day of and first two trading days after the public announcement of FDA advisory panel’s recommendation, the daily trading volume of our common stock went from an average of approximately 166,000 shares per day to an average of over approximately 3 million shares per day for those same three days and then back down to an average of approximately 140,000 shares per day. 
Securities class action litigation is sometimes brought against a company following periods of volatility in the market price of its securities. We may be the target of similar litigation. Securities litigation, whether with or without merit, could result in substantial costs and divert management’s attention and resources, which could harm our business and financial condition, as well as the market price of our common stock. 
Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our stock price. 
We are in the process of documenting and testing our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessment of the effectiveness of our internal controls over financial reporting (ICFR) a report by our Registered Independent Public Accounting Firm addressing management’s assessment and independent audit of ICFR. The Committee of Sponsoring Organizations of the Treadway Commission (COSO) provides a framework for companies to assess and improve their internal control systems. While we feel that our key controls are currently effective, we continue to enhance our ICFR by adding additional resources in key functional areas and bringing all of our operations up to the level of documentation, 
30 

Table of Contents
segregation of duties, and systems security necessary, as well as transactional control procedures required, under the new standard issued by the Public Company Accounting Oversight Board. 
We cannot be certain as to the timing of completion of our evaluation, testing and remediation actions or their effects on our operations, in part because there is no precedent available by which to measure compliance adequacy. If we are not able to implement the requirements of Section 404 in a timely manner or with adequate compliance, we might be subject to sanctions or investigations by regulatory authorities, such as the Securities and Exchange Commission or the American Stock Exchange. Any such action could adversely affect our financial results, financial position and the market price of our common stock. In addition, if one or more material weaknesses is identified in ICFR, we will be unable to assert that our ICFR is effective. If we are unable to assert that our ICFR is effective as of December 31, 2005 (or such later date, if applicable) (or if our auditors are unable to attest that management’s report is fairly stated, they are unable to express an opinion on our management’s evaluation or on the effectiveness of the internal controls or they issue an adverse opinion on ICFR), we could lose investor confidence in the accuracy and completeness of our financial reports, which in turn could have an adverse effect on our stock price. If we fail to maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective ICFR in accordance with Section 404 of the Sarbanes-Oxley Act. Failure to achieve and maintain effective ICFR could have an adverse effect on our common stock price. 
Available Information 
Our company, which was initially formed as a corporation organized under the laws of the Province of Ontario on August 29, 1996, was continued as a corporation under the laws of the State of Wyoming on December 19, 1996 and pursuant to stockholder approval was reincorporated in Delaware on June 26, 2001. Our company is the continuing corporation resulting from an amalgamation, or consolidation, of three companies — our company, which was previously named “Ben-Abraham Technologies Inc.,” Structured Biologicals Inc., a corporation organized under the laws of the Province of Ontario, and 923934 Ontario Inc., a corporation organized under the laws of the Province of Ontario and a wholly owned subsidiary of Structured Biologicals. The amalgamation was approved by our stockholders on November 27, 1996 and the articles of arrangement were filed and became effective as of December 6, 1996. In November 1999, our stockholders approved the change of our corporate name from Ben-Abraham Technologies Inc. to BioSante Pharmaceuticals, Inc. Our principal executive offices are located at 111 Barclay Boulevard, Lincolnshire, Illinois 60069. Our telephone number is (847) 478-0500, and our Internet web site address is www.biosantepharma.com. The information contained on our web site or connected to our website is not incorporated by reference into and should not be considered part of this annual report on Form 10-KSB. 
We make available, free of charge and through our Internet web site, our annual reports on Form 10-KSB, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. We also make available, free of charge and through our Internet web site, to any stockholder who requests, our corporate governance guidelines, the charters of our board committees and our Code of Conduct and Ethics. Requests for copies can be directed to Investor Relations at (847) 478-0500 x120. 
31 

Table of Contents
Item 2. DESCRIPTION OF PROPERTY 
Our principal executive office is located in Lincolnshire, Illinois. In December 2003, we entered into a lease agreement for approximately 4,000 square feet of office space for approximately $7,400 per month. In March 2004, we signed an amendment to this lease effective April 1, 2004. Pursuant to that amendment, we have moved to approximately 6,800 square feet in the same building for rent equal to approximately $12,000 per month. This lease will expire in June 2006. Our CAP development operations are located in Smyrna, Georgia where we lease approximately 11,840 square feet of laboratory space for approximately $7,400 per month. This lease expires in June 2006. Management of our company considers our leased properties suitable and adequate for our current and immediately foreseeable needs. 
Item 3. LEGAL PROCEEDINGS 
We are not a party to any material, threatened or pending legal proceedings. 
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS 
No matter was submitted to a vote of our security holders during the fourth quarter ended December 31, 2004. 
Item 4A. EXECUTIVE OFFICERS OF THE REGISTRANT 
Our executive officers, their ages and the offices held, as of March 16, 2005, are as follows: 
 	 	 	 	 	 	 	
Name	 	Age	 	Title	
Stephen M. Simes 	 	 	53	 	 	Vice Chairman, President and Chief Executive Officer	
 	 	 	 	 	 	 	
Phillip B. Donenberg 	 	 	44	 	 	Chief Financial Officer, Treasurer and Secretary	
 	 	 	 	 	 	 	
Leah M. Lehman, Ph.D. 	 	 	43	 	 	Vice President, Product Development	
 	 	 	 	 	 	 	
Steven J. Bell, Ph.D. 	 	 	45	 	 	Vice President, Research and Pre-Clinical Development	
Information regarding the business experience of the executive officers is set forth below. 
Stephen M. Simes has served as our Vice Chairman, President and a director of our company since January 1998 and Chief Executive Officer since March 1998. From October 1994 to January 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., (currently a wholly owned subsidiary of Solvay Pharmaceuticals, Inc.) a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes’ career in the pharmaceutical industry started in 1974 with G.D. Searle & Co. (now a part of Pfizer Inc.). 
32 

Table of Contents
Phillip B. Donenberg, CPA has served as our Chief Financial Officer, Treasurer and Secretary since July 1998. Before joining our company, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of Solvay Pharmaceuticals, Inc.) from January 1995 to July 1998. Prior to Unimed Pharmaceuticals, Inc., Mr. Donenberg held similar positions with other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. (currently Savient Pharmaceuticals, Inc.), Applied NeuroSolutions, Inc. (formerly Molecular Geriatrics Corporation) and Xtramedics, Inc. 
Leah M. Lehman, Ph.D. has served as our Vice President, Product Development since March 2005. Ms. Lehman served as our Vice President, Clinical and Regulatory Affairs from March 2004 to March 2005 and as our Vice President, Clinical Development from January 2001 to March 2004. Prior to joining our company, Dr. Lehman was Director of Clinical Research with Scientific Research Development Corp., a research consulting company, from April 1995 to December 2000. From 1993 to 1995, Dr. Lehman was a clinical statistician at Abbott Laboratories. 
Steven J. Bell, Ph.D. has served as our Vice President, Research and Pre-Clinical Development since October 2000 and served as a Director of Research and Development of BioSante from July 1997 to October 2000. Prior to joining our company, Dr. Bell held various positions with Boehringer Mannheim, Hoffman-LaRoche, The Upjohn Company and Boehringer Ingelheim. 
33 

Table of Contents
PART II 

Item 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 
Market Price 
Our common stock is listed for trading on the American Stock Exchange, under the symbol “BPA.” Our common stock has traded on the American Stock Exchange since October 1, 2003. From June 1, 2002 to September 30, 2003, our common stock was quoted on the Over-the-Counter Bulletin Board under the symbol “BISP” and under the symbol “BTPH” from May 5, 2000 to May 31, 2002. From December 20, 1996 to July 20, 2001, our common stock traded in Canada on the Canadian Venture Exchange, formerly known as the Alberta Stock Exchange, under the symbol “BAI.” 
The following table sets forth, in dollars and cents (in lieu of fractions), the high and low daily closing prices for our common stock, as reported by the American Stock Exchange (AMEX), for each calendar quarter on which our common stock was listed for trading during on the AMEX. 
American Stock Exchange 
 	 	 	 	 	 	 	 	 	
2003	 	High	 	 	Low	 	
Fourth Quarter (beginning October 1, 2003)	 	$	4.50	 	 	$	3.20	 	
 	 	 	 	 	 	 	 	 	
2004	 	High	 	 	Low	 	
First Quarter	 	$	6.40	 	 	$	4.08	 	
Second Quarter	 	$	8.38	 	 	$	4.61	 	
Third Quarter	 	$	9.89	 	 	$	4.75	 	
Fourth Quarter	 	$	10.44	 	 	$	4.54	 	
The following table sets forth, in dollars and cents (in lieu of fractions), the high and low sales prices, as reported by the Over-the-Counter Bulletin Board, for each of the calendar quarters indicated on which our common stock was quoted during 2003 through September 30, 2003. The prices in the table may not represent actual transactions. These quotations reflect inter-dealer prices, without retail mark up, mark down or commissions and may not represent actual transactions. 
OTC Bulletin Board 
 	 	 	 	 	 	 	 	 	
2003	 	High	 	 	Low	 	
First Quarter	 	$	3.60	 	 	$	1.65	 	
Second Quarter	 	$	3.10	 	 	$	1.85	 	
Third Quarter (ending on September 30, 2003)	 	$	3.10	 	 	$	2.45	 	
Number of Record Holders; Dividends 
As of March 16, 2005, there were 1,661 record holders of our common stock and six record holders of our class C stock. To date, we have not declared or paid any cash dividends on our common stock and our class C stock is not eligible to receive dividends. 
34 

Table of Contents
Previous Sales of Unregistered Securities 
During the fourth quarter ended December 31, 2004, we did not issue any securities without registration under the Securities Act of 1933, except that we issued 643,088 shares of our common stock as a result of the exercise of warrants at a weighted average exercise price of $2.15 per share. No underwriting commissions or discounts were paid with respect to the sales of these unregistered securities. All of the sales were made in reliance on either Section 4(2) of the Securities Act of 1933 as transactions by an issuer not involving any public offering or Regulation D of the Securities Act. In all such transactions, certain inquiries were made by BioSante to establish that such sales qualified for such exemption from the registration requirements. In particular, BioSante confirmed that with respect to the exemption claimed under Section 4(2) of the Securities Act (i) all offers of sales and sales were made by personal contact from officers and directors of BioSante or other persons closely associated with BioSante, (ii) each investor made representations that he or she was sophisticated in relation to his or her investment (and BioSante has no reason to believe that such representations were incorrect), (iii) each purchaser gave assurance of investment intent and the certificates for the shares bear a legend accordingly, and (iv) offers and sales within any offering were made to a limited number of persons. 
Small Business Issuer Purchases of Equity Securities 
Except for holders of warrants who exercised their warrants on a cashless basis by surrendering to us an aggregate of 210,635 underlying shares of our common stock to pay the exercise price of their warrants, and optionees who surrendered 18,838 shares of common stock that had been held by the optionees for at least six months as payment for the exercise price of their stock options, we did not purchase any shares of our common stock or other equity securities of ours during the fourth quarter ended December 31, 2004. Our Board of Directors has not authorized any repurchase plan or program for purchase of our shares of common stock or other securities on the open market or otherwise, other than in connection with the cashless exercise of outstanding warrants and stock options. 
35 

Table of Contents
Item 6. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION 
This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. Statements that are not historical are forward-looking and involve risks and uncertainties discussed under the caption “Forward-Looking Statements” in Item 1 of this Annual Report on Form 10-KSB. The following discussion of the results of the operations and financial condition of BioSante should be read in conjunction with our financial statements and the related notes thereto. 
Overview 
We are a development stage biopharmaceutical company that is developing a pipeline of hormone therapy products to treat men and women. We also are engaged in the development of our proprietary calcium phosphate nanotechnology, or CAP, for primarily vaccine adjuvants or immune system boosters and drug delivery systems. 
All of our revenue to date has been derived from upfront and milestone payments earned on licensing and sub-licensing transactions, and most recently, from subcontract revenue. We have not commercially introduced any products and do not expect to do so until mid-2006 at the earliest depending upon the timing of our filing with FDA of a New Drug Application with respect to our Bio-E-Gel product and the approval of such application. 
To date, we have used primarily equity financing and licensing income to fund our ongoing business operations and short-term liquidity needs, and we expect to continue this practice for the foreseeable future. On May 14, 2004, we completed a private placement of approximately 2.9 million shares of common stock and warrants to purchase approximately 0.4 million shares of common stock raising $16.4 million in net proceeds. We also received approximately $2.0 million from warrant and option exercises during 2004. Our cash, cash equivalents and short-term investments were $17,268,688 as of December 31, 2004. We currently do not have sufficient resources on a long-term basis to complete the commercialization of any of our proposed products. Based on our current cash resources and commitments, we believe we should be able to maintain our current planned development activities and the corresponding level of expenditures through at least the next twelve months, although no assurance can be made that we will not need additional cash prior to such time. 
Our business operations to date have consisted mostly of research and development activities, and we expect this to continue for the immediate future. If and when our Bio-E-Gel or other proposed products receive FDA approval, we may begin to incur other expenses, including sales and marketing related expenses if we choose to co-market the product ourselves. 
We spent an average of approximately $700,000 to $800,000 per month on research and development activities in 2004. Our research and development expenses increased $5,471,019 or 148 percent, to $9,162,439 for the year ended December 31, 2004 from $3,691,420 for the year ended December 31, 2003, primarily as a result of the increased expense associated with the clinical development of certain of our hormone therapy products, consisting of the Phase III clinical trial of our Bio-E-Gel product and the Phase II trial of our LibiGel product. We expect our research and development expenses to remain at that level for the first quarter of 2005 and then upon the completion of the Phase III trial and subsequent NDA filing for our Bio-E-Gel product to decrease until the commencement of our LibiGel Phase III trial, which we expect to commence sometime during the later half of 2005. The amount of our actual research and development expenditures, however, may fluctuate from quarter-to-quarter and year-to-year depending upon: (1) resources available; (2) our development schedule, including the timing of our clinical trials; (3) results of studies, clinical trials and regulatory decisions; (4) whether we or our licensees are funding the 
36 

Table of Contents
development of our proposed products; and (5) competitive developments. We are required under the terms of our license agreement with the University of California to have available certain amounts of funds for research and development activities. 
Our general and administrative expenses for the year ended December 31, 2004 increased 32 percent, compared to general and administrative expenses for the year ended December 31, 2003 primarily as a result of increased expenses related to investor relations efforts, increased legal fees and an increase in the recognition of non-cash compensation expense during the year ended December 31, 2004. Our general and administrative expenses may fluctuate from year-to-year depending upon the amount of legal, public and investor relations, accounting and corporate governance and other fees and expenses incurred. 
Since our inception, we have experienced significant operating losses. We incurred a net loss of $12,016,207 for the year ended December 31, 2004, resulting in an accumulated deficit of $40,037,284. We expect to incur substantial and continuing losses for the foreseeable future as our product development programs expand and various preclinical and clinical trials commence and continue. The amount of these losses may vary significantly from year-to-year and quarter-to-quarter and will depend upon, among other factors: 
 	•  	the timing and cost of product development;		
 	
 	•  	the progress and cost of preclinical and clinical development programs;		
 	
 	•  	the costs of licensure or acquisition of new products;		
 	
 	•  	the timing and cost of making necessary regulatory filings and obtaining approvals;		
 	
 	•  	the timing and cost of obtaining third party reimbursement; and		
 	
 	•  	the cost of sales and marketing activities.		
Hormone Therapy Products. Our hormone therapy products address a variety of hormone therapies for symptoms that affect both men and women. The products are gel formulations of testosterone, estradiol, a combination of estradiol and testosterone and a combination of estradiol and progestogen. Our hormone therapy products under development include Bio-E-Gel, LibiGel, Bio-E/P-Gel, Bio-E/T-Gel and Bio-T-Gel. Human clinical trials have begun on several of our hormone therapy products, which are required to obtain FDA approval to market the products. Our proposed Bio-E-Gel product is currently completing a pivotal Phase III clinical trial. Our proposed LibiGel product recently successfully completed a Phase II clinical trial, and we are currently in the planning stage for our Phase III clinical trials. Our proposed Bio-E/P-Gel product is licensed to Solvay Pharmaceuticals, B.V. Phase II clinical trials have been completed and we are hopeful Solvay will initiate Phase III clinical trials in 2005. Our proposed Bio-T-Gel product is also currently in development. 
Under the terms of our license agreement with Antares, we acquired exclusive marketing rights, with the right to grant sublicenses, to the single active ingredient products containing testosterone and estradiol for all therapeutic indications in the U.S. and several foreign countries. We acquired exclusive marketing rights, with the right to grant sublicenses, for the combination estradiol and progestogen product in the U.S. and Canada. In partial consideration for the license of these hormone therapy products, we paid Antares an upfront license fee of $1.0 million in June 2000. In addition, under the terms of the license agreement, we agreed to fund the development of the proposed products, make milestone payments and, pay royalties to Antares on sales of the products if and when the products are brought to market. In a series of amendments executed during 2001 between BioSante and Antares, we returned to Antares the 
37 

Table of Contents
license rights to the estradiol patch in all the countries and the estradiol and testosterone gel products in Malaysia and Australia, and Antares granted us a credit for approximately $600,000 of manufacturing and formulation services, which have been fully utilized, and a license for the combination estradiol plus testosterone gel product for all countries described above. 
In August 2001, we entered into a sublicense agreement with Solvay Pharmaceuticals, B.V. covering the U.S. and Canadian rights to the estrogen/progestogen combination transdermal hormone therapy gel product licensed from Antares. Under the terms of the agreement, Solvay sublicenses our estrogen/progestogen combination transdermal hormone therapy gel product for an initial payment of $2.5 million ($1.7 million net of the related payments due to Antares and Paladin), future milestone payments and escalating sales-based royalties. During the third quarter ended September 30, 2002, we received a $950,000 milestone payment pursuant to the Solvay sublicense agreement. Solvay is responsible for all costs of development and marketing of the product. We have retained co-promotion rights to the product and will be compensated for sales generated by us over and above those attributable to Solvay’s marketing efforts. 
We have sublicensed the marketing rights to our portfolio of female hormone therapy products in Canada to Paladin Labs Inc. In exchange for the sublicense, Paladin agreed to make an initial investment in our company, make future milestone payments and pay royalties on sales of the products in Canada. The milestone payments will be in the form of a series of equity investments by Paladin in our common stock at a 10 percent premium to the market price of our stock at the time the equity investment is made. 
In April 2002, we exclusively in-licensed from Wake Forest University and Cedars-Sinai Medical Center three issued U.S. patents claiming triple hormone therapy (the combination use of estrogen plus progestogen plus androgen, e.g. testosterone) and an option for triple hormone contraception. The financial terms of the license include an upfront payment by us, regulatory milestones, maintenance payments and royalty payments by us if the product gets approved and subsequently marketed. 
In December 2002, we entered into a development and license agreement with Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which Teva USA agreed to develop one of our hormone therapy products for the U.S. market. The financial terms of the development and license agreement included a $1.5 million upfront payment by Teva USA and royalties on sales of the commercialized product upon approval in exchange for rights to develop and market a hormone therapy product. Teva USA is also responsible under the terms of this agreement for continued development, regulatory filings and all manufacturing and marketing associated with the product. 
Bio-E-Gel and LibiGel are both non-partnered products; and therefore, we can control better the timing and future development and commercialization of these products, subject to customary and inevitable uncertainties associated with the product development process, regulatory approvals and market acceptance of such products. 
Those products we have licensed to others (e.g. Bio-E/P-Gel) are reliant on our partners for timely development, obtaining required regulatory approvals, commercialization and an ongoing commitment to the products, subject to regulatory and market conditions. From time to time, based on various circumstances including market analysis or a change in the strategic plan of the partner, a partner may elect to restructure its arrangement which may result in entering into a revised agreement or a mutual termination. Any restructuring or termination of these agreements by such partners as Solvay or Teva could adversely affect our business if we are unable to license the proposed products to another qualified partner on substantially the same or better economic terms or continue the development and future commercialization of the proposed products ourselves. 
38 

Table of Contents
CAP Technology and Proposed Products. Our CAP technology, several of whose issued patents we license on an exclusive basis from the University of California, is based on the use of extremely small, solid, uniform particles, which we call “nanoparticles,” as immune system boosters, for drug delivery and to purify the milk of transgenic animals, among other uses. Our strategy with respect to CAP is to continue development of our nanoparticle technology and actively seek collaborators and licensees to fund and accelerate the development and commercialization of products incorporating the technology. In addition to continuing our own product development in the potential commercial applications of our CAP technology, we have sought and continue to seek opportunities to enter into business collaborations or joint ventures with vaccine companies and others interested in development and marketing arrangements with respect to our CAP technology. We believe these collaborations may enable us to accelerate the development of potential improved vaccines and vaccines that can be delivered other than by injection as well as delivery by non-injected routes products that now must be injected. 
In January 2003, we announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy’s Naval Medical Research Center’s (NMRC) Malaria Program for the development of a malaria vaccine. The development agreement leverages our expertise with NMRC’s expertise to develop an enhanced vaccine for malaria. Under the agreement, we will provide the NMRC with BioVant, our proprietary vaccine adjuvant and delivery system, and the NMRC will provide DNA plasmids or proteins encoding antigens for Plasmodium spp., the parasite that causes malaria. It is hoped that the resulting DNA vaccine will improve the effectiveness of the ensuing humoral and cell-mediated immunity against malaria and therefore be more effective as it activates both arms of the immune system. The NMRC will cover all costs associated with the CRADA. 
In June 2003, we announced the signing of another CRADA with the U.S. Army’s Medical Research Institute of Infectious Disease (USAMRIID) for the development of non-injected biodefense vaccines, including anthrax, staph and ricin. The USAMRIID has agreed to grant us an exclusive license to any U.S. patent application or issued patent as a result of the work under the CRADA. The USAMRIID will cover all costs associated with the CRADA. 
In September 2003, we announced that we were awarded a $100,000 Small Business Innovation Research grant from the National Institutes of Health to support our development of formulations for the oral delivery of insulin using our CAP technology. We recognized $90,000 as a contra-expense for this grant in our December 31, 2004 financial statements. We receive the funds as reimbursement of research and development expenses. We have completed the work outlined under this grant and are currently investigating our options with respect to a Phase II SBIR grant. 
In January 2004, we announced the signing of a subcontract with DynPort Vaccine Company LLC for the development of anthrax vaccines for delivery via alternative routes of administration, including nasal, oral and needle-free transcutaneous routes. Under the subcontract, we provide BioVant and DynPort provides recombinant antigens to be used in potential vaccines against anthrax. The objective is to assess the immunogenic potential of BioVant when used in anthrax vaccines versus the immunogenic response of anthrax vaccines that use Alhydrogel as the vaccine adjuvant. The subcontract is in support of the U.S. Department of Defense Joint Vaccine Acquisition Program. The subcontract is valued at approximately $658,000 per the terms of the contract. We have successfully completed the first year of this three year contract and have progressed to the second phase. Revenue related to this contract of $67,886 was recorded in 2004. 
39 

Table of Contents
Critical Accounting Policies 
Our significant accounting policies are described in Note 2 to our financial statements included in Item 7 of this Form 10-KSB. The discussion and analysis of the financial statements and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amount of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The SEC has defined a company’s most critical accounting policies as those that are most important to the portrayal of its financial condition and results of operations, and which the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the following critical accounting policies. Although we believe that our estimates and assumptions are reasonable, they are based upon information available when they are made. Actual results may differ significantly from these estimates under different assumptions or conditions. 
Revenue Recognition 
We recognize revenue from licensing arrangements in the form of upfront license fees, milestone payments, royalties and other fees and most recently, from subcontract revenue. Licensing income is recognized when we have completed all of our obligations under the licensing or subcontract arrangements which are required for the payment to be non-refundable. Licensing income also includes reimbursement for certain research and development expenses, which we recognize as both revenue and expense at the time the expense is incurred. Any ancillary payments related to the products being licensed, such as royalties to the head licensor, are netted against revenues at the time of revenue recognition. To date, there has been no royalty revenue recognized. 
Research and Development Costs 
Research and development (“R&D”) costs are charged to expense as incurred. Costs associated with production of products are capitalized only when FDA approval has occurred. Government grants are recorded as an offset to the related research and development costs when the Company has complied with the conditions attached to the grant and there is reasonable assurance that the funds will be received. To date, none of our products has received FDA approval. 
Results of Operations 
The following table sets forth, for the periods indicated, our results of operations. 
 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	Year Ended December 31,	 	
 	 	2004	 	 	2003	 	 	2002	 	
Revenue	 	$	77,886	 	 	$	65,494	 	 	$	2,770,063	 	
Expenses	 	 	12,344,517	 	 	 	6,111,437	 	 	 	6,644,541	 	
Research and development	 	 	9,162,439	 	 	 	3,691,420	 	 	 	4,786,818	 	
General and administrative	 	 	3,080,135	 	 	 	2,327,090	 	 	 	1,765,624	 	
Interest income	 	 	250,424	 	 	 	86,589	 	 	 	63,788	 	
Net loss	 	$	(12,016,207	)	 	$	(5,959,354	)	 	$	(3,810,690	)	
40 

Table of Contents
Year Ended December 31, 2004 Compared to Year Ended December 31, 2003 
Revenue for the year ended December 31, 2004 increased 19 percent compared to revenue during 2003 primarily due to $67,886 received from our Dynport subcontract in 2004, offset by a reduction of $55,494 in licensing revenue for 2004 compared to licensing revenue during 2003. 
Research and development expenses for the year ended December 31, 2004 increased 148 percent compared to research and development expenses during 2003 primarily as a result of increased expenses during 2004 associated with the Phase III clinical trial of our Bio-E-Gel product and the completion of our Phase II trial of our LibiGel product. 
General and administrative expenses for the year ended December 31, 2004 increased 32 percent compared to general and administrative expenses for 2003 primarily as a result of an increase in non-cash compensation related to $572,541 associated with changing the life of previously issued options to officers and compensation paid in common stock to board members. The majority of this non-cash compensation expense was a result of an amendment to certain options to purchase an aggregate of 285,000 shares of common stock at an exercise price of $2.10 per share that were granted in the second quarter 2003 and were amended in first quarter 2004 to change the vesting periods from milestone-based vesting schedules to time-based vesting schedules. The amended stock options now vest in three equal annual installments over a three-year period from the date of the amendment as opposed to upon a change in control of the company. As a result of the stock option amendments, we will recognize $1,054,500 in compensation expense over a three-year period which began in the first quarter 2004 . 
Interest income for the year ended December 31, 2004 increased 189 percent compared to interest income during 2003 primarily as a result of higher invested cash and short term investment balances during 2004. We expect interest income to decline in future periods as we use our cash and short term investment balances for operations. 
The overall increase in the net loss for the year ended December 31, 2004 compared to 2003 was primarily the result of increased clinical trial costs as well as the non-cash stock compensation expense as described above. 
Year Ended December 31, 2003 Compared to Year Ended December 31, 2002 
Revenue for the year ended December 31, 2003 decreased 97 percent compared to revenue during 2002 primarily due to minimal net licensing income received in 2003 compared to 2002 and a $1.5 million upfront payment by Teva USA and a $950,000 ($750,000 net of payment to licensor) milestone payment by Solvay Pharmaceuticals received by BioSante in 2002. 
Research and development expenses for the year ended December 31, 2003 decreased 23 percent compared to research and development expenses for the year ended December 31, 2002 as a result of decreased expenses during 2003 associated with the clinical development of certain of our hormone therapy products. 
General and administrative expenses for the year ended December 31, 2003 increased 32 percent compared to general and administrative expenses for 2002. This increase was due primarily to recognition of payment of board compensation expenses and legal and filing fees associated with the listing of our common stock on the American Stock Exchange in 2003. 
Interest income for the year ended December 31, 2003 increased 36 percent compared to interest income for 2002 as a result of higher invested cash balances in 2003. 
41 

Table of Contents
The overall increase in the net loss for the year ended December 31, 2003 compared to 2002 was largely the result of lower licensing income and higher board compensation, filing and legal expenses as described above. 
Liquidity and Capital Resources 
Working Capital 
All of our revenue to date has been derived from upfront and milestone payments earned on licensing and sub-licensing transactions and most recently, from a subcontract. To date, we have used primarily equity financing and received licensing income to fund our ongoing business operations and short-term liquidity needs, and we expect to continue this practice for the foreseeable future. Since inception, we have raised net proceeds of approximately $50.3 million from equity financings, class A and class C stock conversions, warrant and option exercises and the issuance of a $500,000 convertible debenture, and have received $4.6 million, net of sublicensing costs, as a result of licensing upfront payments and milestones. 
Our cash, cash equivalents and short-term investments available to fund current operations were $17,268,688 and $9,134,327 at December 31, 2004 and 2003, respectively. Our accounts payable were $1,169,037 and $238,743 at December 31, 2004 and 2003, respectively, and our other accrued expenses were $202,086 and $110,467 at December 31, 2004 and 2003, respectively. The increase in our cash and short term investment balances were primarily due to our $17.7 million ($16.4 million net of transaction costs) private placement of approximately 2.9 million shares of common stock and warrants to purchase approximately 0.4 million shares of common stock that closed in May 2004. We also received approximately $2.0 million from the exercise of warrants and stock options in 2004. We expect our cash balance to decrease as we continue to use cash to fund our operations. The increase in our accounts payable and other accrued expenses was primarily due to increased expenses during 2004 associated with the Phase III clinical trial of our Bio-E-Gel product and the completion of the Phase II trial of our LibiGel product. We do not have any debt for borrowed money. 
We currently do not have sufficient resources on a long-term basis to complete the commercialization of any of our proposed products. Based on our current cash balance and commitments, we believe we should be able to maintain our current planned development activities and the corresponding level of expenditures through at least the next twelve months, although no assurance can be given that we will not need additional cash prior to such time. Our future capital requirements will depend upon numerous factors, including: 
 	•  	the progress and costs of our research and development programs;		
 	
 	•  	the scope, timing and results of our clinical trials;		
 	
 	•  	patient recruitment and enrollment in our current and future clinical trials;		
 	
 	•  	the cost, timing and outcome of regulatory reviews;		
 	
 	•  	the rate of technological advances;		
 	
 	•  	ongoing determinations of the potential commercial success of our proposed products;		
 	
 	•  	our general and administrative expenses, and if we receive FDA approval of any of our proposed products, the amount of resources we devote to sales and marketing capabilities;		
42 

Table of Contents
 	•  	the activities of our competitors; and		
 	
 	•  	our opportunities to acquire new products or take advantage of other unanticipated opportunities.		
If we raise additional funds through the issuance of equity securities, our stockholders may experience dilution, which could be significant. Furthermore, additional financing may not be available when needed or, if available, financing may not be on terms favorable to us or our stockholders. If financing is not available when required or is not available on acceptable terms, we may be required to delay, scale back or eliminate some or all of our programs designed to facilitate the development of our proposed products, commercial introduction of our products or restrict us from acquiring new products that we believe may be beneficial to our business. 
Uses of Cash and Cash Flow 
We used cash in operating activities of $10,442,443 for the year ended December 31, 2004 versus cash used in operating activities of $5,521,992 for the year ended December 31, 2003. The increase in cash used in operating activities largely reflects the increased net loss, offset by the increase in accounts payable and accrued expenses as well as payments received from grants related to reimbursement of development costs of products within our CAP product portfolio and non-cash stock compensation expense described above. We used cash in investing activities of $103,204 for the year ended December 31, 2004, for the purchase of computer equipment, cubicles, office furniture and new lab equipment and $16,098,663 to purchase auction rate securities, versus $8,865 for the year ended December 31, 2003, which was used for the purchase of computer equipment and filing cabinets. Net cash provided by financing activities during the year ended December 31, 2004 was $18,680,008 and was primarily the result of our $16.4 million private placement, which closed in May 2004. Net cash provided by financing activities during the year ended December 31, 2003 was $9,781,487 and was primarily the result of our $10.3 million private placement, which closed in August 2003. 
We used cash in operating activities of $5,521,992 for the year ended December 31, 2003 versus cash used in operating activities of $3,962,493 for the year ended December 31, 2002. The increase in cash used in operating activities in 2003 reflects a decrease in net licensing income combined with an increase in cash expenditures in: (1) research and development and associated personnel-related expenses, and (2) expenses related to the clinical development of our hormone therapy products. Net cash used in investing activities for capital expenditures for computer equipment and filing cabinets was $8,865 for the year ended December 31, 2003 versus $38,992 for computer equipment for the year ended December 31, 2002. Net cash provided by financing activities was $9,781,487 for the year ended December 31, 2003 compared to $4,382,795 for the year ended December 31, 2002. Net cash provided by financing activities during 2002 was primarily the result of our $4.4 million equity offering, which closed in September 2002. 
Commitments and Contractual Obligations 
We did not have any material commitments for capital expenditures as of December 31, 2004. We have, however, several potential financial commitments, including product development milestone payments to the licensors of our hormone therapy products, payments under our license agreements with the University of California and Wake Forest University, as well as minimum annual lease payments. 
43 

Table of Contents
The following table summarizes the timing of these future contractual obligations and commitments as of December 31, 2004: 

 	 	 	Payments Due by Period	 	
 	 	 	 	 	 	 	 	 	Less Than	 	 	 	 	 	 	 	 	 	 	 	 	 	After 5	 	 	
 	Contractual Obligations	 	 	Total	 	 	 	1 Year	 	 	 	1-3 Years	 	 	 	4-5 Years	 	 	 	Years	 	 	
 	Operating Leases	 	 	$	305,118	 	 	 	$	216,133	 	 	 	$	88,985	 	 	 	$	— 	 	 	 	$	— 	 	 	
 	Commitments Under License Agreement with UCLA	 	 	 	3,400,000	 	 	 	 	25,000	 	 	 	 	125,000	 	 	 	 	300,000	 	 	 	 	2,950,000	 	 	
 	Commitments Under License Agreement with Wake Forest	 	 	 	1,740,000	 	 	 	 	55,000	 	 	 	 	145,000	 	 	 	 	230,000	 	 	 	 	1,310,000	 	 	
 	Total Contractual Cash Obligations	 	 	$	5,445,118	 	 	 	$	296,133	 	 	 	$	358,985	 	 	 	$	530,000	 	 	 	$	4,260,000	 	 	
 	
We expect to continue to spend capital on: 
 	•  	research and development programs;		
 	
 	•  	pre-clinical studies and clinical trials;		
 	
 	•  	regulatory processes;		
 	
 	•  	establishment of our own marketing capabilities or a search for third party sales and marketing partners to sell and market our products for us; and		
 	
 	•  	the licensure or acquisition of new products.		
The amount of capital we may need will depend on many factors, including the: 
 	•  	progress, timing and scope of our research and development programs;		
 	
 	•  	progress, timing and scope of our pre-clinical studies and clinical trials;		
 	
 	•  	time and cost necessary to obtain regulatory approvals;		
 	
 	•  	time and cost necessary to establish our own sales and marketing capabilities or to seek marketing partners to market our products for us;		
 	
 	•  	time and cost necessary to respond to technological and market developments;		
 	
 	•  	changes made or new developments in our existing collaborative, licensing and other commercial relationships; and		
 	
 	•  	new collaborative, licensing and other commercial relationships that we may establish.		
In addition, our license agreement with the licensor of our hormone therapy products requires us to make certain payments as development milestones are achieved, and our license agreement with the University of California requires us to have available minimum amounts of funds each year for research and development activities relating to our licensed technology and to achieve research and development milestones. Moreover, our fixed expenses, such as rent, license payments and other contractual commitments, may increase in the future, as we may: 
44 

Table of Contents
•  	enter into additional leases for new facilities and capital equipment;		
 	
•  	enter into additional licenses and collaborative agreements; and		
 	
•  	incur additional expenses associated with being a public company.		
Off-Balance Sheet Arrangements 
Except for operating leases entered in the ordinary course of business and customary indemnification obligations under our license, financing and other agreements, we do not have any off-balance sheet arrangements. 
Quantitative and Qualitative Disclosure About Market Risk 
We are exposed to interest rate risk on the investments of our excess cash and short term investments, although due to the nature of our short-term investments, we have concluded that such risk is not material. The primary objective of our investment activities is to preserve principal while at the same time maximize yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high quality debt securities. To minimize the exposure due to adverse shifts in interest rates, we invest in short-term securities with maturities of less than one year. 
45 

Table of Contents
Item 7. FINANCIAL STATEMENTS 
 	 	 	 	 	 	 	
Description	 	Page	 	 	
Report of Independent Registered Public Accounting Firm 	 	 	47	 	 	 	
 	 	 	 	 	 	 	
Balance Sheets as of December 31, 2004 and 2003 	 	 	48	 	 	 	
 	 	 	 	 	 	 	
Statements of Operations for the years ended December 31, 2004, 2003 and 2002 and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 	 	 	49	 	 	 	
 	 	 	 	 	 	 	
Statements of Stockholders’ Equity for the years ended December 31, 2004, 2003 and 2002 and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 	 	 	50	 	 	 	
 	 	 	 	 	 	 	
Statements of Cash Flows for the years ended December 31, 2004, 2003 and 2002 and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 	 	 	51	 	 	 	
 	 	 	 	 	 	 	
Notes to the Financial Statements for the years ended December 31, 2004, 2003 and 2002 and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 	 	 	52-70	 	 	 	
46 

Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 
To the Board of Directors and Stockholders of
BioSante Pharmaceuticals, Inc.
Lincolnshire, Illinois 
We have audited the accompanying balance sheets of BioSante Pharmaceuticals, Inc. (the “Company”) (a development stage company) as of December 31, 2004 and 2003, and the related statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2004, and for the period from August 29, 1996 (date of incorporation) through December 31, 2004. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. 
In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of BioSante Pharmaceuticals, Inc. as of December 31, 2004 and 2003, and the related statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2004 and for the period from August 29, 1996 (date of incorporation) through December 31, 2004 in conformity with accounting principles generally accepted in the United States of America. 
As discussed in Note 1, the Company is in the development stage. 
/s/ DELOITTE & TOUCHE LLP 
Chicago, Illinois
March 24, 2005 
47 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company) 
Balance Sheets
 	 	 	 	 	 	 	 	 	
December 31, 2004 and 2003	 	2004	 	 	2003	 	
ASSETS	 	 	 	 	 	 	 	 	
 	 	 	 	 	 	 	 	 	
CURRENT ASSETS	 	 	 	 	 	 	 	 	
Cash and cash equivalents	 	$	1,170,025	 	 	$	9,134,327	 	
Short-term Investments	 	 	16,098,663	 	 	 	—	 	
Prepaid expenses and other sundry assets	 	 	309,585	 	 	 	183,316	 	
 	
 	 	 	17,578,273	 	 	 	9,317,643	 	
 	 	 	 	 	 	 	 	 	
PROPERTY AND EQUIPMENT, NET (Note 5)	 	 	249,088	 	 	 	247,827	 	
 	
 	 	$	17,827,361	 	 	$	9,565,470	 	

LIABILITIES AND STOCKHOLDERS’ EQUITY	 	 	 	 	 	 	 	 	
 	 	 	 	 	 	 	 	 	
CURRENT LIABILITIES	 	 	 	 	 	 	 	 	
Accounts payable (Note 12)	 	$	1,169,037	 	 	$	238,743	 	
Accrued compensation	 	 	531,882	 	 	 	514,130	 	
Other accrued expenses	 	 	202,086	 	 	 	110,467	 	
Due to Antares (Note 4)	 	 	3,750	 	 	 	17,865	 	
 	
 	 	 	1,906,755	 	 	 	881,205	 	

COMMITMENTS (Notes 11 and 13)	 	 	 	 	 	 	 	 	
 	 	 	 	 	 	 	 	 	
STOCKHOLDERS’ EQUITY (Note 8)	 	 	 	 	 	 	 	 	
Capital stock	 	 	 	 	 	 	 	 	
Issued and Outstanding	 	 	 	 	 	 	 	 	
2004 - 391,286; 2003 - 404,102 Class C special stock	 	 	398	 	 	 	404	 	
2004 - 18,955,181; 2003 - 13,548,875 Common stock	 	 	56,455,451	 	 	 	36,704,938	 	
 	
 	 	 	56,455,849	 	 	 	36,705,342	 	
 	 	 	 	 	 	 	 	 	
Deferred unearned compensation	 	 	(497,959	)	 	 	—	 	
Deficit accumulated during the development stage	 	 	(40,037,284	)	 	 	(28,021,077	)	
 	
 	 	 	15,920,606	 	 	 	8,684,265	 	
 	
 	 	$	17,827,361	 	 	$	9,565,470	 	
 	
See accompanying notes to the financial statements. 
48 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Statements of Operations
Years ended December 31, 2004, 2003 and 2002
and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 

 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cumulative	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	period from	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	August 29, 1996	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	(date of	 	
 	 	Year ended	 	 	Year ended	 	 	Year ended	 	 	incorporation) to	 	
 	 	December 31,	 	 	December 31,	 	 	December 31,	 	 	December 31,	 	
 	 	2004	 	 	2003	 	 	2002	 	 	2004	 	
REVENUE	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Licensing income	 	$	10,000	 	 	$	65,494	 	 	$	2,770,063	 	 	$	4,592,943	 	
Other income	 	 	67,886	 	 	 	—	 	 	 	—	 	 	 	67,886	 	
 	 	 	
 	 	 	77,886	 	 	 	65,494	 	 	 	2,770,063	 	 	 	4,660,829	 	
 	 	 	
EXPENSES	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Research and development	 	 	9,162,439	 	 	 	3,691,420	 	 	 	4,786,818	 	 	 	24,066,993	 	
General and administration	 	 	3,080,135	 	 	 	2,327,090	 	 	 	1,765,624	 	 	 	15,281,746	 	
Depreciation and amortization	 	 	101,943	 	 	 	92,927	 	 	 	92,099	 	 	 	761,363	 	
Loss on disposal of capital assets	 	 	—	 	 	 	—	 	 	 	—	 	 	 	157,545	 	
Costs of acquisition of Structured Biologicals Inc.	 	 	—	 	 	 	—	 	 	 	—	 	 	 	375,219	 	
Purchased in-process research and development	 	 	—	 	 	 	—	 	 	 	—	 	 	 	5,377,000	 	

 	 	 	12,344,517	 	 	 	6,111,437	 	 	 	6,644,541	 	 	 	46,019,866	 	

 	
OTHER — Interest income	 	 	250,424	 	 	 	86,589	 	 	 	63,788	 	 	 	1,321,753	 	

NET LOSS	 	$	(12,016,207	)	 	$	(5,959,354	)	 	$	(3,810,690	)	 	$	(40,037,284	)	

BASIC AND DILUTED NET LOSS PER SHARE (Note 2)	 	$	(0.70	)	 	$	(0.54	)	 	$	(0.51	)	 	 	 	 	

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	 	 	17,145,387	 	 	 	11,038,595	 	 	 	7,503,134	 	 	 	 	 	
 	 	 	 	 	
See accompanying notes to the financial statements. 
49 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Statements of Stockholders’ Equity
Years ended December 31, 2004, 2003 and 2002
and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 

 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Deficit	 	 	 	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Accumulated	 	 	 	 	
 	 	Class A	 	 	Class C	 	 	 	 	 	 	 	 	 	 	Deferred	 	 	During the	 	 	 	 	
 	 	Special Shares	 	 	Special Shares	 	 	Common Stock	 	 	Unearned	 	 	Development	 	 	 	 	
 	 	Shares	 	 	Amount	 	 	Shares	 	 	Amount	 	 	Shares	 	 	Amount	 	 	Compensation	 	 	Stage	 	 	Total	 	
Balance, August 29, 1996, Date of incorporation	 	 	—	 	 	$	—	 	 	 	—	 	 	$	—	 	 	 	—	 	 	$	—	 	 	$	—	 	 	$	—	 	 	$	—	 	
Issuance of Class “C” shares August 29, 1996 ($0.0001 per share)	 	 	—	 	 	 	—	 	 	 	415,000	 	 	 	415	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	415	 	
Issuance of Class “A” shares September 23, 1996 ($0.0001 per share)	 	 	2,000,000	 	 	 	2,000	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	2,000	 	
Issuance of common shares	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	535,427	 	 	 	5,037,364	 	 	 	 	 	 	 	 	 	 	 	5,037,364	 	
November 27, 1996 - issued as consideration upon acquisition of SBI (Note 3)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	743,432	 	 	 	4,545,563	 	 	 	—	 	 	 	—	 	 	 	4,545,563	 	
Exercise of warrants	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	28,971	 	 	 	376,462	 	 	 	—	 	 	 	—	 	 	 	376,462	 	
Conversion of shares	 	 	 	 	 	 	 	 	 	 	(76,537	)	 	 	(76	)	 	 	76,537	 	 	 	191,416	 	 	 	 	 	 	 	 	 	 	 	191,340	 	
Adjustment for partial shares issued upon amalgamation	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	13	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	
Conversion of shares	 	 	(1,700,000	)	 	 	(1,700	)	 	 	 	 	 	 	 	 	 	 	1,700,000	 	 	 	4,251,700	 	 	 	 	 	 	 	 	 	 	 	4,250,000	 	
Return of shares to treasury	 	 	(146,861	)	 	 	(147	)	 	 	(25,000	)	 	 	(25	)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	(172	)	
Private placements of common shares, net	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	3,237,500	 	 	 	7,857,251	 	 	 	 	 	 	 	 	 	 	 	7,857,251	 	
Issuance of Warrants for services received	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	42,290	 	 	 	 	 	 	 	 	 	 	 	42,290	 	
Share redesignation	 	 	(153,139	)	 	 	(153	)	 	 	153,139	 	 	 	153	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	
Net loss	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	(18,251,033	)	 	 	(18,251,033	)	
 	
Balance, December 31, 2001	 	 	—	 	 	 	—	 	 	 	466,602	 	 	 	467	 	 	 	6,321,880	 	 	 	22,302,046	 	 	 	—	 	 	 	(18,251,033	)	 	 	4,051,480	 	
Reverse stock stock split	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
May 31, 2002 - Fractional share adjustment	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(711	)	 	 	(3,050	)	 	 	—	 	 	 	—	 	 	 	(3,050	)	
Issuance of registered common shares, net	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
September 6, 2002	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	2,250,000	 	 	 	4,385,845	 	 	 	—	 	 	 	—	 	 	 	4,385,845	 	
Net loss	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(3,810,690	)	 	 	(3,810,690	)	
 	
Balance, December 31, 2002	 	 	—	 	 	 	—	 	 	 	466,602	 	 	 	467	 	 	 	8,571,169	 	 	 	26,684,841	 	 	 	—	 	 	 	(22,061,723	)	 	 	4,623,585	 	
Conversion of shares	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
October 30, 2003	 	 	—	 	 	 	—	 	 	 	(62,500	)	 	 	(63	)	 	 	62,500	 	 	 	156,313	 	 	 	—	 	 	 	—	 	 	 	156,250	 	
Private placement of common shares, net August 6, 2003	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	4,791,982	 	 	 	9,593,237	 	 	 	—	 	 	 	—	 	 	 	9,593,237	 	
Issuance of common shares	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Board Compensation — Various	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	89,686	 	 	 	193,000	 	 	 	—	 	 	 	—	 	 	 	193,000	 	
2002 bonus paid to executives in May 2003	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	33,538	 	 	 	77,547	 	 	 	—	 	 	 	—	 	 	 	77,547	 	
Net loss	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(5,959,354	)	 	 	(5,959,354	)	
 	
Balance, December 31, 2003	 	 	—	 	 	 	—	 	 	 	404,102	 	 	 	404	 	 	 	13,548,875	 	 	 	36,704,938	 	 	 	—	 	 	 	(28,021,077	)	 	 	8,684,265	 	
Conversion of shares	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
October 1, 2004	 	 	—	 	 	 	—	 	 	 	(1,816	)	 	 	(1	)	 	 	1,816	 	 	 	4,541	 	 	 	—	 	 	 	—	 	 	 	4,540	 	
October 8, 2004	 	 	—	 	 	 	—	 	 	 	(10,000	)	 	 	(4	)	 	 	10,000	 	 	 	25,004	 	 	 	—	 	 	 	—	 	 	 	25,000	 	
December 16, 2004	 	 	—	 	 	 	—	 	 	 	(1,000	)	 	 	(1	)	 	 	1,000	 	 	 	2,501	 	 	 	—	 	 	 	—	 	 	 	2,500	 	
Private placement of common shares, net May 14, 2004	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	2,949,000	 	 	 	16,370,247	 	 	 	—	 	 	 	—	 	 	 	16,370,247	 	
Issuance of common shares	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Option exercises - Various	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	142,670	 	 	 	234,495	 	 	 	—	 	 	 	—	 	 	 	234,495	 	
Warrant exercises - Various	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	2,317,670	 	 	 	1,990,120	 	 	 	—	 	 	 	—	 	 	 	1,990,120	 	
Board Compensation - Various	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	2,988	 	 	 	16,000	 	 	 	—	 	 	 	—	 	 	 	16,000	 	
Treasury Shares Cancellation - December 15, 2004	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(18,838	)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	
Stock Option Compensation - Executive Officers	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	1,054,500	 	 	 	(497,959	)	 	 	—	 	 	 	556,541	 	
Section 16B Short Swing Profit	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	53,105	 	 	 	—	 	 	 	—	 	 	 	53,105	 	
Net loss	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(12,016,207	)	 	 	(12,016,207	)	
 	
Balance, December 31, 2004	 	 	—	 	 	 	—	 	 	 	391,286	 	 	$	398	 	 	 	18,955,181	 	 	$	56,455,451	 	 	 	(497,959	)	 	$	(40,037,284	)	 	$	15,920,606	 	
 	
See accompanying noters to the financial statements. 
50 

Table of Contents
\ 
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Statements of Cash Flows
Years ended December 31, 2004, 2003 and 2002
and the cumulative period from August 29, 1996 (date of incorporation) to December 31, 2004 

 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cumulative	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	period from	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	August 29, 1996	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	(date of	 	
 	 	Year ended	 	 	Year ended	 	 	Year ended	 	 	incorporation) to	 	
 	 	December 31,	 	 	December 31,	 	 	December 31,	 	 	December 31,	 	
 	 	2004	 	 	2003	 	 	2002	 	 	2004	 	
CASH FLOWS USED IN OPERATING ACTIVITIES	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Net loss	 	$	(12,016,207	)	 	$	(5,959,354	)	 	$	(3,810,690	)	 	$	(40,037,284	)	
Adjustments to reconcile net loss to net cash used in operating activities	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Depreciation and amortization	 	 	101,943	 	 	 	92,927	 	 	 	92,099	 	 	 	761,363	 	
Amortization of deferred unearned compensation	 	 	—	 	 	 	—	 	 	 	—	 	 	 	42,290	 	
Repurchase of licensing rights	 	 	—	 	 	 	—	 	 	 	—	 	 	 	125,000	 	
Employee & director compensation - noncash	 	 	572,541	 	 	 	193,000	 	 	 	—	 	 	 	916,541	 	
Purchased in-process research and development	 	 	—	 	 	 	—	 	 	 	—	 	 	 	5,377,000	 	
Loss on disposal of equipment	 	 	—	 	 	 	—	 	 	 	—	 	 	 	157,545	 	
Changes in other assets and liabilities affecting cash flows from operations	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Prepaid expenses and other sundry assets	 	 	(126,269	)	 	 	(39,161	)	 	 	(52,296	)	 	 	(306,617	)	
Due from licensee (Teva Pharmaceuticals USA, Inc.)	 	 	—	 	 	 	520,063	 	 	 	(520,063	)	 	 	—	 	
Accounts payable and accrued expenses	 	 	1,039,665	 	 	 	(112,029	)	 	 	526,473	 	 	 	1,208,365	 	
Due to licensor (Antares/Regents)	 	 	(14,115	)	 	 	(217,438	)	 	 	(198,016	)	 	 	3,750	 	
Due from SBI	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(128,328	)	
 	
Net cash used in operating activities	 	 	(10,442,443	)	 	 	(5,521,992	)	 	 	(3,962,493	)	 	 	(31,880,376	)	

CASH FLOWS USED IN INVESTING ACTIVITIES	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Purchase of short term investments, net	 	 	(16,098,663	)	 	 	—	 	 	 	—	 	 	 	(16,098,663	)	
Purchase of capital assets	 	 	(103,204	)	 	 	(8,865	)	 	 	(38,992	)	 	 	(1,133,886	)	
 	
Net cash used in investing activities	 	 	(16,201,867	)	 	 	(8,865	)	 	 	(38,992	)	 	 	(17,232,549	)	

CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Issuance of convertible debenture	 	 	—	 	 	 	—	 	 	 	—	 	 	 	500,000	 	
Proceeds from sale or conversion of shares	 	 	18,680,008	 	 	 	9,781,487	 	 	 	4,385,845	 	 	 	49,786,000	 	
Fractional share payout	 	 	—	 	 	 	—	 	 	 	(3,050	)	 	 	(3,050	)	
 	
Net cash provided by financing activities	 	 	18,680,008	 	 	 	9,781,487	 	 	 	4,382,795	 	 	 	50,282,950	 	

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	 	 	(7,964,302	)	 	 	4,250,630	 	 	 	381,310	 	 	 	1,170,025	 	
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	 	 	9,134,327	 	 	 	4,883,697	 	 	 	4,502,387	 	 	 	—	 	
 	
CASH AND CASH EQUIVALENTS AT END OF PERIOD	 	$	1,170,025	 	 	$	9,134,327	 	 	$	4,883,697	 	 	$	1,170,025	 	

SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Acquisition of SBI	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Purchased in-process research and development	 	$	—	 	 	$	—	 	 	$	—	 	 	$	5,377,000	 	
Other net liabilities assumed	 	 	—	 	 	 	—	 	 	 	—	 	 	 	(831,437	)	
 	
 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	4,545,563	 	
Less: subordinate voting shares issued therefor	 	 	—	 	 	 	—	 	 	 	—	 	 	 	4,545,563	 	
 	
 	 	$	—	 	 	$	—	 	 	$	—	 	 	$	—	 	
 	
Income tax paid	 	$	—	 	 	$	—	 	 	$	—	 	 	$	—	 	
 	
Interest paid	 	$	1,426	 	 	$	1,995	 	 	$	—	 	 	$	3,421	 	
 	
SIGNIFICANT NON-CASH TRANSACTIONS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Fair value of common stock warrants issued in connection with the sale of capital stock	 	$	513,551	 	 	$	539,872	 	 	$	—	 	 	$	1,053,423	 	
 	
See accompanying notes to the financial statements. 
51 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

1. ORGANIZATION 
On December 19, 1996, Ben-Abraham Technologies, Inc. (“BAT”) was continued under the laws of the State of Wyoming, U.S.A. Previously, BAT had been incorporated under the laws of the Province of Ontario, Canada, effective August 29, 1996. Pursuant to the shareholders meeting to approve the arrangement on November 27, 1996 and subsequent filing of the articles of arrangement on December 6, 1996, BAT acquired Structured Biologicals Inc. and its wholly-owned subsidiary 923934 Ontario Inc. (“SBI”), a Canadian public company listed on the Alberta Stock Exchange. The “acquisition” was effected by a statutory amalgamation wherein the stockholders of BAT were allotted a significant majority of the shares of the amalgamated entity. Upon amalgamation, the then existing stockholders of SBI received 743,432 subordinate voting shares of BAT (1 such share for every 35 shares held in SBI). On November 10, 1999, BAT changed its name to BioSante Pharmaceuticals, Inc. (“the Company”). 
On May 31, 2002, the Company effected a one-for-ten reverse split of its issued and outstanding shares of common stock and class C stock. All share and per share stock numbers in these financial statements have been adjusted to reflect the reverse stock split. 
The Company was established to develop prescription pharmaceutical products, vaccines, vaccine adjuvants and drug delivery systems using its nanoparticle technology (“CAP”) licensed from the University of California. The research and development on the CAP technology is conducted in the Company’s Smyrna, Georgia laboratory facility. In addition to its nanoparticle technology, the Company also is developing its pipeline of hormone therapy products to treat hormone deficiencies in men and women, many of which products were licensed from Antares Pharma, Inc. The Company’s business office is located in Lincolnshire, Illinois. 
The Company has been in the development stage since its inception. The Company’s successful completion of its development program and its transition to profitable operations is dependent upon obtaining regulatory approval from the United States (the “U.S.”) Food and Drug Administration (“FDA”) prior to selling its products within the U.S., and foreign regulatory approval must be obtained to sell its products internationally. There can be no assurance that the Company’s products will receive regulatory approvals, and a substantial amount of time may pass before the achievement of a level of sales adequate to support the Company’s cost structure. The Company will also incur substantial expenditures to achieve regulatory approvals and will need to raise additional capital during its developmental period. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. It is not possible at this time to predict with assurance the outcome of these activities. 
We currently do not have sufficient resources to complete the commercialization of any of our proposed products. Based on our current cash resources and commitments, we believe we should be able to maintain our current planned development activities and the corresponding level of expenditures through December 2005, although no assurance can be given that we will not need additional cash prior to such time. Unexpected increases in general and administrative expenses and research and development expenses may cause us to seek additional financing prior to December 2005. 
52 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 
Basis of Presentation 
These financial statements are expressed in U.S. dollars. 
The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) and Statement of Financial Accounting Standards (“SFAS”) No. 7 “Accounting and Reporting by Development Stage Enterprises.” The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. 
Cash and Cash Equivalents 
For purposes of reporting cash flows, the Company considers all instruments with original maturities of three months or less to be cash equivalents. Interest income on invested cash balances is recognized on the accrual basis as earned. 
Short-term Investments 
Short-term investments, which consist of market auction rate securities, are classified as “available for sale” under the provisions of SFAS No. 115, “Accounting for Certain Investments in Debt and Equity Securities.” Accordingly, the short-term investments are reported at fair value, with any related unrealized gains and losses included as a separate component of stockholders’ equity, net of applicable taxes. Realized gains and losses and interest and dividends are included in interest income. 
Property and Equipment 
Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation of computer, office and laboratory equipment is computed primarily by accelerated methods over estimated useful lives of seven years. Leasehold improvements are amortized on a straight-line basis over the terms of the leases, plus optional renewals. 
Long-Lived Assets 
Long-lived assets are reviewed for possible impairment whenever events indicate that the carrying amount of such assets may not be recoverable. If such a review indicates an impairment, the carrying amount of such assets is reduced to estimated recoverable value. 
53 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) 
Research and Development 
Research and development (“R&D”) costs are charged to expense as incurred. Costs associated with production of products are capitalized only when FDA approval has occurred. Government grants are recorded as an offset to the related research and development costs when the Company has complied with the conditions attached to the grant and there is reasonable assurance that the funds will be received. 
Basic and Diluted Net Loss Per Share 
The basic and diluted net loss per share is computed based on the weighted average number of the aggregate of common stock and Class C shares outstanding, all being considered as equivalent of one another. Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of shares outstanding for the reporting period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The computation of diluted loss per share does not include the Company’s stock options, 
warrants or convertible debt with dilutive potential because of their antidilutive effect on loss per share. 
Stock-based Compensation 
The Company follows the provisions of APB Opinion No. 25, “Accounting For Stock-Based Compensation” (“APB No. 25”) which requires compensation cost for stock-based employee compensation plans be recognized based on the difference, if any, between the quoted market price of the stock on the measurement date (generally the date of grant) and the amount the employee must pay to acquire the stock. As a result of the Company’s application of APB No. 25, SFAS No. 148, “Accounting for Stock-Based Compensation — Transition and Disclosure” (SFAS 148), requires certain additional disclosures of the pro forma compensation expense arising from the Company’s fixed and performance stock compensation plans. The expense is measured as the fair value of the award at the date it was granted using an option-pricing model that takes into account the exercise price and the expected term of the option, the current price of the underlying stock, its expected volatility, expected dividends on the stock and the expected risk-free rate of return during the term of the option. The compensation cost is recognized over the service period, usually the period from the grant date to the vesting date. The following table illustrates the effect on net loss and loss per share if the Company had applied the fair value based method. 
54 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) 
 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	2004	 	 	2003	 	 	2002	 	
Net loss	 	 	 	 	 	 	 	 	 	 	 	 	
As reported	 	$	(12,016,207	)	 	$	(5,959,354	)	 	$	(3,810,690	)	
Stock-based compensation included in net loss as reported	 	 	572,541	 	 	 	193,000	 	 	 	 	 	
Total stock-based employee compensation determined under fair value based method for all awards	 	 	(1,042,589	)	 	 	(685,932	)	 	 	(374,866	)	
Net loss, pro forma	 	$	(12,486,255	)	 	$	(6,452,286	)	 	$	(4,185,556	)	
 	 	 	 	 	 	 	 	 	 	 	 	 	
Basic and diluted net loss per share	 	 	 	 	 	 	 	 	 	 	 	 	
As reported	 	$	(0.70	)	 	$	(0.54	)	 	$	(0.51	)	
Pro forma	 	$	(0.73	)	 	$	(0.58	)	 	$	(0.56	)	
 	 	 	 	 	 	 	 	 	 	 	 	 	
Cumulative net loss	 	 	 	 	 	 	 	 	 	 	 	 	
As reported	 	$	(40,037,284	)	 	 	 	 	 	 	 	 	
Stock-based compensation included in net loss as reported	 	 	916,541	 	 	 	 	 	 	 	 	 	
Total stock-based employee compensation determined under fair value based method for all awards	 	 	(4,546,576	)	 	 	 	 	 	 	 	 	
Pro forma	 	$	(43,667,319	)	 	 	 	 	 	 	 	 	
 		
The weighted average fair value of the options at the date of grant for options granted during 2004, 2003 and 2002 was $4.32, $1.57, and $2.44, respectively. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:		
 		
 	 	2004	 	 	2003	 	 	2002	 	
Expected option life (years)	 	 	10	 	 	 	10	 	 	 	10	 	
Risk free interest rate	 	 	4.75	%	 	 	3.98	%	 	 	4.61	%	
Expected stock price volatility	 	 	100.28	%	 	 	64.17	%	 	 	45.47	%	
Dividend yield	 	 	—	 	 	 	—	 	 	 	—	 	
Warrants issued to non-employees as compensation for services rendered are valued at their fair value on the date of issue. 
55 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) 
Revenue Recognition 
The Company recognizes revenue from licensing arrangements in the form of upfront license fees, milestone payments, royalties and other fees and most recently, from subcontract revenue. Licensing income is recognized when the Company has completed all of its obligations under the licensing or subcontract arrangements which are required for the payment to be non-refundable. Licensing income also includes reimbursement for certain research and development expenses, which the Company recognizes as both revenue and expense at the time the expense is incurred. Any ancillary payments related to the products being licensed, such as royalties to the head licensor, are netted against revenues at the time of revenue recognition. To date, there has been no royalty revenue recognized. 
Recent Accounting Pronouncements 
In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard 123 (Revised), Share-Based Payment (“SFAS 123R”). Among other changes, SFAS 123R requires companies to record share-based compensation using the fair value method, versus the intrinsic value method allowed by APB No. 25. SFAS 123R is effective in the third quarter of 2005. The Company has not completed the process of evaluating the effect of SFAS 123R on its financial position and results of operations and is therefore unable to disclose the impact when such statement is adopted. 
3. ACQUISITION 
Pursuant to the shareholders meeting to approve the arrangement held on November 27, 1996 and the subsequent filing of the articles of arrangement December 6, 1996, the Company completed the acquisition of 100% of the outstanding shares of SBI. The acquisition was effected by a statutory amalgamation wherein the stockholders of the Company were allotted a significant majority of the shares of the amalgamated entity. Upon amalgamation, the then existing shareholders of SBI received 743,432 shares of common stock of the Company (1 such share for every 35 shares they held in SBI). SBI’s results of operations have been included in these financial statements from the date of acquisition. The acquisition was accounted for by using the purchase method of accounting, as follows: 
 	 	 	 	 	
Assets	 	 	 	 	
In-process research and development	 	$	5,377,000	 	
Other	 	 	37,078	 	
 	
 	 	 	5,414,078	 	
 	
Liabilities	 	 	 	 	
Current liabilities	 	 	679,498	 	
Due to directors	 	 	60,689	 	
Due to the Company	 	 	128,328	 	
 	
 	 	 	868,515	 	
 	
Net assets acquired	 	$	4,545,563	 	
 	
Consideration	 	 	 	 	
Common stock	 	$	4,545,563	 	
 	
56 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

3. ACQUISITION (continued) 
In connection with the acquisition of SBI, accounted for under the purchase method, the Company acquired the rights to negotiate with the Regents of the University of California for licenses of specific CAP-related technologies and products. The specific technologies and products relate to investigative research funded by SBI. At the time of acquisition, the technologies and products had not yet been approved for human clinical research. The value ascribed to the rights, based on an independent evaluation, was $5,377,000. This amount was immediately expensed as the technologies and products did not have their technological feasibility established and had no identified future alternative use. 
As of the date of acquisition, the technology related to the development of products for six indications (i.e. applications of the technology). The Company determined the value of the in process research and development related to the acquired rights based on an independent valuation using discounted cash flows. Principle assumptions used in the valuation were as follows: 
 	•  	FDA approval for the CAP-related six indications was expected to be received at various dates between 2002 and 2004, however, there are many competitive products in development. There are also many requirements that must be met before FDA approval is secured. There is no assurance that the products will be successfully developed, proved to be safe in clinical trials, meet applicable regulatory standards, or demonstrate substantial benefits in the treatment or prevention of any disease.		
 	
 	•  	The estimated additional research and development expenditures required before FDA approval was $26.5 million, to be incurred over 8 to 10 years.		
 	
 	•  	Future cash flows were estimated based on estimated market size, with costs determined based on industry norms, an estimated annual growth rate of 3%.		
 	
 	•  	The cash flows were discounted at 25%. The rate was preferred due to the high-risk nature of the biopharmaceutical business.		
 	
 	•  	The Company is continuing to develop the technology related to five of the six indications.		
 	
 	•  	In June 1997, the Company exercised its option and entered into a license agreement with UCLA for the technology that it had previously supported.		
4. LICENSE AGREEMENTS 
In June 1997, the Company entered into a licensing agreement with the Regents of the University of California, which has subsequently been amended, pursuant to which the University has granted the Company an exclusive license to seven United States patents owned by the University, including rights to sublicense such patents. The University of California has filed patent applications for this licensed technology in several foreign jurisdictions, including Canada, Europe and Japan. The license agreement requires the Company to undertake various obligations as described in Note 13. 
57 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004

4. LICENSE AGREEMENTS (continued) 
On June 13, 2000, the Company entered into a license agreement with Antares Pharma, Inc. (Antares), covering four hormone products for the treatment of men and women. The license agreement requires the Company to pay Antares a percentage of future net sales, if any, as a royalty. Under the terms of the license agreement, the Company is also obligated to make milestone payments upon the occurrence of certain future events. 
As allowed by the licensing agreement with Antares, on September 1, 2000, the Company entered into a sub-license agreement with Paladin Labs Inc. (Paladin) to market the hormone therapy products in Canada. In exchange for the sub-license, Paladin agreed to make an initial investment in the Company, milestone payments and pay royalties on sales of the products in Canada. The milestone payments, to date, have been made in the form of a series of equity investments by Paladin in the Company’s common stock at a 10% premium to the market price of the Company’s common stock at the date of the equity investment. 
These equity investments resulted in the Company issuing an additional 18,940 shares of its common stock to Paladin at a 10 percent premium to the Company’s market price. The dollar value of the premium, $39,394, was recorded as licensing income in the statements of operations. 
In a series of amendments executed during 2001 and 2002 between the Company and Antares, the Company returned to Antares the license rights to one of the four previously licensed hormone products, namely the estradiol patch, in all countries of the licensed territory. It was agreed, that the 
Company is the owner of Bio-T-Gel, its testosterone gel for men with no milestone or royalty obligations to Antares. Additionally, the Company returned to Antares the license rights to the single entity estrogen and testosterone gel products in Malaysia and Australia. In exchange for the return to Antares of the estradiol patch in all the countries and the estradiol and testosterone gel products in Malaysia and Australia, Antares granted the Company a credit for approximately $600,000 of manufacturing and formulation services and a license for LibiGel E/T, a transdermal combination gel of bioidentical estrogen and bioidentical testosterone. During the third quarter of 2001, Antares informed the Company that the total costs for manufacturing and formulation services had exceeded the $600,000 credit. Accordingly, beginning in third quarter of 2001 and going forward, the Company will be required to reimburse Antares for such services. At December 31, 2004 and 2003, the amount owed to Antares for such services was $3,750 and $17,865 respectively. 
On August 7, 2001, the Company entered into a sub-license agreement with Solvay Pharmaceuticals, B.V. (Solvay) covering the U.S. and Canadian rights to the estrogen/progestogen combination transdermal hormone therapy gel product licensed from Antares in June 2000. Under the terms of the agreement, Solvay sub-licenses the Company’s estrogen/progestogen combination transdermal hormone gel product for an initial payment of $2.5 million ($1.7 million net of the related payments due to Antares and Paladin), future milestone payments and escalating sales-based royalties. During the third quarter ended September 30, 2002, the Company received a $950,000 ($750,000 net of the related payment due to Antares as a result of a series of amendments executed during 2002 between the Company and Antares) milestone payment pursuant to the Solvay sub-license agreement. Solvay is responsible for all costs of development and marketing of the product. The Company has retained co-promotion rights to the product and will be compensated for sales 
58 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

4.  	LICENSE AGREEMENTS (continued)		
 	
   	generated by the Company over and above those attributable to Solvay’s marketing efforts. The Canadian rights to this product had previously been sub-licensed to Paladin as part of that sub-license arrangement and were repurchased by the Company prior to the Solvay transaction in exchange for $125,000, paid by the issuance of 17,361 shares of the Company’s common stock with a market value of $125,000 at the date of the transaction.		
 	
   	In April 2002, the Company exclusively in-licensed from Wake Forest University and Cedars-Sinai Medical Center three issued U.S. patents claiming triple hormone therapy (the combination use of estrogen plus progestogen plus androgen, e.g. testosterone) and an option for triple hormone contraception. The financial terms of the license include an upfront payment by the Company, regulatory milestones, maintenance payments and royalty payments by the Company if the product gets approved and subsequently marketed.		
 	
   	In December 2002, the Company signed a development and license agreement with Teva Pharmaceuticals USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. under which Teva USA and the Company collaborate on the development of a hormone therapy product for the U.S. market. Upon signing the U.S. development and license agreement, the Company received an upfront payment of $1.5 million. In addition, Teva will pay the Company royalties on sales of the product commercialized in this collaboration. In exchange, the Company granted Teva exclusive rights to develop and market a certain hormone therapy product. Teva also is responsible for continued development, regulatory filings and all manufacturing and marketing associated with the product.		
 	
5.  	PROPERTY AND EQUIPMENT		
 	
   	Property and equipment, net of accumulated depreciation at December 31, 2004 and 2003 comprise:		
 	 	 	 	 	 	 	 	 	
 	 	2004	 	 	2003	 	
Computer equipment	 	$	164,036	 	 	$	135,156	 	
Office equipment	 	 	145,700	 	 	 	87,024	 	
Laboratory equipment	 	 	123,878	 	 	 	108,230	 	
Leasehold improvements – Laboratory	 	 	477,339	 	 	 	477,339	 	
 	
 	 	 	910,953	 	 	 	807,749	 	
Accumulated depreciation and amortization	 	 	(661,865	)	 	 	(559,922	)	
 	
 	 	$	249,088	 	 	$	247,827	 	
 	
59 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

6.  	INCOME TAXES		
 	
   	The components of the Company’s net deferred tax asset at December 31, 2004 and 2003 were as follows:		
 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	2004	 	 	2003		
Net operating loss carryforwards	 	$	12,918,553	 	 	$	8,484,151	 	 		
Amortization of intangibles	 	 	944,783	 	 	 	1,032,968	 	 		
Research & development credits	 	 	1,711,000	 	 	 	1,375,959	 	 		
Stock option expense	 	 	210,094	 	 	 	—	 	 		
Other	 	 	123,397	 	 	 	96,347	 	 		
 	 	 	 	 	 	 	 		
 	 	 	15,907,827	 	 	 	10,989,425	 	 		
Valuation allowance	 	 	(15,907,827	)	 	 	(10,989,425	)	 		

 	 	$	—	 	 	$	—	 	 		
 	 	 	 	 	 	 	 		
   	The Company has no current tax provision due to its accumulated losses, which result in net operating loss carryforwards. At December 31, 2004, the Company had approximately $34,221,000 of net operating loss carryforwards that are available to reduce future taxable income for a period of up to 20 years. The net operating loss carryforwards expire in the years 2011-2024. The net operating loss carryforwards as well as amortization of various intangibles, principally acquired in-process research and development, generate deferred tax benefits, which have been recorded as deferred tax assets and are entirely offset by a tax valuation allowance. The valuation allowance has been provided at 100% to reduce the deferred tax assets to zero, the amount management believes is more likely than not to be realized. Additionally, the Company has approximately $1,711,000 of research and development credits available to reduce future income taxes through the year 2024.		
 	
   	The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate of 34.5% to pre-tax income as follows:		
 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	2004	 	 	2003	 	 	2002	 	
Tax at U.S. federal statutory rate	 	$	(4,145,591	)	 	$	(2,085,774	)	 	$	(1,333,742	)	
State taxes, net of federal benefit	 	 	(393,531	)	 	 	(193,679	)	 	 	(123,847	)	
Research and development credits	 	 	(208,454	)		 	(232,559	)	 	 	(268,806	)	
Change in valuation allowance	 	 	4,918,402	 	 	 	2,448,894	 	 	 	1,695,946	 	
Other, net	 	 	(170,826	)	 	 	63,118	 	 	 	30,449	 	

 	 	$	—	 	 	$	—	 	 	$	—	 	
 	 	 	 	 	 	 	 	 	 	
60 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

7.  	CONVERTIBLE DEBENTURE		
 	
   	In September 2000, in connection with entering into a sub-license agreement, the Company issued a convertible debenture to Paladin Labs Inc. (Paladin) in the face amount of $500,000. The debenture did not bear interest and was due September 1, 2001, unless converted into shares of the Company’s common stock. On August 13, 2001, the Company exercised its right and declared the debenture converted in full at a price of $10.50 per share. Accordingly, 47,619 shares of the Company’s common stock were issued to Paladin. This was a non-cash financing transaction.		
 	
8.  	STOCKHOLDERS’ EQUITY		
 	
   	By articles of amendment dated July 20, 1999 (effective as of July 13, 1999), the subordinate voting shares of the Company were redesignated as common stock, the Class A special shares were reclassified as Class C special shares and the Class B special shares were eliminated. There were no changes in the number of shares outstanding.		
 	
   	On May 31, 2002, the Company effected a one-for-ten reverse split of its issued and outstanding shares of common stock and class C stock. All share and per share stock numbers in this Form 10-KSB have been adjusted to reflect the reverse stock split.		
 	a)  	Authorized		
 	
 	   	Preference shares		
 	
 	   	Ten million preference shares, $0.0001 par value per share, issuable in series subject to limitation, rights, and privileges as determined by the directors. No preference shares have been issued as of December 31, 2004.		
 	
 	   	Special Shares		
 	
 	   	4,687,684 Class C special shares, $0.0001 par value per share, convertible to common stock, to be held a minimum of one year from date issue, on the basis of one Class C special share and U.S. $2.50. These shares are not entitled to a dividend and carry one vote per share. There are 391,286 and 404,102 shares of Class C special shares issued and outstanding as of December 31, 2004 and 2003, respectively.		
 	
 	   	Common Stock		
 	
 	   	One hundred million common shares of stock, $0.0001 par value per share, which carry one vote per share. There are 18,955,181 and 13,548,875 shares of common stock issued and outstanding as of December 31, 2004 and 2003, respectively.		
 	
 	   	Significant Equity Transactions		
 	
 	   	Significant equity transactions since the date of the Company’s incorporation are as follows:		
 	•  	Prior to the Amalgamation on December 6, 1996, the Company issued 2,000,000 shares of the Company’s Class A stock for $0.001 per share, 415,000 shares of Class C stock for $0.001 per share and 410,000 shares of the Company’s common stock for $10.00 per share.	
61 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

8.  	STOCKHOLDERS’ EQUITY (continued)	
 	•  	Pursuant to the shareholders meeting to approve the arrangement held on November 27, 1996 and the subsequent filing of articles of arrangement on December 6, 1996, the Company completed the acquisition of 100% of the outstanding shares of SBI. Upon the effectiveness of this Amalgamation, the then existing stockholders of SBI received 743,432 shares of common stock of the Company (1 common share of the Company for every 35 shares of SBI). The deemed fair market value of this stock was $4,545,563.		
 	
 	•  	In May 1998, the Company and Avi Ben-Abraham, M.D., a then director and a founder of the Company and the Company’s then Chief Executive Officer and Chairman of the Board, entered into an agreement pursuant to which Dr. Ben-Abraham would relinquish his executive position and remain as a director of the Company. Effective May 21, 2002, Dr. Ben-Abraham chose not to stand for re-election as a director of the Company. Pursuant to the agreement, Dr. Ben-Abraham converted shares of the Company’s Class A stock held by him into 1,500,000 shares of common stock at $2.50 per share for proceeds to the Company of $3,750,000. In addition, Dr. Ben-Abraham agreed to return to the Company 146,861 shares of Class A stock and 25,000 shares of Class C stock to the Company, and also agreed not to sell any of his shares of common stock or any other securities of the Company for a period of 15 months. The Company and Dr. Ben-Abraham agreed to cross-indemnify each other upon the occurrence of certain events.		
 	
 	•  	In June 1998, the Company issued an aggregate of 200,000 shares of common stock pursuant to the conversion of Class A stock at a conversion price of $2.50 per share.		
 	
 	•  	On May 6, 1999, the Company sold an aggregate of 2,312,500 common shares and warrants to purchase 1,156,250 shares of common stock at an exercise price of $3.00 per share to 31 accredited investors in a private placement, including several current members of the board of directors and one executive officer. Net proceeds to the Company from this private placement were approximately $4.2 million.		
 	
 	•  	In August 1999, an outstanding liability of $25,000 was converted into 7,000 shares of common stock.		
 	
 	•  	In July 2000, 19,007 shares of common stock were issued to certain corporate officers in lieu of a cash bonus.		
 	
 	•  	On April 4, 2001, the Company sold an aggregate of 925,000 common shares and warrants to purchase 462,500 shares of common stock at an exercise price of $5.00 per share to 48 accredited investors in a private placement, including several current members of the board of directors and five executive officers. Net proceeds to the Company from this private placement were approximately $3.7 million.		
 	
 	•  	During the third quarter 2001, Paladin made a series of equity investments in the Company as result of certain sub-licensing transactions and the Company reaching certain milestones. These equity investments resulted in the Company issuing an additional 18,940 shares of its common stock to Paladin at a 10 percent premium to the Company’s market price on the date of the transactions. The dollar value of the premium is recorded as licensing income in the statements of operations.		
62 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

8.  	STOCKHOLDERS’ EQUITY (continued)	
 	•  	On August 7, 2001, the Company entered into a sub-license agreement with Solvay Pharmaceuticals, B.V. (Solvay) covering the U.S. and Canadian rights to the estrogen/progestogen combination transdermal hormone therapy gel product licensed from Antares in June 2000. The Canadian rights to this product had previously been sub-licensed to Paladin as part of that sub-license arrangement and were repurchased by the Company prior to the Solvay transaction in exchange for $125,000, paid by the issuance of 17,361 shares of the Company’s common stock with a market value of $125,000 at the date of the transaction.		
 	
 	•  	In August 2001, 15,500 shares of common stock were issued to certain corporate officers in lieu of a cash bonus.		
 	
 	•  	On August 13, 2001, the Company exercised its right and declared a convertible debenture in the face amount of $500,000 issued to Paladin Labs Inc. (“Paladin”) converted in full at a price of $10.50 per share. See Note 7. Accordingly, 47,619 shares of the Company’s common stock were issued to Paladin.		
 	
 	•  	On September 6, 2002, the Company sold an aggregate of 2,250,000 common shares in a “best efforts” self-underwritten offering to 39 accredited investors, including several current members of the board of directors and three executive officers. Net proceeds from this offering were approximately $4.4 million.		
 	
 	•  	In June 2003, BioSante issued 119,613 shares of common stock to its officers and directors as partial payment of the officers’ 2002 annual bonus (approximately $79,000) and payment of fees to BioSante’s directors for their significant involvement during 2002 and 2003 for director-related services rendered, including attendance at board and committee meetings (approximately $181,500). The 2002 officer bonuses of approximately $79,000 had been previously accrued at December 31, 2002. However, as BioSante had historically not paid fees to directors, the $181,500 of fees paid to directors was expensed in the three month period ended June 30, 2003. The number of shares issued was determined by dividing the dollar amount of bonus or director fees owed to the officer or director, respectively, by the closing market price of BioSante’s common stock on the date of issuance. The share price used in computing the number of shares to issue was approximately $2.16. Shares were issued in lieu of cash in order to conserve the cash funds of BioSante.		
 	
 	•  	On August 6, 2003, BioSante closed a private placement, raising approximately $10.3 million, ($9.6 million net of transaction costs) upon the issuance of units, which consisted of an aggregate of approximately 4.8 million shares of common stock and five-year warrants to purchase an aggregate of approximately 2.8 million shares of common stock (includes placement agent warrants issued in conjunction with the financing). The price of each unit, which consisted of one share of common stock plus a warrant to purchase one half-share of common stock, was $2.15. The exercise price of the warrants is $2.15 per share. The estimated fair value of the warrants issued to the placement agent represents a non cash financing activity.		
63 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

8.  	STOCKHOLDERS’ EQUITY (continued)	
 	•  	In September 2003, BioSante issued 2,641 shares of common stock to its directors as payment of fees to BioSante’s directors for their involvement during the third quarter ended September 30, 2003 for director-related services rendered, including attendance at board and committee meetings ($7,500). The number of shares issued was determined by dividing the dollar amount of director fees owed to the directors by the closing market price of BioSante’s common stock on the date of issuance. The share price used in computing the number of shares issued was between $2.70 and $2.90. Shares were issued in lieu of cash in order to conserve the cash funds of BioSante.		
 	
 	•  	In October 2003, 62,500 shares of common stock were issued pursuant to a conversion of class C special stock to common stock at a conversion price of $2.50 per share. Accordingly, BioSante raised $156,250 on the conversion.		
 	
 	•  	In November 2003, BioSante issued 226 shares of common stock to certain directors as payment of fees to those certain BioSante directors for their involvement during the fourth quarter ended December 31, 2003 for director-related services rendered, including attendance at a committee meeting ($1,000).		
 	
 	•  	In December 2003, BioSante issued 744 shares of common stock to certain directors as payment of fees to BioSante’s directors for their involvement during the fourth quarter ended December 31, 2003 for director-related services rendered, including attendance at a board meeting ($3,000).		
 	
 	•  	On May 14, 2004, the Company completed a private placement of 2,949,000 shares of its common stock and warrants to purchase 442,350 shares of its common stock at a purchase price of $6.00 per unit to certain institutional and other accredited investors. The private placement resulted in net proceeds to the Company of approximately $16.4 million, after deduction of transaction expenses. The Company also issued warrants to purchase 92,646 shares of common stock to its placement agent in this private placement and its placement agent in its prior August 2003 private placement. The exercise price of the warrants is $7.00 per share.		
 	b)  	Warrants		
 	
 	   	The Company, upon the acquisition of SBI, assumed 257,713 exercisable warrants to purchase common stock, all of which expired prior to or as of December 31, 1998. Of this amount, 7,257 were exercised in 1997 prior to their expiration.		
 	
 	   	Pursuant to the Company’s private placement financing in May 1999, warrants to purchase an aggregate of 1,156,250 shares of common stock were issued at an exercise price of $3.00 per share with a term of five years. All of these warrants were exercised in 2004 except for 75,000 which expired in May 2004.		
 	
 	   	In June 2000, a five-year warrant to purchase 25,000 shares of common stock at an exercise price of $8.80 was issued to a communications firm for various consulting services. The Company recognized expense of approximately $18,000 for this warrant grant during 2000 and 2001. This warrant was exercised in 2004.		
64 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

8.  	STOCKHOLDERS’ EQUITY (continued)	
Pursuant to the Company’s private placement financing in April 2001, warrants to purchase an aggregate of 462,500 shares of common stock were issued at an exercise price of $5.00 per share with a term of five years. 64,063 of these warrants were exercised during 2004 and 398,437 remain outstanding and are exercisable as of December 31, 2004. 
Pursuant to the Company’s private placement financing in August 2003, warrants to purchase an aggregate of 2,767,366 shares of common stock were issued at an exercise price of $2.15 per share with a term of five years. 2,038,694 of these warrants were exercised during 2004 and 728,672 remain outstanding and are exercisable as of December 31, 2004. 
Pursuant to the Company’s private placement financing in May 2004, warrants to purchase an aggregate of 92,646 shares of common stock were issued at an exercise price of $7.00 per share with a term of five years. These warrants remain outstanding and are all exercisable as of December 31, 2004. 
As described individually, by financing above, during 2004, 767,062 common stock warrants were exercised for total cash proceeds of $1,990,120, and 2,491,945 common stock warrants were exercised on a cashless basis, resulting in the issuance of 1,550,608 shares of common stock and the withholding of 941,337 shares of common stock to pay the exercise price of such warrants. The 941,337 shares of common stock withheld to pay the exercise price of the warrants were cancelled by the Company, and, as a result, reduced the number of outstanding shares of common stock, on a fully diluted basis. 
During January and February 2005, 31,250 common stock warrants were exercised for total cash proceeds of $156,250, and 11,500 warrants were exercised on a cashless basis resulting in the issuance of 6,575 shares of common stock, and the withholding of 4,925 shares of common stock to pay the exercise price of such warrants. The 4,925 shares of common stock withheld to pay the exercise price of the warrants were cancelled by the Company, and, as a result, reduced the number of outstanding shares of common stock on a fully diluted basis. 
 	c)  	Options		
 	
 	   	In 2004, 75,170 common stock options were exercised for total cash proceeds of $234,495, and 67,500 common stock options were exercised on a cashless basis. In lieu of cash for payment of the exercise price, the optionees surrendered to the Company 18,838 shares of the Company’s common stock that had been held by the optionees for at least six months. The 18,838 shares surrendered to the Company as payment for the options, were cancelled by the Company, and, as a result reduced the number of outstanding shares of common stock.		
 	
 	   	In January and February 2005, 270 common stock options were exercised for total cash proceeds of $918.		
65 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

9.  	STOCK OPTIONS		
 	
   	The Company has a stock option plan for certain officers, directors and employees whereby 2,000,000 shares of common stock have been reserved for issuance. Options for 1,254,468 shares of common stock have been granted as of December 31, 2004 under this plan at prices equal to either the ten-day weighted average closing price, or the closing bid price of the stock at the date of the grant, and are exercisable and vest in a range substantially over a three-year period. The options expire either in substantially five or ten years from the date of the grants.		
 	
   	The following table summarizes the Company’s stock option activity:		
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	 	 	 	 	Weighted	 	 	 	 	 	 	Weighted	 	 	 	 	 	 	Weighted	 	
 	 	 	 	 	 	Average	 	 	 	 	 	 	Average	 	 	 	 	 	 	Average	 	
 	 	 	 	 	 	Exercise	 	 	 	 	 	 	Exercise	 	 	 	 	 	 	Exercise	 	
 	 	2004	 	 	Price	 	 	2003	 	 	Price	 	 	2002	 	 	Price	 	
Options outstanding, Beginning of period	 	 	1,237,634	 	 	$	3.13	 	 	 	997,300	 	 	$	3.74	 	 	 	699,467	 	 	$	3.80	 	
Options granted	 	 	61,000	 	 	$	5.63	 	 	 	307,000	 	 	$	2.10	 	 	 	327,167	 	 	$	3.71	 	
Options cancelled/expired	 	 	(44,166	)	 	$	3.93	 	 	 	(66,666	)	 	$	7.60	 	 	 	(29,334	)	 	$	3.44	 	
Options exercised	 	 	(142,670	)	 	$	3.01	 	 	 	—	 	 	$	—	 	 	 	—	 	 	$	—	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Options outstanding, End of period	 	 	1,111,798	 	 	$	3.25	 	 	 	1,237,634	 	 	$	3.13	 	 	 	997,300	 	 	$	3.74	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Options exercisable, End of year	 	 	668,378	 	 	$	3.47	 	 	 	694,461	 	 	$	3.29	 	 	 	631,611	 	 	$	3.55	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
The following table summarizes information about stock options outstanding at December 31, 2004: 
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	Outstanding Options	 	 	Options Exercisable	 	
Range of	 	 	 	 	 	Weighted Avg.	 	 	Weighted Avg.	 	 	 	 	 	 	Weighted Avg.	 	
Exercise	 	Number	 	 	Remaining	 	 	Exercise	 	 	Number	 	 	Exercise	 	
Prices	 	Outstanding	 	 	Contractual Life	 	 	Price	 	 	Outstanding	 	 	Price	 	
$2.10	 	 	293,666	 	 	9.0 years	 	$	2.10	 	 	 	667	 	 	$	2.10	 	
$2.30	 	 	237,813	 	 	1.2 years	 	$	2.30	 	 	 	237,813	 	 	$	2.30	 	
$2.80 - $2.90	 	 	89,500	 	 	0.7 years	 	$	2.82	 	 	 	89,500	 	 	$	2.82	 	
$3.40 - $7.60	 	 	490,819	 	 	7.3 years	 	$	4.47	 	 	 	340,398	 	 	$	4.47	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	 	1,111,798	 	 	 	 	 	 	 	 	 	 	 	668,378	 	 	 	 	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
66 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

9.  	STOCK OPTIONS (continued)	
   	During the second quarter 2003, BioSante issued 285,000 options to certain officers of BioSante which vested only upon the achievement of certain milestones in connection with BioSante’s evaluation of strategic alternatives. In March 2004, the vesting period related to these options was amended whereby the options now vest over a three year period from the date of grant. As a result of the amended option terms, $556,541 was recognized as compensation expense during 2004, and $497,959 will be recognized over the remaining vesting period.		
 	
10.  	RETIREMENT PLAN		
 	
   	The Company offers a discretionary 401(k) Plan (the Plan) to all of its employees. Under the Plan, employees may defer income on a tax-exempt basis, subject to IRS limitation. Under the Plan the Company can make discretionary matching contributions. Company contributions expensed in 2004, 2003 and 2002 totaled $62,701, $60,005, and $44,605 respectively.		
 	
11.  	LEASE ARRANGEMENTS		
 	
   	The Company has entered into lease commitments for rental of its office space and laboratory facilities which were extended in 2004 and expire in 2006. The future minimum lease payments during 2005 and 2006 are $216,133 and $88,985, respectively.		
 	
   	Rent expense amounted to $218,545, $147,088, and $148,184 for the years ended December 31, 2004, 2003 and 2002, respectively. Effective September 16, 1999, the Company entered into a sublease agreement for its previous Atlanta office space under which the Company received approximately $3,400 per month from the sub-tenant through May 14, 2002.		
 	
12.  	RELATED PARTY TRANSACTIONS		
 	
   	Included in current liabilities are $10,231 and $16,184, which represent amounts due to directors and officers of the Company as of December 31, 2004 and 2003, respectively.		
 	
   	Prior to the Amalgamation on December 6, 1996, the Company issued 2,000,000 shares of class A stock and 415,000 shares of class C stock for $0.001 per share. 1,700,000 of the class A shares were sold to a director of the Company. 105,000 of the class C shares were sold to the same director of the Company to be held by him in trust for the benefit of others; 50,000 of the class C shares were sold to a separate company controlled by a then officer of the Company; and 200,000 of the class C shares were sold to other directors of the Company.		
 	
   	The 2,000,000 class A shares and 415,000 class C shares were founder’s shares and the terms under the authorization of these shares, provided for their conversion to common stock at $2.50 per share.		
 	
   	In May 1998, the Company and Avi Ben-Abraham, M.D., a then director and a founder of the Company and the Company’s then Chief Executive Officer and Chairman of the Board, entered into an agreement pursuant to which Dr. Ben-Abraham would relinquish his executive position and remain as a director of the Company. See Note 8.		
67 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

12.  	RELATED PARTY TRANSACTIONS (continued)		
 	
   	In connection with the May 1999 private placement of 2,312,500 shares of common stock and warrants to purchase 1,156,250 shares of common stock, the Company’s Chief Executive Officer purchased 25,000 shares of the common stock sold and warrants to purchase 12,500 shares of common stock. Three other individuals, who purchased either individually or through affiliated entities, an aggregate 1,025,000 shares of common stock and warrants to purchase 512,500 shares of common stock, became directors of the Company upon their acquisition of the shares or sometime later.		
 	
   	In connection with the April 2001 private placement of 925,000 shares of common stock and warrants to purchase 462,500 shares of common stock, the Company’s Chief Executive Officer, Chief Financial Officer and other senior officers purchased an aggregate of 52,875 shares of the common stock sold and warrants to purchase 26,437 shares of common stock. Three directors, either individually or through affiliated entities, purchased an aggregate 312,500 shares of common stock and warrants to purchase 156,250 shares of common stock.		
 	
   	In connection with the September 2002 best-efforts, self-underwritten offering of 2,250,000 shares of common stock, the Company’s Vice President of Clinical Development, Chief Executive Officer and Chief Financial Officer purchased an aggregate of 164,701 shares of the common stock sold. Three directors, either individually or through affiliated entities, purchased an aggregate 453,504 shares of common stock.		
 	
   	In connection with the August 2003 best-efforts offering of 4,791,982 shares of common stock, the Company’s Vice President of Clinical Development, Chief Executive Officer and Chief Financial Officer purchased an aggregate of 3,000 shares of the common stock sold. Three directors, either individually or through affiliated entities, purchased an aggregate 736,023 shares of common stock.		
 	
   	In January 2001, BioSante entered into a consulting agreement with Scientific Research Development Corporation, a company owned and operated by Ronald B. McCright, Ph.D., the husband of Leah M. Lehman, Ph.D., an executive officer of BioSante. Under the agreement, Scientific Research Development Corporation provided the Company with database and statistical programming, database management, medical writing and project management services. In consideration for such services, $12,870, $103,035, and $199,229 are included in research and development expenses for the years ended December 31, 2004, 2003 and 2002, respectively.		
 	
13.  	COMMITMENTS AND CONTINGENCIES		
 	
   	The Company may incur contingent liabilities which may arise during the normal course of business. Management believes the ultimate outcome of such matters will not have a material adverse impact on the financial position or results of operations of the Company.		
68 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

13.  	COMMITMENTS AND CONTINGENCIES (continued)		
 	
   	University of California License		
 	
   	The Company’s license agreement with the University of California as amended most recently in June 2004, requires the Company to undertake various obligations, including:		
 	•  	Payment of royalties to the University based on a percentage of the net sales of any products incorporating the licensed technology;		
 	
 	•  	Payment of minimum annual royalties beginning for the year 2005 to be paid by February 28 of the following year in the amounts set forth below, to be credited against any earned royalties, for the life of the agreement;		
 	 	 	 	 	 	 	
 	 	Minimum Annual	 	 	 	
Year	 	Royalty Due	 	 	Due Date	
2005	 	$	50,000	 	 	February 28, 2006	
2006	 	 	75,000	 	 	February 28, 2007	
2007	 	 	100,000	 	 	February 28, 2008	
2008	 	 	200,000	 	 	February 28, 2009	
2009	 	 	300,000	 	 	February 28, 2010	
2010	 	 	400,000	 	 	February 28, 2011	
2011	 	 	750,000	 	 	February 28, 2012	
2012	 	 	750,000	 	 	February 28, 2013	
2013	 	 	750,000	 	 	February 28, 2014	
 	 	 	 	 	 	
Total	 	$	3,375,000	 	 	 	
 	 	 	 	 	 	
Minimum royalties of $25,000 were accrued for the year ended December 31, 2004. 
 	•  	Development of products incorporating the licensed technology until a product is introduced to the market;		
 	
 	•  	Payment of the costs of patent prosecution and maintenance of the patents included in the agreement, which for the years ended December 31, 2004, 2003 and 2002 amounted to $13,404, $15,371, and $12,240 respectively;		
 	
 	•  	Meeting performance milestones relating to:		
 	º  	Hiring or contracting with personnel to perform research and development, regulatory and other activities relating to the commercial launch of a proposed product;		
 	
 	º  	Testing proposed products and obtaining government approvals;		
 	
 	º  	Conducting clinical trials; and		
 	
 	º  	Introducing products incorporating the licensed technology into the market;		
69 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC.
(a development stage company)
Notes to the Financial Statements
For the years ended December 31, 2004, 2003 and 2002, and the cumulative period
from August 29, 1996 (date of incorporation) to December 31, 2004 

13.  	COMMITMENTS AND CONTINGENCIES (continued)	
 	•  	Indemnifying, holding harmless and defending the University of California and its affiliates, as designated in the license agreement, against any and all claims, suits, losses, damage, costs, fees and expenses resulting from or arising out of the license agreement, including but not limited to, any product liability claims. The Company has not recorded any liability related to this obligation as no events occurred that would require indemnification.	
 	   	Antares Pharma, Inc. License		
 	
 	   	The Company’s license agreement with Antares Pharma, Inc. required the Company to make a $1.0 million upfront payment to Antares. The Company expects to fund the development of the products, has made and will continue to make milestone payments and once regulatory approval to market is received, pay royalties on the sales of products.		
 	
 	   	Wake Forest License		
 	
 	   	In April 2002, the Company exclusively in-licensed from Wake Forest University and Cedars-Sinai Medical Center three issued U.S. patents claiming triple hormone therapy (the combination use of estrogen plus progestogen plus androgen, e.g. testosterone) and an option for triple hormone contraception. The financial terms of the license include an upfront payment by the Company in exchange for exclusive rights to the license, and regulatory milestones, maintenance payments and royalty payments by the Company if a product incorporating the licensed technology gets approved and subsequently marketed.		
 	
 	   	Future minimum payments due under this agreement are as follows:		
 	 	 	 	 	 	 	
 	 	Minimum Amount	 	 	
Year	 	Due	 	Due Date	
2005 	 	 	45,000	 	 	March 31, 2005	
2006 	 	 	80,000	 	 	March 31, 2006	
2007 	 	 	65,000	 	 	March 31, 2007	
2008 	 	 	90,000	 	 	March 31, 2008	
2009 	 	 	140,000	 	 	March 31, 2009	
2010 	 	 	90,000	 	 	March 31, 2010	
2011 	 	 	40,000	 	 	March 31, 2011	
2012 	 	 	140,000	 	 	March 31, 2012	
2013 	 	 	240,000	 	 	March 31, 2013	
Thereafter 	 	 	800,000	 	 	 	
 	   	Minimum royalties of $10,000 were accrued for the year ended December 31, 2004.		
 	
 	   	The Company has agreed to indemnify, hold harmless and defend Wake Forest University and Cedars-Sinai Medical Center against any and all claims, suits, losses, damages, costs, fees and expenses resulting from or arising out of exercise of the license agreement, including but not limited to, any product liability claims. The Company has not recorded any liability in connection with this obligation as no events occurred that would require indemnification.		
70 

Table of Contents
Item 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 
None. 
Item 8A. CONTROLS AND PROCEDURES 
Evaluation of Disclosure Controls and Procedures 
We maintain disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this Annual Report on Form 10-KSB. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period. 
Change in Internal Control Over Financial Reporting 
There was no change in our internal control over financial reporting that occurred during our fourth quarter ended December 31, 2004 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 
Item 8B. OTHER INFORMATION 
Not applicable. 
71 

Table of Contents
PART III 
Item 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT 
Directors, Executive Officers, Promoters and Control Persons 
The information required under Item 9 of this Form 10-KSB is to be contained under the captions “Election of Directors — Information About Nominees, “Election of Directors — Other Information About Board Nominees” and “Election of Directors — Information About the Board of Directors and its Committees” in our definitive proxy statement to be filed with the SEC with respect to our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
The information concerning our executive officers is included in this Form 10-KSB under Item 4a, “Executive Officers of the Company” and is incorporated herein by reference. 
Section 16(a) Beneficial Ownership Reporting Compliance 
The information required under Item 9 of this Form 10-KSB is to be contained under the caption “Section 16(a) Beneficial Ownership Reporting Compliance” in our definitive proxy statement to be filed with the SEC with respect to our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
Audit Committee Matters 
The information required under Item 9 of this Form 10-KSB is to be contained under the caption “Election of Directors – Information About the Board and its Committees” in the our definitive proxy statement to be filed with the SEC with respect to the our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
Procedures by which Security Holders Recommend Board Nominees 
The information required under Item 9 of this Form 10-KSB is to be contained under the caption “Election of Directors – Information About the Board and its Committees” in the our definitive proxy statement to be filed with the SEC with respect to the our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
72 

Table of Contents
Code of Conduct and Ethics for Employees, Officers and Directors 
Our Code of Conduct and Ethics applies to all of our employees, officers and directors, including our principal executive officer and principal financial officer, and meets the requirements of the Securities and Exchange Commission. A copy of our Code of Conduct and Ethics is filed as an exhibit to this Form 10-KSB. We intend to disclose any amendments to and any waivers from a provision of our Code of Conduct and Ethics on a Form 8-K filed with the SEC. 
Item 10. EXECUTIVE COMPENSATION 
The information required under Item 10 of this Form 10-KSB is to be contained under the captions “Election of Directors — Director Compensation” and “Executive Compensation and Other Benefits” in our definitive proxy statement to be filed with the SEC with respect to our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
Item 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 
The information required under Item 11 of this Form 10-KSB is to be contained under the caption “Security Ownership of Principal Stockholders and Management” in our definitive proxy statement to be filed with the SEC with respect to our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
Securities Authorized for Issuance Under Equity Compensation Plans 
The following table summarizes outstanding options under the BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan as of December 31, 2004. Options granted in the future under the plan are within the discretion of the Compensation Committee of our Board of Directors and therefore cannot be ascertained at this time. 
 	 	 	 	 	 	 	 	 	 	 	 	 	
 	 	(a)	 	 	(b)	 	 	(c)	 	
 	 	 	 	 	 	 	 	 	 	Number of Securities	 	
 	 	 	 	 	 	 	 	 	 	Remaining Available for	 	
 	 	Number of Securities to	 	 	Weighted-Average	 	 	Future Issuance Under	 	
 	 	be Issued Upon Exercise	 	 	Exercise Price of	 	 	Equity Compensation Plans	 	
 	 	of Outstanding Options,	 	 	Outstanding Options,	 	 	(excluding securities reflected	 	
Plan Category	 	Warrants and Rights	 	 	Warrants and Rights	 	 	in column (a))	 	
Equity compensation plans approved by security holders	 	 	1,111,798	 	 	$	3.25	 	 	 	745,532	 	
Equity compensation plans not approved by security holders	 	 	0	 	 	 	N/A	 	 	 	0	 	
 	 	 	 	 	 	 	 	 	 	
Total	 	 	1,111,798	 	 	$	3.25	 	 	 	745,532	 	
 	 	 	 	 	 	 	 	 	 	
73 

Table of Contents
Under the American Stock Exchange rules, we are required to disclose in our annual report the number of outstanding options and options available for grant under our equity compensation plans as of January 1, 2004 and December 31, 2004. As of January 1, 2004, the number of securities to be issued upon exercise of outstanding options, warrants and rights were 1,237,634 shares at a weighted average exercise price of $3.13. The number of securities remaining available for future issuance under our equity compensation plans (excluding securities to be issued upon exercise of outstanding options, warrants and rights) was 762,366 shares. This information as of December 31, 2004 is contained in the table above. Our only equity compensation plan under which shares of BioSante common stock may be issued is the BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan. 
Item 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 
The information required under Item 12 of this Form 10-KSB is to be contained under the caption “Related Party Relationships and Transactions” in our definitive proxy statement to be filed with the SEC with respect to our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
Item 13. EXHIBITS 
The exhibits to this Report are listed on the Exhibit Index on pages 77 – 83. A copy of any of the exhibits listed or referred to above will be furnished at a reasonable cost, upon receipt from any such person of a written request for any such exhibit. Such request should be sent to BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, Illinois 60069, Attn: Stockholder Information. 
The following is a list of each management contract or compensatory plan or arrangement required to be filed as an exhibit to this Annual Report on Form 10-KSB pursuant to Item 13(a): 
A.  	BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan (incorporated by reference to Exhibit 10.1 to BioSante’s Quarterly Report on Form 10-QSB (File No. 0-28637)).		
 	
B.  	Stock Option Agreement, dated December 7, 1997, between BioSante Pharmaceuticals, Inc. and Edward C. Rosenow, III, M.D. (incorporated by reference to Exhibit 10.5 to BioSante’s Amendment No. 1 to the Registration Statement on Form 10-SB (File No. 0-28637)).		
 	
C.  	Form of Stock Option Agreement between BioSante Pharmaceuticals, Inc. and each of BioSante’s executive officers (incorporated by reference to Exhibit 10.5 to BioSante’s Annual Report on Form 10-KSB as filed on March 28, 2002 (File No. 0-28637)).		
 	
D.  	Form of Stock Option Agreement between BioSante Pharmaceuticals, Inc. and each of BioSante’s executive officers (incorporated by reference to Exhibit 10.30 to BioSante’s Annual Report on Form 10-KSB as filed on March 26, 2004 (File No. 1-31812)).		
 	
E.  	Form of Stock Option Agreement between BioSante Pharmaceuticals, Inc. and each of BioSante’s directors (incorporated by reference to Exhibit 10.31 to BioSante’s Annual Report on Form 10-KSB as filed on March 26, 2004 (File No. 1-31812)).		
 	
F.  	Employment Agreement, dated June 11, 1998, between BioSante Pharmaceuticals, Inc. and Phillip B. Donenberg, as amended (incorporated by reference to Exhibit 10.17 to BioSante’s Amendment No. 1 to the Registration Statement on Form 10-SB (File No. 0-28637)).		
74 

Table of Contents
G.  	Employment Agreement, dated January 21, 1998, between BioSante Pharmaceuticals, Inc. and Stephen M. Simes, as amended (filed herewith).		
 	
H.  	Employment Agreement, dated December 15, 2000, between BioSante Pharmaceuticals, Inc. and Leah Lehman, Ph.D. (incorporated by reference to Exhibit 10.19 to BioSante’s Annual Report on Form 10-KSB as filed on March 30, 2001 (File No. 0-28637)).		
 	
I.  	Employment Agreement, dated October 1, 2000, between BioSante Pharmaceuticals, Inc. and Steven J. Bell, Ph.D. (incorporated by reference to Exhibit 10.22 to BioSante’s Annual Report on Form 10-KSB as filed on March 28, 2002 (File No. 0-28637)).		
 	
J.  	Description of Non-Employee Director Compensation Arrangements (filed herewith).		
 	
K.  	Description of Executive Officer Compensation Arrangements (filed herewith).		
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 
The information required under Item 14 of this Form 10-KSB is to be contained under the captions “Ratification of Selection of Independent Registered Public Accounting Firm – Audit, Audit-Related, Tax and Other Fees” and “Ratification of Selection of Independent Registered Public Accounting Firm – Auditor Fees Pre-Approval Policy” in our definitive proxy statement to be filed with the SEC with respect to our next annual meeting of stockholders, which involves the election of directors and is incorporated herein by reference, or, if such proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-KSB, such information will be filed as part of an amendment to this Form 10-KSB not later than the end of the 120-day period. 
75 

Table of Contents
SIGNATURES 
     Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 
 	 	 	 	 	
Dated: March 30, 2005	 	BIOSANTE PHARMACEUTICALS, INC.	
 	 	 	 	 	
	 	By 	 	/s/ Stephen M. Simes	
 	 	 	 	 	
	 	 	 	Stephen M. Simes	
	 	 	 	Vice Chairman, President and Chief Executive Officer	
	 	 	 	(Principal Executive Officer)	
 	 	 	 	 	
	 	By 	 	/s/ Phillip B. Donenberg	
 	 	 	 	 	
	 	 	 	Phillip B. Donenberg	
	 	 	 	Chief Financial Officer, Treasurer and Secretary	
	 	 	 	(Principal Financial and Accounting Officer)	
     Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 30, 2005 by the following persons on behalf of the registrant and in the capacities indicated. 
 	 	 	
Name and Signature	 	Title	
/s/ Stephen M. Simes 	 	Vice Chairman, President and Chief Executive Officer	
 	 	 	
Stephen M. Simes	 	 	
 	 	 	
/s/ Louis W. Sullivan, M.D. 	 	Chairman of the Board	
 	 	 	
Louis W. Sullivan, M.D.	 	 	
 	 	 	
/s/ Fred Holubow 	 	Director	
 	 	 	
Fred Holubow	 	 	
 	 	 	
/s/ Peter Kjaer 	 	Director	
 	 	 	
Peter Kjaer	 	 	
 	 	 	
/s/ Ross Mangano 	 	Director	
 	 	 	
Ross Mangano	 	 	
 	 	 	
/s/ Victor Morgenstern 	 	Director	
 	 	 	
Victor Morgenstern	 	 	
 	 	 	
/s/ Edward C. Rosenow, III, M.D. 	 	Director	
 	 	 	
Edward C. Rosenow, III, M.D.	 	 	
76 

Table of Contents
BIOSANTE PHARMACEUTICALS, INC. 
EXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-KSB
FOR THE YEAR ENDED DECEMBER 31, 2004
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
2.1 	 	Arrangement Agreement, dated October 23, 1996, between Structured Biologicals Inc. and BioSante Pharmaceuticals, Inc. 	 	Incorporated by reference to Exhibit 2.1 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
3.1 	 	Amended and Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc. 	 	Incorporated by reference to Exhibit 3.1 contained in BioSante’s Registration Statement on Form SB-2, as amended, (Reg. No. 333-64218)	
 	 	 	 	 	
3.2 	 	Bylaws of BioSante Pharmaceuticals, Inc. 	 	Incorporated by reference to Exhibit 3.2 contained in BioSante’s Registration Statement on Form SB-2, as amended (Reg. No. 333-64218)	
 	 	 	 	 	
4.1 	 	Form of Warrant issued in connection with April 2001 Private Placement 	 	Incorporated by reference to Exhibit 4.2 contained in BioSante’s Registration Statement on Form SB-2, as amended (Reg. No. 333-64218)	
 	 	 	 	 	
4.2 	 	Form of Warrant issued in connection with the August 2003 Private Placement 	 	Incorporated by reference to Exhibit 10.2 contained in BioSante’s Form 8-K, filed on August 6, 2003 (File No. 0-28637)	
77 

Table of Contents
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
10.1 	 	License Agreement, dated June 18, 1997, between BioSante Pharmaceuticals, Inc. and The Regents of the University of California (1) 	 	Incorporated by reference to Exhibit 10.1 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.2 	 	Amendment to License Agreement, dated October 26, 1999, between BioSante Pharmaceuticals, Inc. and the Regents of the University of California (1) 	 	Incorporated by reference to Exhibit 10.2 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.3 	 	BioSante Pharmaceuticals, Inc. Amended and Restated 1998 Stock Plan 	 	Incorporated by reference to Exhibit 10.1 contained in BioSante’s 10-QSB filed on August 14, 2003 (File 0-28637)	
 	 	 	 	 	
10.4 	 	Stock Option Agreement, dated December 7, 1997, between BioSante Pharmaceuticals, Inc. and Edward C. Rosenow, III, M.D 	 	Incorporated by reference to Exhibit 10.5 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.5 	 	Form of Stock Option Agreement between BioSante Pharmaceuticals, Inc. and each of BioSante’s executive officers 	 	Incorporated by reference to Exhibit 10.5 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.6 	 	Escrow Agreement, dated December 5, 1996, among BioSante Pharmaceuticals, Inc., Montreal Trust Company of Canada, as Escrow Agent, and certain shareholders of BioSante Pharmaceuticals, Inc. 	 	Incorporated by reference to Exhibit 10.9 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
78 

Table of Contents
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
10.7 	 	Registration Rights Agreement, dated May 6, 1999, between BioSante Pharmaceuticals, Inc. and certain shareholders of BioSante Pharmaceuticals, Inc. 	 	Incorporated by reference to Exhibit 10.13 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.8 	 	Securities Purchase Agreement, dated May 6, 1999, between BioSante Pharmaceuticals, Inc. and certain shareholders of BioSante Pharmaceuticals, Inc. 	 	Incorporated by reference to Exhibit 10.14 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.9 	 	Lease, dated September 15, 1997, between BioSante Pharmaceuticals, Inc. and Highlands Park Associates 	 	Incorporated by reference to Exhibit 10.15 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.10 	 	Employment Agreement, dated January 21, 1998, between BioSante Pharmaceuticals, Inc. and Stephen M. Simes, as amended 	 	Filed herewith electronically	
 	 	 	 	 	
10.11 	 	Employment Agreement, dated June 11, 1998, between BioSante Pharmaceuticals, Inc. and Phillip B. Donenberg, as amended 	 	Incorporated by reference to Exhibit 10.17 contained in BioSante’s Registration Statement on Form 10-SB, as amended (File No. 0-28637)	
 	 	 	 	 	
10.12 	 	License Agreement, dated June 13, 2000, between Permatec Technologie, AG (now known as Antares Pharma) and BioSante Pharmaceuticals, Inc. (1) 	 	Incorporated by reference to Exhibit 10.1 contained in BioSante’s Current Report on Form 8-K on July 11, 2000 (File No. 0-28637)	
 	 	 	 	 	
10.14 	 	Employment Agreement, dated December 15, 2000, between BioSante Pharmaceuticals, Inc. and Leah Lehman, Ph.D. 	 	Incorporated by reference to Exhibit 10.19 to BioSante’s Annual Report on Form 10-KSB filed on March 30, 2001 (File No. 0-28637)	
79 

Table of Contents
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
10.15 	 	Form of Subscription Agreement in connection with the April 2001 Private Placement 	 	Incorporated by reference to Exhibit 10.19 to BioSante’s Registration Statement on Form SB-2, as amended (File No. 333-64218)	
 	 	 	 	 	
10.17 	 	Amendment No. 1 to the License Agreement, dated May 20, 2001, between Antares Pharma and BioSante Pharmaceuticals, Inc. (1) 	 	Incorporated by reference to Exhibit 10.18 to BioSante’s Annual Report on Form 10-KSB, filed on March 28, 2002(File No.0-28637)	
 	 	 	 	 	
10.18 	 	Amendment No. 2 to the License Agreement, dated July 5, 2001, between Antares Pharma and BioSante Pharmaceuticals, Inc. (1) 	 	Incorporated by reference to Exhibit 10.19 to BioSante’s Annual Report on Form 10-KSB, filed on March 28, 2002 (File No. 0-28637)	
 	 	 	 	 	
10.19 	 	Amendment No. 3 to the License Agreement, dated August 30, 2001, between Antares Pharma and BioSante Pharmaceuticals, Inc. (1) 	 	Incorporated by reference to Exhibit 10.20 to BioSante’s Annual Report on Form 10-KSB, filed on March 28, 2002 (File No. 0-28637)	
 	 	 	 	 	
10.20 	 	Amendment No. 4 to the License Agreement, dated August 8, 2002, between Antares Pharma and BioSante Pharmaceuticals, Inc. (1) 	 	Incorporated by reference to Exhibit 10.20 to BioSante’s Registration Statement on Form SB-2, as amended (File No. 333-87542)	
 	 	 	 	 	
10.21 	 	Employment Agreement, dated October 1, 2000, between BioSante Pharmaceuticals, Inc. and Steven J. Bell, Ph.D 	 	Incorporated by reference to Exhibit 10.22 to BioSante’s Annual Report on Form 10-KSB, filed on March 28, 2002 (File No. 0-28637)	
80 

Table of Contents
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
10.22 	 	Amendment No. 2 to the License Agreement, dated May 7, 2001, between BioSante Pharmaceuticals, Inc. and The Regents of the University of California (1) 	 	Incorporated by reference to Exhibit 10.23 to BioSante’s Annual Report on Form 10-KSB, filed on March 28, 2002 (File No. 0-28637)	
 	 	 	 	 	
10.23 	 	Amendment No. 5 to the License Agreement, dated December 30, 2002 between Antares Pharma and BioSante Pharmaceuticals, Inc. (1) 	 	Incorporated by reference to Exhibit 10.25 to BioSante’s Annual Report on Form 10-KSB, filed on March 28, 2002 (File No. 0-28637)	
 	 	 	 	 	
10.24 	 	Common Stock and Warrant Purchase Agreement dated August 4, 2003 between BioSante Pharmaceuticals, Inc. and the purchasers listed on schedule 1 thereto 	 	Incorporated by reference to Exhibit 10.1 contained in BioSante’s Form 8-K, filed on August 6, 2003 (File No. 0-28637)	
 	 	 	 	 	
10.25 	 	Investor Rights Agreement dated August 4, 2003 between BioSante Pharmaceuticals, Inc. and the purchasers listed on Schedule 1 attached to the Common Stock and Warrant Purchase Agreement 	 	Incorporated by reference to Exhibit 10.3 contained in BioSante’s Form 8-K, filed on August 6, 2003 (File No. 0-28637)	
 	 	 	 	 	
10.26 	 	First Amendment to Lease, dated September 18, 2003, between BioSante and Highlands Park Associates 	 	Incorporated by reference to Exhibit 10.28 contained in BioSante’s 10-KSB filed on March, 26 2004 (file No. 1-31812)	
 	 	 	 	 	
10.27 	 	Office Lease, dated December 19, 2003, between BioSante and LaSalle National Bank Association, as successor trustee to American National Bank and Trust Company of Chicago 	 	Incorporated by reference to Exhibit 10.29 contained in BioSante’s 10-KSB filed on March, 26 2004 (file No. 1-31812)	
81 

Table of Contents
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
10.28 	 	Form of Stock Option Agreement between BioSante Pharmaceuticals, Inc. and each of BioSante’s executive officers 	 	Incorporated by reference to Exhibit 10.30 contained in BioSante’s 10-KSB filed on March, 26 2004 (file No. 1-31812)	
 	 	 	 	 	
10.29 	 	Form of Stock Option Agreement between BioSante Pharmaceuticals, Inc. and each of BioSante’s directors 	 	Incorporated by reference to Exhibit 10.31 contained in BioSante’s 10-KSB filed on March, 26 2004 (file No.1-31812)	
 	 	 	 	 	
10.30 	 	First Amendment to Lease, dated February 26, 2004, between BioSante and LaSalle National Bank Association, as successor trustee to American National Bank and Trust Company of Chicago 	 	Incorporated by reference to exhibit 10.1 contained in BioSante’s 10-QSB filed on May 17, 2004 (file No.1-31812)	
 	 	 	 	 	
10.31 	 	Third Amendment to the License Agreement dated June 30, 2004, between BioSante and The Regents of the University of California (1) 	 	Incorporated by reference to exhibit 10.3 contained in BioSante’s 10-QSB filed on August 16, 2004 (File No.1-31812)	
 	 	 	 	 	
10.32 	 	Second Amendment to Lease dated as of September 1, 2004, by and between BioSante Pharmaceuticals, Inc. and Highlands Park Associates 	 	Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September1,2004 (File No. 1-31812).	
 	 	 	 	 	
10.33 	 	Form of Subscription Agreement dated as of May 11, 2004 by and between BioSante Pharmaceuticals, Inc. and each of the subscribers party to the Subscription Agreement 	 	Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 12,2004(File No.1-31812).	
82 

Table of Contents
 	 	 	 	 	
Exhibit No.	 	Exhibit	 	Method of Filing	
10.34 	 	Form of Warrant issued by BioSante Pharmaceuticals, Inc. to each of the subscribers party to the Subscription Agreements and the placement agents 	 	Incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 14, 2004(File No.1-31812).	
 	 	 	 	 	
10.35 	 	Description of Non-Employee Director Compensation Arrangements 	 	Filed herewith electronically	
 	 	 	 	 	
10.36 	 	Description of Executive Officer Compensation Arrangements 	 	Filed herewith electronically	
 	 	 	 	 	
14.1 	 	Code of Conduct and Ethics 	 	Incorporated by reference to Exhibit 14.1 contained in BioSante’s 10-KSB filed on March, 26 2004 (file No.1-31812)	
 	 	 	 	 	
23.1 	 	Consent of Deloitte & Touche LLP 	 	Filed herewith electronically	
 	 	 	 	 	
31.1 	 	Certification of Chief Executive Officer Pursuant to SEC Rule 13a-14 	 	Filed herewith electronically	
 	 	 	 	 	
31.2 	 	Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14 	 	Filed herewith electronically	
 	 	 	 	 	
32.1 	 	Certification of Chief Executive Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 	 	Filed herewith electronically	
 	 	 	 	 	
32.2 	 	Certification of Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 	 	Filed herewith electronically	

(1)	 	Confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended, has been granted with respect to designated portions of this document.	
83 
 
EXHIBIT 10.10 
CONFIDENTIAL 
January 21, 1998 
Mr. Stephen M. Simes
1173 RFD
Long Grove, IL 60047 
Dear Stephen: 
     I am pleased to confirm our agreement with you concerning your employment by Ben-Abraham Technologies, Inc. (the “Company”), which is subject to review, approval, and ratification by the Company’s Board of Directors. 
I.  	Employment. Subject to the terms and conditions described in this Employment Agreement (the “Agreement”), the Company agrees to employ you as the President, Chief Operating Officer, and Executive Vice Chairman of the Company, and you accept this employment on the following terms and conditions.		
 	
II.  	Duties.		
 	1.  	You agree to spend substantially all of your business hours on the Company’s business. You will diligently perform the duties of your position, within guidelines to be determined by Avi Ben-Abraham, who is the Company’s Chief Executive Officer and the Chairman of the Board of Directors. In particular, you will actively manage the day-to-day business of the Company and shall set corporate policies, under the direction of the Board of Directors. More particularly, your duties shall include the day-to-day responsibility for running and administering the Company. Said responsibilities shall include, but not be limited to, the following specific areas: shareholder relations, fundraising, Nasdaq listing, direction of R&D, licensing and other business development activities, budgeting and fiscal controls, and all personnel matters. You will report to Dr. Ben-Abraham, who will be responsible for evaluating your job performance in accordance with the Company’s annual performance review process. The Company agrees that during the term of this Agreement, as it may be extended, no one other than Dr. Ben-Abraham shall serve as CEO, except you.		
 	
 	2.  	During the term of this Agreement, you will also serve as a Director of the Company and will perform all such duties incident to such service. Towards this end, the Company shall nominate you as a nominee for director and solicit proxies for your election for so long as this Agreement is in effect.		
 	
     	3.  	While you are employed by the Company, except as otherwise permitted by the Company’s Conflict of Interest policy or this Agreement, you will not engage in any business activity or outside employment that conflicts with the Company’s interests or adversely affect the performance of your duties for the Company.		

 
Mr. Stephen M. Simes
January 21, 1998
Page 2 
CONFIDENTIAL 
 	4.  	You shall be based at, and shall perform your duties at an office located in, Chicago, Illinois, or the surrounding suburban area, where the corporate headquarters of the Company shall also be located. The Company agrees that the other officers and executives of the Company (except for those who are directly involved in the research and development activities of the Company that are currently conducted in Atlanta, Georgia) shall also be located in the same corporate headquarters. However, you shall also travel to other locations at such times as may be appropriate for the performance of your duties under this Agreement.	
III.  	Term. This Agreement is effective January 20, 1998 (the “Effective Date”), and will terminate on December 31, 2000, unless earlier terminated pursuant to Section V of this Agreement (the “Base Term”). Commencing January 1, 2001, and on each January 1st thereafter, the term of your employment will be automatically extended for three (3) additional years unless on or before October 1st immediately preceding any such extension, either party gives written notice to the other of the cessation of further extensions, in which case no further automatic extensions will occur. In the event that the Company elects not to renew this Agreement other than for “cause” as defined herein, you will be paid the amount described in Section V.C.2 below.		
 	
IV.  	Compensation.		
 	A.  	Base Salary. The Company agrees to pay you an annual base salary of Two Hundred Thirty Thousand Dollars ($230,000) in accordance with the Company’s standard payroll practices (“Base Salary”). Beginning January 20, 1999 or sooner if you raise Two Million Dollars ($2,000,000), your Base Salary shall be increased to Two Hundred and Fifty Thousand Dollars ($250,000). In subsequent years, the Board of Directors shall have the sole discretion to establish your Base Salary, except that, at a minimum, it shall be adjusted upward consistent with changes to the Consumer Price Index.		
 	
 	B.  	Annual Bonus. You will be eligible to receive an annual performance bonus not to exceed 50% of your Base Salary in effect during the year under review. The amount of said bonus shall be determined in the sole discretion of the Compensation Committee and approved by the Board of Directors.		
 	
 	C.  	Options.		
 	1.  	Upon execution of this Agreement, the Company will grant you six hundred thousand (600,000) stock options to purchase Subordinate Voting Shares of stock of the Company at the lowest permissible price when this agreement is executed, one hundred thousand of which shall vest at the time of the grant. The remainder shall vest in twelve equal quarterly installments over the Initial Term of this Agreement with the first installment vesting on April 21, 1998. The remaining unvested options shall vest immediately upon a termination without cause by the Company.	

 
Mr. Stephen M. Simes
January 21, 1998
Page 3 
CONFIDENTIAL 
 	2.  	Upon execution of this Agreement, the Company agrees to grant you a combination of an additional four hundred thousand (400,000) Subordinate Voting Shares and/or stock options to purchase Subordinate Voting Shares of stock of the Company during the Initial Term of this Agreement at the lowest permissible price when this agreement is executed. Exercise of these options shall be subject to the stock price being equal to or greater than One Dollar ($1.00) per share at the time the options and/or shares vest. These options shall vest in twelve equal quarterly installments over the Initial Term of this Agreement and shall be exercisable at such time as the foregoing condition precedent is satisfied.		
 	
 	3.  	In the event of any reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend, reverse stock split, combination of shares, rights offering, extraordinary dividend or divestiture (including a spin-off) or any other change in the corporate structure or shares of the Company, (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation), in order to prevent dilution or enlargement of your rights, the Company (or the board of the surviving corporation) shall make appropriate adjustment as to the number of securities subject to this Option.		
 	   	All of the options granted pursuant to this Section IV.C.3 (the “Anti-Dilution Options”) shall automatically vest in accordance with the same vesting schedule set forth in Sections IV.C.1 and IV.C.2 above. (As an illustration, if 200,000 of the 1,000,000 shares and/or options granted pursuant to Section IV.C.1 and IV.C.2 above were vested at the time of the grant of the Anti-Dilution Options pursuant to this Section IV.C.3, then 20% of the Anti-Dilution Options would automatically vest immediately at the time of the grant, and the remaining 80% would vest simultaneously with the vesting of the remaining shares and/or options granted pursuant to Section IV.C.1 and IV.C.2).		
 	
 	   	In the event that your employment is terminated by the Company other than for justifiable cause (as hereinafter defined), or if the Company elects not to renew this Agreement, or if you are not nominated by the Company for reelection to the Board of Directors other than for justifiable cause (as hereinafter defined), all outstanding stock options and shares that are held by you or your estate will immediately become exercisable and all restrictions against disposition, if any, which have not otherwise lapsed shall immediately lapse, and the period within which they may be exercised will be one year following such termination of employment.		
 	
 	D.  	Benefits. In addition to the other compensation to be paid under this Section IV, you will be entitled to participate in all benefit plans available to all full-time, eligible employees hereafter established by the Company, in accordance with the terms and conditions of such plans, which the Company shall adopt promptly		

 
Mr. Stephen M. Simes
January 21, 1998
Page 4 
CONFIDENTIAL 
 	   	following the date hereof. These plans shall include, but not be limited to, the following: a 401(k) plan; group hospitalization, health, dental, disability (for which the Company agrees to obtain the maximum long-term disability insurance benefit allowed by applicable law), and term life insurance (in the amount of $1.1 million); and supplementary long-term disability insurance.		
 	
 	E.  	Reimbursement of Business Expenses. In addition to payment of compensation under this Section IV, the Company agrees to reimburse you for all reasonable out-of-pocket business expenses incurred by you on behalf of the Company, provided that you properly account to the Company for all such expenses in accordance with the rules and regulations of the Internal Revenue Service promulgated under the Internal Revenue Code of 1986, as amended, and in accordance with the standard policies of the Company relating to reimbursement of business expenses.		
 	
 	F.  	Automobile Allowance. The Company shall provide you with a monthly stipend of One Thousand Dollars ($1,000.00) for your automobile use.		
 	
 	G.  	Vacation. You are entitled to four (4) weeks of paid vacation per calendar year.		
V.  	Termination.	
 	A.  	Early Termination. Subject to the respective continuing obligations of the parties pursuant to Sections VI, VII and VIII, this Section sets forth the terms for early termination of this Agreement.		
 	
 	B.  	Termination for Cause. The Company may terminate this Agreement and your employment immediately for cause. For this purpose, “cause” means any of the following: (1) fraud, (2) theft or embezzlement of the Company’s assets, (3) a violation of law involving moral turpitude, (4) your repeated and willful failure to follow instructions of the Board provided that the conduct has not ceased or the offense cured within thirty (30) days following written warning from the Company that sets forth in reasonable detail the facts claimed to provide the basis for such termination. In the event of termination for cause pursuant to this Section V.B, you will be paid at the usual rate your annual Base Salary, car allowance, and any out-of-pocket expenses, through the date of termination specified in any notice of termination and any amounts to which you are entitled under any Company benefit plan in accordance with the terms of such plan.		
 	
 	C.  	Termination Without Cause. Either you or the Company may terminate this Agreement and your employment without cause on thirty (30) days written notice. In the event of termination of this Agreement and of employment pursuant to this Section V.C, compensation will be paid as follows:		
 	1.  	if the termination is by you without cause, you will be paid at the usual rate of your annual Base Salary, car allowance, and any out-of-pocket expenses incurred on behalf of the Company and accounted for pursuant	

 
Mr. Stephen M. Simes
January 21, 1998
Page 5 
CONFIDENTIAL 
 	   	to Section IV.E through the date of termination specified in such notice (but not to exceed thirty (30) days from the date of such notice); or		
 	
 	2.  	Notwithstanding any provision to the contrary contained herein, in the event your employment is terminated by the Company at any time for any reason other than justifiable cause, disability or death, the Company shall:		
     (i) pay you a severance benefit, in a lump sum payable no later than the fifth business day following the date of termination, an amount equal to your total compensation over the preceding twelve months, including the car allowance; 
     (ii) continue to provide you, at the Company’s expense, with term life insurance, as provided herein until the earlier of (A) the expiration of the “Severance Period” (which shall mean the longer of these two periods: one year from the date of termination or the remaining term of this Agreement), or (B) your obtaining full-time employment; 
     (iii) continue to allow you to participate, at the Company’s expense, in the Company’s group hospitalization, health, dental and disability insurance programs until the earlier of (A) the expiration of the Severance Period, or (B) your becoming eligible to participate in another employer’s corresponding group insurance and disability plans; 
     (iv) provide you with outplacement services at a qualified agency selected by you and the use of an office and reasonable secretarial support for one year (unless you become otherwise employed within such period); 
     (v) reimburse out-of-pocket expenses incurred by you on behalf of the Company and accounted pursuant to Section IV.E; and 
     (vi) reimburse you for any and all unused vacation days accrued to the date of such termination. 
 	D.  	Termination for Good Reason. You may terminate this Agreement upon thirty (30) days written notice to the Company for good reason. For this purpose, “good reason” means: (i) the assignment to you of any duties inconsistent with your positions, duties, responsibilities and status with the Company as of the date hereof, or a change in your reporting responsibilities, titles or offices, or any removal of you from or any failure to re-elect you to any of such positions; (ii) the failure of the Company to continue in effect any fringe benefit or compensation plan, retirement plan, life insurance plan, health or disability plan in which you were participating (except as such change is prompted in good faith by a change in the law), or the taking of any action by the Company, which could reasonably be expected to adversely affect your participation in or materially reduce your benefits under any such plans or deprive you of any material fringe benefit	

 
Mr. Stephen M. Simes
January 21, 1998
Page 6 
CONFIDENTIAL 
 	   	enjoyed by you, (iii) the reduction of your salary or car allowance or failure to increase such salary as is provided in Section IV.A above, or any other breach of this Agreement by the Company; or (iv) the occurrence of a Change in Control as defined in Section IX. In any such case the Company will pay you the amounts, and provide you the benefits, all as set forth in Section V.C.2 above.		
 	
 	E.  	Termination In The Event of Death or Permanent Disability. This agreement and your employment will terminate in the event of your death or permanent disability.		
 	1.  	In the event of your death, Base Salary and car allowance will be terminated as of the end of the month in which death occurs.		
 	
 	2.  	For the purposes of this Agreement, the term “disability” shall mean your inability, due to illness, accident or any other physical or mental incapacity, to substantially perform your duties for a period of four (4) consecutive months or for a total of six (6) months (whether or not consecutive) in any twelve (12) month period during the term of this Agreement.		
 	
 	3.  	Upon your “disability”, the Company shall have the right to terminate your employment. Notwithstanding any inability to perform your duties, you shall be entitled to receive your compensation (including bonuses, if any) as provided herein until the later of (i) the date of your termination of employment for disability in accordance with this Agreement, or (ii) the date upon which you begin to receive long-term disability insurance benefits under the policy provided by the Company pursuant to this Agreement. Any termination pursuant to Section V.E.2 shall be effective on the date thirty (30) days after which you shall have received written notice of the Company’s election to terminate.		
 	F.  	Entire Termination Payment.	
 	1.  	The compensation provided for in Sections V.B, V.C, V.D and V.E for early termination of this Agreement will constitute your sole remedy for such termination. You will not be entitled to any other termination or severance payment which might otherwise be payable to you under any other agreement between you and the Company or under any policy of the Company. This Section will not have any effect on distributions to which you may be entitled at termination from any qualified tax plan or any other plan (other than a severance payment or similar plan).		
 	
 	2.  	Notwithstanding any other provisions of this Agreement or any other agreement, contract or understanding heretofore or hereafter entered into between you and the Company, if any “payments” (including, without limitation, any benefits or transfers of property or the acceleration of the vesting of any benefits) in the nature of compensation under any 		

 
Mr. Stephen M. Simes
January 21, 1998
Page 7 
CONFIDENTIAL 
 	   	arrangement that is considered contingent on a Change in Control for purposes of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), together with any other payments that you have the right to receive from the Company or any corporation that is a member of an “affiliated group” (as defined in Section 1504(a) of the Code without regard to Section 1504(b) of the Code) of which the Company is a member, would constitute a “parachute payment” (as defined in Section 280G of the Code), such payments will be reduced to the largest amount as will result in no portion of such payments being subject to the excise tax imposed by Section 4999 of the Code; provided, however, that you will be entitled to designate those payments that will be reduced or eliminated in order to comply with the foregoing provision.	
 	G.  	Required Resignations Upon Early Termination or Expiration. You agree that upon any termination of your employment with the Company or expiration of this Employment Agreement, such termination or expiration under this Agreement will automatically and without further action be deemed to constitute your simultaneous resignation from all director, officer, trustee, agent and any other positions within the Company, all of its affiliates (including but not limited to any entity that is a shareholder of the Company and any subsidiaries and any parent of the Company), the Company’s employee benefit plans, trusts and foundations (charitable or otherwise) or any other similar position associated with the Company. Simultaneously upon such termination of employment or expiration of this employment agreement, you agree to execute and deliver to the Company any and all documents, agreements, certificates, letters or other written instruments confirming all such resignations.	
VI.  	Inventions.	
 	A.  	You agree that all Inventions (as defined below) you make, conceive, reduce to practice or author (either alone or with others) during or within one year after the term of this Agreement will be the Company’s sole and exclusive property. You will, with respect to any such Invention: (i) keep current, accurate, and complete records, which will belong to the Company and be kept and stored on the Company’s premises while you are employed by the Company; (ii) promptly and fully disclose the existence and describe the nature of the Invention to the Company in writing (and without request); (iii) assign (and you do hereby assign) to the Company all of your rights to the Invention, any applications you make for patents or copyrights in any country, and any patents or copyrights granted to you in any country; and (iv) acknowledge and deliver promptly to the Company any written instruments, and perform any other acts necessary in the Company’s opinion to preserve property rights in the Invention against forfeiture, abandonment, or loss and to obtain and maintain patents and/or copyrights on the Invention and to vest the entire right and title to the Invention in the Company.	

 
Mr. Stephen M. Simes
January 21, 1998
Page 8 
CONFIDENTIAL 
 	B.  	“Inventions,” as used in this Section, means any discoveries, improvements, creations, ideas and inventions, including without limitation software and artistic and literary works (whether or not they are described in writing or reduced to practice) or other works of authorship (whether or not they can be patented or copyrighted) that: (i) relate directly to the Company’s business or the Company’s research or development during the term of this Agreement; (ii) result from any work you perform for the Company; (iii) use the Company’s equipment, supplies, facilities or trade secret information; or (iv) you develop during any time that Section II above obligates you to perform your employment duties.		
 	
 	   	The requirements of this Section do not apply to an Invention for which no equipment, supplies, facility or trade secret information of the Company was used and which was developed entirely on your own time, and which neither (1) relates directly to the Company’s business or to the Company’s actual or demonstrably anticipated research or development, nor (2) results from any work you performed for the Company. Except as previously disclosed to the Company in writing, you do not have, and will not assert, any claims to or rights under any Inventions as having been made, conceived, authored or acquired by you prior to your employment by the Company.		
VII.  	Proprietary Information.	
 	A.  	Except as required in your duties to the Company, you will never, either during or after your employment by the Company, use or disclose Proprietary Information to any person not authorized by the Company to receive it. When your employment with the Company ends, you will promptly turn over to the Company all records and any compositions, articles, devices, apparatus and other items that disclose, describe or embody Proprietary Information, including all copies, reproductions and specimens of the Proprietary Information in your possession, regardless of who prepared them.		
 	
 	B.  	“Proprietary Information,” as used in this Section VII, means any nonpublic information concerning the Company, including information relating to the Company’s research, product development, engineering, purchasing, product costs, accounting, leasing, servicing, manufacturing, sales, marketing, administration and finances. This information includes, without limitation: (i) trade secret information about the Company and its products; (ii) “Inventions,” as defined in Section VI.B; (iii) information concerning any of the Company’s past, current or possible future products. Proprietary Information or confidential information also includes any information which is not generally disclosed and which is useful or helpful to the Company and/or which would be useful or helpful to competitors. More specific examples include financial data, sales figures for individual projects or groups of projects, planned new projects or planned advertising programs, areas where the Company intends to expand, lists of suppliers, lists of customers, wage and salary data, capital investment plans, projected earnings, changes in management or policies of the Company, testing		

 
Mr. Stephen M. Simes
January 21, 1998
Page 9 
CONFIDENTIAL 
 	   	data, manufacturing methods, suppliers’ prices to us, or any plans we may have for improving any of our products. This information is confidential or Proprietary Information regardless of its form, e.g. oral, written, electronic or other, and whether or not it is labeled as “proprietary” or “confidential.” The Company’s Proprietary Information or confidential information includes our information and that of our affiliates and third parties concerning or relating to us.	
VIII.  	Competitive Activities.	
 	A.  	You agree that during your employment with the Company, you will not alone, or in any capacity with another person or entity, (i) directly or indirectly engage in any employment or activity that competes with the Company’s business at the time your employment with the Company ends, within any state in the United States or within Canada, (ii) interfere with the Company’s relationships with any of its current or potential customers.		
 	
 	B.  	You also agree that for a period of one year after the termination of this Agreement for any one of the following reasons: (i) for “cause” as defined above, (ii) voluntarily by you without “good reason” as defined above; or (iii) in the event of a non-renewal of the Agreement by you other than for “good reason”, you will abide by clauses (ii) and (iii) of Section VIII.A above.		
IX.  	Change in Control.	
 	A.  	For purposes of this Agreement, a “Change in Control” of the Company will mean the following:	
(i) the sale, lease, exchange or other transfer, directly or indirectly, of substantially all of the assets of the Company (in one transaction or in a series of related transactions) to a person or entity that is not controlled by the Company; 
(ii) the approval by the shareholders of the Company of any plan or proposal for the liquidation or dissolution of the Company; 
(iii) a change in control of the Company of a nature that would be required to be reported in response to Item 5(f) of Schedule 14A of Regulation 14A or to Item 1 of Form 8-K promulgated under the Securities Exchange Act of 1934, as amended (the “Act”), provided that, without limitation, a Change in Control shall be deemed to have occurred if (i) any “person” (as such term is used in Sections 13(d) and 14(d)(2) of the Act) is or shall become the beneficial owner, directly or indirectly, of securities of the Company representing 30% or more of the Company’s then outstanding securities; or (ii) during any period of twenty-four (24) consecutive months, individuals who at the beginning of such period constitute the entire Board of Directors shall cease for any reason to constitute a majority thereof unless the election, or the nomination for 

 
Mr. Stephen M. Simes
January 21, 1998
Page 10 
CONFIDENTIAL 
election by the Company’s stockholders, of each new director was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of the period. 
 	B.  	If a Change in Control occurs, the Option will become immediately exercisable in full and will remain exercisable for the remainder of its term, regardless of whether you remain in the employ or service of the Company.		
 	
 	C.  	For purposes of this Section IX, you shall be entitled to the severance benefits provided in Section V.D if the date of termination occurs either (i) while there is to the Company’s knowledge actively pending a proposed transaction, which, if consummated, could reasonably be expected to result within one (1) year in a Change in Control, or (ii) within two (2) years following a Change in Control; unless, in the case of either (i) or (ii), your employment is terminated or this Agreement is not renewed because of death or disability or by the Company for “cause” or voluntarily by you other than for “good reason”.		
X.  	Miscellaneous.	
 	A.  	No Adequate Remedy. You understand that if you fail to fulfill your obligations under this Agreement, the damages to the Company would be very difficult to determine. Therefore, in addition to any other rights or remedies available to the Company at law, in equity, or by statute, you hereby consent to the specific enforcement of this Agreement by the Company through an injunction or restraining order issued by an appropriate court.		
 	
 	B.  	Governing Law. The laws of Illinois will govern the validity, construction, and performance of this Agreement.		
 	
 	C.  	Arbitration. Any and all disputes which arise concerning the rights, duties or obligations of either party under any provision of this Agreement shall be resolved exclusively by binding arbitration in accordance with the following terms and conditions. The party seeking arbitration shall commence a proceeding in arbitration in Chicago, Illinois under the Rules of the American Arbitration Association. Within one month from one of the party’s request for arbitration, the party requesting arbitration shall appoint one arbitrator and within one month of the date of such appointment, the other party shall appoint an arbitrator. Within three weeks of the date that the second arbitrator is appointed, and prior to any examination of the merits of the case, the two arbitrators shall mutually select a third arbitrator. If either of the parties fails to appoint an arbitrator or if the two arbitrators fail to appoint the third arbitrator within the periods referred to above, one shall be appointed in accordance with the Rules within fifteen (15) days of the expiry date of the respective period referred to above. The three arbitrators so selected shall constitute the arbitral panel. The arbitral panel shall make its decisions by the majority of its members. The arbitral panel shall render its decision and award in writing within ninety (90) days from its final constitution.		

 
Mr. Stephen M. Simes
January 21, 1998
Page 11 
CONFIDENTIAL 
 	   	There shall be no appeal from the decision and award of the arbitral panel, which shall be final and binding on the parties and may be entered in any court having jurisdiction thereof.		
 	
 	D.  	Rights in the Event of Dispute. If, with respect to any alleged failure by the Company to comply with any of the terms of this Agreement, you hire legal counsel with respect to this Agreement or institute any negotiations or institute or respond to legal action to assert or defend the validity of, enforce your rights under, or recover damages for breach of this Agreement, the Company shall pay, as they are incurred, your actual expenses for attorneys’ fees and disbursements, together with such additional payments, if any, as may be necessary so that the net-after-tax payments to you equal such fees and disbursements, provided that such payments shall be reimbursed by you to the Company if the Arbitration panel rules in favor of the Company and further decides that such reimbursement is appropriate. Further, pending the resolution of any such claim or dispute, you shall not be deemed terminated for purposes of this Agreement.		
 	
 	E.  	Mitigation. You are not required to mitigate the amount of any payments to be made pursuant to this Agreement by seeking other employment or otherwise, nor shall the amount of any payments provided for in this Agreement be reduced by any compensation earned by you as the result of your self-employment or your employment by another employer after the date of termination of your employment with the Company.		
 	
 	F.  	Construction. Wherever possible, each provision of this agreement will be interpreted so that it is valid under the applicable law. If any provision of this agreement is to any extent invalid under the applicable law, that provision will still be effective to the extent it remains valid under the applicable law. The remainder of this agreement also will continue to be valid, and the entire agreement will continue to be valid in other jurisdictions.		
 	
 	G.  	Waivers. No failure or delay by either the Company or you in exercising any right or remedy under this agreement will waive any provision of the agreement. Nor will any single or partial exercise by either the Company or you of any right or remedy under this agreement preclude either the Company or you from otherwise or further exercising these rights or remedies, or any other rights or remedies granted by any law or any related document.		
 	
 	H.  	Entire Agreement. This Agreement is the entire agreement between the parties and replaces all other oral negotiations, commitments, writings and understandings between the parties concerning the matters in this agreement. This Agreement can only be modified by mutual written consent of the parties. You acknowledge that you have been advised to seek legal counsel to review this Agreement with you before you sign it.		

 
Mr. Stephen M. Simes
January 21, 1998
Page 12 
CONFIDENTIAL 
 	I.  	Successors and Assigns. Except as otherwise provided in Section IX, this Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company whether by way of merger, consolidation, operation of law, purchase or other acquisition of substantially all of the assets or business of the Company, and any such successor or assign will absolutely and unconditionally assume all of the Company’s obligations under this Agreement.		
 	
 	J.  	Notices. All notices, requests and demands given to or made pursuant hereto will, except as otherwise specified herein, be in writing and be delivered or mailed to any such party at its address which:		

 
Mr. Stephen M. Simes
January 21, 1998
Page 13 
CONFIDENTIAL 
 	1.  	In the case of the Company will be:	
                                        Ben-Abraham Technologies
                                        225 Peachtree Street, NE
                                        Suite 1400, South Tower
                                        Atlanta, GA 30303
                                        Attention: Avi Ben-Abraham, CEO 
 	2.  	In the case of employee will be:	
                                        Stephen M. Simes
                                        1173 RFD
                                        Long Grove, IL 60047 
 	   	Any party may, by notice to the other party, designate a changed address. Any notice, if mailed properly addressed, postage prepaid, registered or certified mail, will be deemed dispatched on the registered date or that date stamped on the certified mail receipt, and will be deemed received within the second business day thereafter or when it is actually received, whichever is sooner.	
 	K.  	Captions. The various headings or captions in this agreement are for convenience only and will not affect the meaning or interpretation of this agreement.	
       Would you please confirm that this agreement is in accordance with your understanding and that you have received a copy of this letter by signing an dating it where indicated below, and returning an executed copy for our records. 
Very truly yours, 
BEN-ABRAHAM TECHNOLOGIES, INC. 
/s/ Avi Ben-Abraham 
*By: Avi Ben-Abraham, M.D.
Its: Chief Executive Officer 
Agreed to and confirmed as of January 21, 1998: 
 	
/s/ Stephen M. Simes	
	
Stephen M. Simes	

*	 	Subject to approval by the Company’s Board of Directors.	
/s/ ABA 

Exhibit 10.35 
BIOSANTE PHARMACEUTICALS, INC. 
DESCRIPTION OF NON-EMPLOYEE DIRECTOR
COMPENSATION ARRANGEMENTS 
     Retainer and Meeting Fees. Except as described below, each of our non-employee directors is paid a $20,000 annual retainer and $1,000 for each board or committee meeting attended in person and $500 for each board or committee meeting attended via telephone. Our Chairman of the Board is paid a $45,000 annual retainer and our Chairman of the Audit and Finance Committee is a paid a $25,000 annual retainer. 
     Stock Options. Non-employee directors are granted options to purchase shares of BioSante common stock from time to time in the sole discretion of the board of directors. 
     Reimbursement of Expenses. Non-employee directors are reimbursed for actual expenses, include travel expenses, incurred in attending board and committee meetings. 
 
Exhibit 10.36 
BIOSANTE PHARMACEUTICALS, INC. 
DESCRIPTION OF EXECUTIVE OFFICER
COMPENSATION ARRANGEMENTS 
     BioSante Pharmaceuticals, Inc. has entered into employment agreements with each of its executive officers, copies of which agreements have been filed with the Securities and Exchange Commission, as exhibits to BioSante’s annual report on Form 10-KSB. The following is a description of oral amendments to those employment agreements or additional oral compensation arrangements between BioSante and the following executive officers of BioSante: 

 	Name of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
 	Executive	 	 	 	 	 	Base	 	 	Bonus	 	 	Stock	 	 	 	 	
 	Officer	 	 	Title	 	 	Salary	 	 	Arrangements	 	 	Options	 	 	Other	 	
 	Stephen M. Simes 	 	 	Vice Chairman, President and Chief Executive Officer 	 	 	$360,000 per year. See footnote (1) below 	 	 	See footnote (2)
below 	 	 	Stock options to purchase shares of BioSante common stock are granted from time to time in the sole discretion of the Compensation Committee of the BioSante Board of Directors. Historically, such options have been granted on an annual basis. See footnote (3) 	 	 	Under the BioSante Pharmaceuticals, Inc. 401(k) Savings Plan, participants, including executive officers, may voluntarily request that BioSante reduce pre-tax compensation by up to 100% (subject to certain special limitations) and contribute such amounts to a trust. BioSante contributed an amount equal to 50% of the amount that each participant contributed under this plan.

Executive officers receive other benefits received by other BioSante employees, including health, dental and life insurance benefits.	 	
 	Phillip B. Donenberg 	 	 	Chief Financial Officer, Treasurer and Secretary 	 	 	$191,000 per year. See footnote (1) below 	 	 	See footnote (2)
below 	 	 	See above 	 	 	See above	 	
 	Leah M. Lehman, Ph.D. 	 	 	Vice President,
Product Development 	 	 	$240,000 per year. See footnote (1) below 	 	 	See footnote (2)
below 	 	 	See above 	 	 	See above	 	
 	Steven J. Bell, Ph.D. 	 	 	Vice President, Research and Pre-Clinical Development 	 	 	$160,000 per year . See footnote (1) below 	 	 	See footnote (2)
below 	 	 	See above 	 	 	See above	 	

 

(1)	 	Annual base salaries for BioSante’s executive officers are determined each year by BioSante’s Compensation Committee. The base salaries listed in this table are base salaries for 2004. As of March 24, 2005, the Compensation Committee had not made a final determination of the annual base salaries to be paid to BioSante’s executive officers for 2005. Once determined, the new annual base salaries will be effective retroactively as of January 1, 2005.	
 		
(2)	 	Annual performance bonuses for BioSante’s executive officers are determined each year by BioSante’s Compensation Committee. As of March 24, 2005, the Compensation Committee had not made a final determination of the amount, if any, of annual performance bonuses to be paid to BioSante’s executive officers for the year ended December 31, 2004.	
 		
(3)	 	As of March 24, 2005, the Compensation Committee had not made a final determination of how many, if any, stock options would be granted this year to BioSante’s executive officers.	

 	 	 	 	 	
EXHIBIT 23.1 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 
We consent to the incorporation by reference in Registration Statement Nos. 333-109474, 333-100238, and 333-53384 of BioSante Pharmaceuticals, Inc. (BioSante) on Form S-8 and Registration Statement Nos. 333-64218 and 333-116110 of BioSante on Form S-3 of our report dated March 24, 2005 (which report expresses an unqualified opinion and includes an explanatory paragraph that indicates that BioSante is in the development stage), appearing in this Annual Report on Form 10-KSB of BioSante Pharmaceuticals, Inc. for the year ended December 31, 2004. 
/s/ DELOITTE & TOUCHE LLP 
Chicago, Illinois 
March 30, 2005 

EXHIBIT 31.1 
Certification of CEO Pursuant to SEC Rule 13a-14 
I, Stephen M. Simes, certify that: 
1.  	I have reviewed this annual report on Form 10-KSB of BioSante Pharmaceuticals, Inc.;		
 	
2.  	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;		
 	
3.  	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;		
 	
4.  	The small business issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:		
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
(b) Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
(c) Disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and 
5.  	The small business issuer’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):	
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting. 
Date: March 30, 2005 

 	/s/ Stephen M. Simes  	 	
 	Stephen M. Simes 	 	
 	Vice Chairman, President and Chief Executive Officer 	 	

 	 	 	 	 	
EXHIBIT 31.2 
Certification of CFO Pursuant to SEC Rule 13a-14 
I, Phillip B. Donenberg, certify that: 
1.  	I have reviewed this annual report on Form 10-KSB of BioSante Pharmaceuticals, Inc.;		
 	
2.  	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;		
 	
3.  	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;		
 	
4.  	The small business issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:		
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
(b) Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
(c) Disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and 
5.  	The small business issuer’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):	
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting. 
Date: March 30, 2005 

 	/s/ Phillip B. Donenberg  	 	
 	Phillip B. Donenberg 	 	
 	Chief Financial Officer, Treasurer and Secretary 	 	

 	 	 	 	 	
EXHIBIT 32.1 
Certification of CEO Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 
In connection with the Annual Report of BioSante Pharmaceuticals, Inc. (the “Company”) on Form 10-KSB for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen M. Simes, Vice Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 
 	 	 	
	 	/s/ Stephen M. Simes	
	 	 	
	 	Stephen M. Simes	
	 	Vice Chairman, President and Chief Executive Officer	
	 	March 30, 2005	

EXHIBIT 32.2 
Certification of CFO Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 
In connection with the Annual Report of BioSante Pharmaceuticals, Inc. (the “Company”) on Form 10-KSB for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Phillip B. Donenberg, Chief Financial Officer, Treasurer and Secretary of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

 	/s/ Phillip B. Donenberg  	 	
 	Phillip B. Donenberg 	 	
 	Chief Financial Officer, Treasurer and Secretary 	 	
 	March 30, 2005